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ABSTRACT 
 
Herein are described the total syntheses of all members of the transtaganolide and basiliolide natural 
product family.  Utilitzation of an Ireland–Claisen rearrangement/Diels–Alder cycloaddition cascade 
(ICR/DA) allowed for rapid assembly of the transtaganolide and basiliolide oxabicyclo[2.2.2]octane core.  
This methodology is general and was applicable to all members of the natural product family. 
A brief introduction outlines all the synthetic progress previously disclosed by Lee, Dudley, and 
Johansson.  This also includes the initial syntheses of transtaganolides C and D, as well as basiliolide B and 
epi-basiliolide B accomplished by Stoltz in 2011.  Lastly, we discuss our racemic synthesis of basililide C 
and epi-basiliolide C, which utilized an ICR/DA cascade to constuct the oxabicyclo[2.2.2]octane core and 
formal [5+2] annulation to form the ketene-acetal containing 7-membered C-ring. 
Next, we describe a strategy for an asymmetric ICR/DA cascade, by incorporation of a chiral silane 
directing group.  This allowed for enantioselective construction of the C8 all-carbon quaternary center 
formed in the Ireland–Claisen rearrangement.  Furthermore, a single hydride reduction and subsequent 
translactonization of a C4 methylester bearing oxabicyclo[2.2.2]octane core demonstrated a viable strategy 
for the desired skeletal rearrangement to obtain pentacyclic transtaganolides A and B.  Application of the 
asymmetric strategy culminated in the total syntheses of (–)-transtaganolide A, (+)-transtaganolide B, (+)-
transtaganolide C, and (–)-transtaganolide D.  Comparison of the optical rotation data of the synthetically 
derived transtaganolides to that from the isolated counterparts has overarching biosynthetic implications 
which are discussed. 
Lastly, improvement to the formal [5+2] annulation strategy is described.  Negishi cross-coupling of 
methoxyethynyl zinc chloride using a palladium Xantphos catalyst is optimized for iodo-cyclohexene.  
Application of this technology to an iodo-pyrone geranyl ester allowed for formation and isolation of the 
eneyne product.  Hydration of the enenye product forms natural metabolite basiliopyrone.  Furthermore, the 
eneyne product can undergo an ICR/DA cascade and form transtaganolides C and D in a single step from 
an achiral monocyclic precursor. 
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CHAPTER 1 
Transtaganolide and Basiliolide Natural Products and Early Efforts 
Toward their Total Synthesis 
1.1 INTRODUCTION 
1.1.1 ISOLATION AND BIOLOGICAL ACTIVITY 
Indigenous to the Mediterranean, plants of the genus Thapsia have been recognized to 
possess valuable therapeutic properties since the birth of western medicine.1  In modern 
times, their bioactivity has been attributed to major metabolite thapsigargin (1), a potent 
histamine releaser2 and non-tetradecanoylphorbol acetate (TPA) type tumor promoter3 
(Figure 1.1.1A).  More importantly, thapsigargin (1) is a powerful, irreversible, 
sacroplasmatic-endoplasmatic reticulum Ca2+-ATPase (SERCA-ATPase) inhibitor, which 
allows for the net transfer of endoplasmic reticular Ca2+ to the cytosol and eventual 
apoptosis resulting from the endoplasmic reticular stress.4  Furthermore, thapsigargin’s 
(1) potent SERCA-ATPases inhibitory activity has been exploited and widely utilized as 
an invaluable biochemical tool5 (Figure 1.1.1B)6. 
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Figure 1.1.1.  A) Thapsigargin (1).  B)  Crystal structure of thapsigargin (1) bound SERCA-ATPase. 
 
Further investigations of the chemical components of Thapsia have elucidated the 
existence of several additional novel metabolites (Figure 1.1.2).  These include 7-O-
geranylscopoletin (2),7 basiliopyrone (3),8 haplolonide (4),9 lactonic meroterpenoid 5,8a 
thapsitranstagin (6),10 transtaganolides A–D (7–10),11 and basiliolides B and C (11 and 
12).12  In particular, the transtaganolides and basiliolides (7–12), like thapsigargin (1), 
demonstrated SERCA-ATPase inhibitory activity, despite bearing characteristically 
different structural cores than that of thapsigargin (1), suggesting a mechanistically 
different mode of action.  Appendino, Muñoz, and coworkers found that unlike 
thapsigargin (1), Ca2+ mobilization resulting from transtaganolide C (9) and basiliolides B 
and C (11 and 12) was reversible and did not induce apoptosis.13  Furthermore, the 
possibility of trace thapsigargin (1) contamination of the transtaganolide and basiliolide 
(9, 11, and 12) samples was later ruled out when synthetically derived transtaganolide C 
was assayed and gave similar results to those of the original study.14 
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Figure 1.1.2. Natural products isolated from Thapsia. 
 
1.1.2 BIOSYNTHETIC PROPOSALS 
Following the initial isolation of transtaganolides A–D and basiliolides B and C (7–
12), Appendino and coworkers proposed a possible biosynthetic route to the tetracyclic 
framework of transtaganolides C and D (9 and 10, Scheme 1.1.1).12  Starting with 
farnesyl pyrophosphate (13), olefin cyclization triggered by carbon dioxide incorporation 
and subsequent cation quenching gives monocyclic pyrophosphate 15.  Another round of 
olefin cyclization and cation quenching forms bicycle 17, which upon addition of carbon 
dioxide and water gives bicycle 19.  Oxidation and lactonization forms tricycle 20, and 
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subsequent aldol condensation forms the tricycle 21 to give the necessary 2-carbon 
homologation observed in the carbon skeleton.  Lastly, anhydride formation and 
methylation yield the desired natural products 9 and 10. 
Scheme 1.1.1.  Appendino’s biosynthetic proposal. 
 
Two years after Appendino’s initial proposal,12 Massanet and coworkers proposed a 
different biosynthetic hypothesis for the transtaganolides C and D (9 and 10), which 
better explained the existence of many of the other co-isolated secondary metabolites 
(Scheme 1.1.2).8  From co-isolated 7-O-geranylscopoletin (2), they propose two possible 
transtaganolide C (9,
C8:  β−Me,  α−vinyl);
transtaganolide D (10,
C8: α−Me,  β−vinyl)
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paths toward the biosynthesis of the transtaganolides.  Both path A (Claisen 
rearrangement, oxidation, then 6π electrocyclic rearrangement) and path B (oxidation, 6π 
electrocyclic rearrangement, followed lastly by Claisen rearrangement) form bicycle 26, 
which upon undergoing an intramoleculer Diels–Alder cycloaddition gives 
transtaganolides C and D (9 and 10).  Furthermore, co-isolated basiliopyrone (3) could be 
the hydration product of biosynthetic precursor 27, giving further credence to this 
biosynthetic hypothesis. 
Scheme 1.1.2. Massanet’s biosynthetic proposal. 
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Lastly, Johansson and coworkers, proposed a variation to Massanet’s biomimetic 
hypothesis (Scheme 1.1.2), suggesting basiliopyrone (3) was not a byproduct of the 
biosynthesis but rather a biosynthetic precursor to transtaganolides C and D (9 and 10, 
Scheme 1.1.3).15  Biosynthesis would commence with an initial Ireland–Claisen 
rearrangement of basiliopyrone (3) to form pyrone 28 with all-carbon quaternary center at 
C8.  Diels–Alder cycloaddition of 28 followed by C-ring closure could then form the 
naturals products 9 and 10.  Additionally, they hypothesized that the stereochemistry at 
the C8 all-carbon quaternary center could be set by a rare and unprecedented “Ireland–
Claisenase” enzyme. 
Scheme 1.1.3. Johansson’s biosynthetic proposal. 
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OO
O
O
8
4
basiliopyrone (3)
O
MeO
O
O
O
O
MeO
OH
8
4
[enzyme]
psuedo-enantiomers
set by
enzyme
28
99
O
O
MeO
H
O
O
8
4
O
O
MeO
H
O
O
8
4
+
transtaganolide C
(9)
transtaganolide D
(10)
9 9
Chapter 1–Transtaganolide and Basiliolide Natural Products and Early Efforts 
Toward their Total Synthesis 
7 
considerable challenge for total synthesis.  Using Massanet’s biomimetic proposal 
(Scheme 1.1.2) as a guide, initial efforts to form the ABD rings of transtaganolides C and 
D and basiliolides B and C utilized intramolecular pyrone Diels–Alder cycloadditions. 
Figure 1.2.1. The transtaganolide and basiliolide structural features. 
 
Stoltz and coworkers were the first to report the successful construction of the ABD 
tricyclic core via an intramolecular pyrone Diels–Alder cycloaddition reaction (Scheme 
1.2.1).16  Synthesis began with the one hydride reduction of γ-butyrolactone (29) and 
subsequent Wittig olefination to form alcohol-bearing enoate 31.  Iodine displacement of 
the primary alcohol of enoate 31 with I2 formed alkylating agent 32, to be used later for 
elaboration of pyrone 35a.  Pyrone 35a was made concurrently by dimethyl malonate 
substitution of chloro pyrone 33 followed by bromination.  Alkylation of pyrone 35a with 
iodo-enoate 32, was accomplished using standard conditions, and the subsequent product, 
pyrone 36, underwent the desired intramolecular pyrone Diels–Alder cycloaddition in 
76% yield to form tricycle 37, containing the transtaganolide and basiliolide ABD 
tricyclic core and C4 all-carbon quaternary center.  Furthermore, it was shown that 
intramolecular pyrone Diels–Alder cycloaddition could not be accomplished without 
prior bromination of the pyrone ring to avoid decarboxylation during the reaction.17 
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Scheme 1.2.1. Stoltz’s synthesis of ABD tricyclic core of the transtaganolides and basiliolides. 
 
Subsequent studies published by both Dudley18 and Lee19 further demonstrated the 
efficacy of an intramolecular pyrone Diels–Alder cycloaddition to construct the 
transtaganolide and basiliolide (9–12) ABD tricyclic core (Scheme 1.2.2A and B).  Using 
iodo pyrone 38, Dudley and coworkers could effect the desired Diels–Alder 
cycloaddition in 39% yield (Scheme 1.2.2A).  On the other hand, Lee and coworkers, 
following oxidation of 40, were able to effect a base catalyzed Diels–Alder cycloaddition 
at ambient temperature in 50% yield over the two reactions (Scheme 1.2.2B). 
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Scheme 1.2.2. A) Dudley’s synthesis of ABD tricyclic core of the transtaganolides and basiliolides.  
B). Lee’s synthesis of ABD tricyclic core of the transtaganolides and basiliolides. 
 
1.3 PROGRESS TOWARD THE SYNTHESIS OF TRANSTAGANOLIDES C 
AND D AND BASILIOLIDES B AND C 
1.3.1 RETROSYNTHETIC ANALYSIS 
Despite having successfully constructed the transtaganolide and basiliolide (9–12, 
Figure 1.2.1) ABD tricyclic core, none of the previously discussed methods16,18,19 had 
addressed construction of the C8 all-carbon quaternary stereocenter characteristic of this 
family of natural products.  In 2009, both Stoltz20 and Johansson15 simultaneously 
divulged similar strategies toward the synthesis of transtaganolides C and D as well as 
basiliolides B and C that included successful construction of the C8 all-carbon quaternary 
stereocenter.  Though neither group at the time could successfully construct the final 
cycloheptene C-ring, Stoltz and coworkers would eventually accomplish this feat and 
publish the first total syntheses of transtaganolides C and D (9 and 10) as well as 
basiliolide B (11) in 2011.21 
Consider the retrosynthetic analysis outlined by Stoltz and coworkers (Scheme 
1.3.1).21  The first disconnection breaks apart the 7-membered ketene-acetal containing 
C-ring, allowing natural products 9–12, 42, and 43 to form by a formal [5+2] annulation 
of a methoxy acetylene species and tricycle 43.  Tricycle 43 arises from an intramolecular 
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pyrone Diels–Alder cycloaddition of acid 45, which builds the ABD tricyclic core.  The 
next disconnection is formation of the C8 all carbon quaternary center of acid 45, which 
we envision to arise from an Ireland–Claisen rearrangement of pyrone 46, the coupling 
product of acid 47 and geraniol derivative 48.  Furthermore the sequential Ireland–
Claisen, Diels–Alder cycloaddition reactions (46⇒48), could be accomplished in a single 
operation, allowing the simultaneous construction of the ABD tricyclic core as well as C4 
and C8 all-carbon quaternary stereocenters. 
Scheme 1.3.1. Retrosynthetic analysis of transtaganolides C and D (9 and 10) and basiliolides B and 
C (11 and 12). 
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1.3.2 PROGRESS FOR THE FORWARD SYNTHESIS 
Stoltz and coworkers’ original synthetic approach began with the synthesis of 
homoallylic alcohol 50 via Sonagashira cross-coupling (Scheme 1.3.2).20  Bromo 
lactonization of ester 50 followed by subsequent oxidation provided the bromo acid 52 in 
good yield.  DCC coupling of acid 52 to geraniol formed the bromo pyrone 53, which 
successfully underwent the sequential Ireland–Claisen and Diels–Alder cyclization in 
good yield over the two steps. 
Scheme 1.3.2. Stoltz’s progress toward the synthesis of transtaganolides C and D (9 and 10). 
 
Johansson15 and coworkers’ synthetic strategy was nearly identical to that of Stoltz19 
and coworkers (Scheme 1.3.3),15 the major difference being the synthesis and use of iodo 
pyrone 57, rather than bromo pyrone 53, for use in the sequential Ireland–Claisen and 
Diels–Alder cyclizations, to form tricycle 58.  Furthermore, Johansson and coworkers 
were able to demonstrate a successful cross-coupling, forming eneyne 59, and providing 
a possible strategy for the eventual formation of the elusive transtaganolide and 
basiliolide C-ring (7–12, Figure 1.2.1). 
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Scheme 1.3.3. Johansson’s progress toward the synthesis of transtaganolides C and D (9 and 10). 
 
1.4 TOTAL SYNTHESES OF TRANSTAGANOLIDES C AND D 
Following initial progress reports by Stoltz20 and Johannson15, Stoltz and coworkers 
published the first successful total synthesis of (±)-transtaganolides C and D (9 and 10) in 
2011.21  By using the information learned from their own work20 and that published by 
Johannson15, Stoltz and coworkers were able to develop an Ireland–Claisen 
rearrangement/Diels–Alder cycloaddition cascade reaction (ICR/DA), which has become 
their general synthetic strategy for all members of the natural product family (Scheme 
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allowed for the simultaneous construction of the ABD tricyclic core as well as C4 and C8 
all-carbon quaternary centers in a single step. 
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Scheme 1.4.1. Ireland–Claisen/Diels–Alder cycloaddition cascade (ICR/DA). 
 
Having developed a successful strategy for the formation of tricycles 58a and 58b, it 
then became a question of forming the elusive C-ring to finish the synthesis of 
transtaganolides C and D (9 and 10).  Using the formal [5+2] annulation strategy outlined 
in the retrosynthetic analysis (Scheme 1.3.1), it became instantly clear that a direct 
coupling of methoxy acetylene to iodides 58a and 58b followed by an in situ cyclization 
was unachievable.  Drawing from the few reported successful cross-couplings of zinc and 
tin ethoxyacetylide,23 Stoltz and coworkers began synthesis of a suitable stannyl 
methoxyacetylide derivative 62 (Scheme 1.4.2).21  Treatment of known 1,1-dimethoxy-2-
chloro-acetaldehyde (60) with 3 equivalents of lithium diethyl amide formed the putative 
lithium acetylide 61, which was then trapped as the stannyl acetylide 62 by the addition 
of tributyl tin chloride in 78% yield. 
Scheme 1.4.2. Synthesis of stannyl methoxyacetylide 62. 
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silyl esters 63a and 63b followed by the in situ cyclization upon the addition of water 
gave the natural products, transtaganolides C and D (9 and 10), in 31% yield. 
Scheme 1.4.3. Total syntheses of transtaganolides C and D (9 and 10). 
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followed by the in situ cyclization formed natural product, basiliolide B (11), and 
previously unreported epi-basiliolide B (42) in 6% and 12% yield, respectively. 
Scheme 1.5.1. Stoltz’s total syntheses of basiliolide B and epi-basiliolide B (11 and 42).
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allowed for diastereoselective C8 all-carbon quaternary center formation and access to 
basiliolide B (11). 
Lee’s synthesis began with the coupling of furfural (68) and geranyl diazoacetate (69) 
to form diazo ester  70 (Scheme 1.5.2).  Treatment of diazo 70 with copper (II) allowed 
for a diastereoselective intramolecular cyclopropanation, forming cyclopropane 71 in 
good yield.  Reduction followed by saponification and iodine displacement formed 
cyclopropane 73.  Finally, treatment of cyclopropane 73 with n-BuLi effected the desired 
ring opening reaction, giving a single diastereomer 74 that contained the required C8 all-
carbon quaternary center indicative of basiliolide B (11).   
Scheme 1.5.2. Lee’s synthesis of basiliolide B (11) 
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Having formed ester 74 with C8 all-carbon quaternary center, Lee and coworkers 
sought to finish their synthesis of basiliolide B (11, Scheme 1.5.3).  Oxidative cleavage of 
74 followed by Wittig olefination furnished enone 75 in 70% yield over the two steps.  
Achmatowicz reaction of furan 75 followed by methylation and Wittig olefination 
afforded lactal 78.  Jones oxidation of lactal 78 and subsequent olefin isomerization 
formed Diels–Alder substrate 80 in good yield.  Finally, intramolecular Diels–Alder 
cycloaddition of pyrone 80 gave tricycle 81, which following palladium assisted allyl 
ester cleavage, and intramolecular O-acylation produced basiliolide B (11) as a single 
diastereomer. 
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Scheme 1.5.3. Lee’s continued synthesis of basiliolide B (11). 
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aldehyde 83,27 with triphenylphosphonium ylide 30, to give the enoate 84 (Scheme 1.6.1).  
Subsequent reduction of α,β-unsaturated ester 84 with DIBAL-H afforded allylic alcohol 
85 in 89% yield.  Following protecting group manipulations (85→86), DCC coupling of 
alcohol 86 with pyrone acid 56 efficiently generated the ICR/DA cascade substrate 87.  
Submission of pyrone ester 87 to our ICR/DA protocol proved successful, affording 
tricycles 88a and 88b in 65% combined yield and as a 1:2 mixture of C8 diastereomers, 
respectively.  Only two diastereomers, 88a and 88b, are formed in the reaction resulting 
from the diastereoselective Diels–Alder cycloaddition, where diastereoselectivity is 
dictated by the C7 ester formed in the Ireland–Claisen rearrangement.  Protection of 
tricycles 88a and 88b gave silyl esters 89a and 89b in 74% yield.  Completion of the 
synthesis was achieved via a palladium promoted formal [5+2] annulation of tricycles 
89a and 89b with stannyl methoxyacetylide 62 to form basiliolide C (12) and previously 
unreported epi-basiliolide C (43), respectively, albeit in low yield (17% yield). 
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Scheme 1.6.1. Total syntheses of basiliolide C (12) and epi-basiliolide C (43). 
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syntheses of (±)-transtaganolides C and D (9 and 10), (±)-basiliolide B (11), (±)-epi-
basiliolide B (42), (±)-basiliolide C (12), and (±)-epi-basiliolide C (43). 
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1.8 EXPERIMENTAL SECTION 
1.8.1 MATERIALS AND METHODS 
Unless otherwise stated, reactions were performed in flame-dried glassware under an 
argon or nitrogen atmosphere using dry deoxygenated solvents.  Solvents were dried by 
passage through an activated alumina column under argon.  Chemicals were purchased 
from Sigma-Aldrich Chemical Company and used as received.  Pd(PPh3)4 was prepared 
using known methods.  Thin layer chromatography (TLC), both preparatory and 
analytical, was performed using E. Merck silica gel 60 F254 precoated plates (0.25 mm) 
and visualized by UV fluorescence quenching, p-anisaldehyde, I2, or KMnO4 staining.  
ICN Silica gel (particle size 0.032-0.063 mm) was used for flash chromatography.  1H 
NMR and 13C NMR spectra were recorded on a Varian Mercury 300 (at 300 MHz) or on 
a Varian Unity Inova 500 (at 500 MHz) spectrometer.  1H NMR spectra are reported 
relative to CDCl3 (7.26 ppm).  Data for 1H NMR spectra are reported as follows: chemical 
shift (ppm), multiplicity, coupling constant (Hz), and integration.  Multiplicities are 
reported as follows: s = singlet, d = doublet, t = triplet, q = quartet, sept. = septet, m = 
multiplet, bs = broad singlet.  13C NMR spectra are reported relative to CDCl3 (77.16 
ppm).  FTIR spectra were recorded on a Perkin Elmer SpectrumBX spectrometer and are 
reported in frequency of absorption (cm-1).  HRMS were acquired using an Agilent 6200 
Series TOF with an Agilent G1978A Multimode source in electrospray ionization (ESI), 
atmospheric pressure chemical ionization (APCI), or multimode-ESI/APCI. 
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1.8.2 PREPARATIVE PROCEDURES 
 
Enoate 84.  To a 23 °C solution of aldehyde 83 (1.39 g, 5.74 mmol) in benzene (57 
mL, 0.1 M) was added ylide 30 (2.92 g, 8.38 mmol).  The reaction was stirred at 60 °C 
for 6 h.  The reaction flask was then cooled to ambient temperature.  The crude mixture 
was poured directly onto a short pad of silica and subsequently flushed with Et2O (150 
mL).  Solvent was removed by rotary evaporation.  The crude oil was redissolved in 
CH2Cl2 (50 mL) and then dry loaded onto silica (5 g).  Purification by column 
chromatography (EtOAc in hexanes 1%→1.5% on silica) yielded 722 mg (41% yield) of 
enoate 84 as clear oil and a single diastereomer; 1H NMR (300 MHz, CDCl3) δ 6.72 (tq, J 
= 7.3, 1.5 Hz, 1H), 5.31 (tq, J = 6.3, 1.3 Hz, 1H), 4.18 (dd, J = 6.3, 0.8 Hz, 2H), 3.71 (s, 
3H), 2.34–2.23 (m, 2H), 2.16–2.06 (m, 2H), 1.82 (s, 3H), 1.62 (s, 3H), 0.88 (s, 9H), 0.05 
(s, 6H); 13C NMR (75 MHz, CDCl3) δ 168.7, 142.0, 135.8, 127.8, 125.3, 60.3, 51.8, 38.1, 
27.0, 26.1, 18.5, 16.5, 12.5, -5.0; FTIR (Neat Film NaCl) 2952, 2930, 2896, 2857, 1717, 
1672, 1651, 1472, 1463, 1436, 1387, 1361, 1259, 1218, 1193, 1124, 1107, 1065, 1006, 
939, 837, 814, 776, 744 cm-1; HRMS (ESI) m/z calc’d for C17H32O3SiNH4 [M+NH44]+: 
330.2459, found 330.2468. 
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Allyl alcohol 85.  To a –78 °C solution of enoate 84 (722 mg, 2.31 mmol) in Et2O (23 
mL, 0.1 M) was added neat DIBAL-H (1.03 mL, 5.78 mmol) in a dropwise fashion.  The 
reaction mixture was then stirred for 45 min at –78 °C before being carefully quenched 
by the dropwise addition of a saturated solution of Rochelle’s salt (6 mL over 5 min).  
The reaction mixture was then removed from the cold bath and allowed to warm to 
ambient temperature while being vigorously stirred for another 2 h.  The aqueous phase 
was extracted with Et2O (4 x 10 mL), and the organics were combined, washed with 
saturated brine (40 mL), and then dried over MgSO4.  Solvent was removed by rotary 
evaporation and purification by column chromatography (EtOAc in hexanes 3.5%→15% 
on silica) resulted in the isolation of 587 mg (89% yield) of allyl alcohol 85 as a clear oil; 
1H NMR (300 MHz, CDCl3) δ 5.37 (tq, J = 7.0, 1.3 Hz, 1H), 5.29 (tq, J = 6.3, 1.3 Hz, 
1H), 4.18 (dd, J = 6.4, 0.8 Hz, 2H), 3.97 (s, 2H), 2.22–2.08 (m, 2H), 2.09–1.98 (m, 2H), 
1.65 (s, 3H), 1.61 (s, 3H), 0.89 (s, 9H), 0.06 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 136.6, 
135.1, 125.8, 124.7, 69.0, 60.4, 39.2, 26.1, 25.9, 18.6, 16.4, 13.8, -4.9; FTIR (Neat Film 
NaCl) 3346, 2955, 2929, 2857, 1671, 1472, 1463, 1407, 1385, 1361, 1255, 1111, 1094, 
1066, 1006, 939, 836, 814, 776 cm-1; HRMS (ESI) m/z calc’d for C16H32O2SiNa 
[M+Na]+: 307.2064, found 307.2052. 
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Allyl acetate 85.5.  To a 0 °C solution of allyl alcohol 85 (585 mg, 2.06 mmol) in 
pyridine (2 mL, 1 M) was added acetic anhydride (390 µL, 4.11 mmol).  The reaction 
was allowed to warm to 23 °C and stirred for 3.5 h.  At this time the reaction mixture was 
diluted with Et2O (15 mL) and washed with saturated NaHCO3 solution (3 x 10 mL), 
saturated CuSO4 solution (3 x 10 mL), and brine (10 mL).  The organic fraction was dried 
with MgSO4 and the solvent was removed by rotary evaporation.  Purification by column 
chromatography (2.5% EtOAc in hexanes on silica) yielded 423 mg (63% yield) of the 
acetate protected product 85.5 as a clear oil; 1H NMR (300 MHz, CDCl3) δ 5.43 (tq, J = 
7.0, 1.3 Hz, 1H), 5.30 (tq, J = 6.3, 1.3 Hz, 1H), 4.43 (s, 2H), 4.18 (dq, J = 6.3, 0.9 Hz, 
2H), 2.23–2.09 (m, 2H), 2.06–1.99 (m, 5H), 1.64 (s, 3H), 1.61 (s, 3H), 0.89 (s, 9H), 0.06 
(s, 6H); 13C NMR (75 MHz, CDCl3) δ 171.1, 136.4, 130.3, 129.4, 124.9, 70.4, 60.4, 39.0, 
26.1, 21.1, 18.6, 16.5, 14.1, -4.9; FTIR (Neat Film NaCl) 2954, 2930, 2886, 2857, 1744, 
1671, 1472, 1462, 1445, 1377, 1360, 1249, 1230, 1111, 1065, 1024, 836, 776 cm-1; 
HRMS (APCI) m/z calc’d for C18H34O3SiNa [M+Na]+: 349.2169, found 349.2180. 
 
 
Allyl acetate 86.  Cleavage of the silyl protecting group could be accomplished by 
the addition of 1M TBAF solution in THF (1.95 mL, 1.94 mmol) to a 0°C solution of the 
previously isolated acetate protected product 85.5 (423 mg, 1.30 mmol) in THF (6.5 mL, 
0.2 M).  The reaction was allowed to warm to 23 °C and then was stirred for an 
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additional hour, prior to quenching with saturated NH4Cl (5 mL).  The aqueous phase 
was extracted with Et2O (3 x 5 mL), and the organics were combined, washed with brine 
(15 mL), and dried over MgSO4.  Solvent was removed by rotary evaporation and 
purification by column chromatography (EtOAc in hexanes 10%→20% on silica) 
resulted in the isolation of 253 mg (92% yield) of allyl acetate 86 as a clear oil; 1H NMR 
(300 MHz, CDCl3) δ 5.44–5.30 (m, 2H), 4.39 (s, 2H), 4.08 (d, J = 6.8 Hz, 2H), 2.19–1.97 
(m, 7H), 1.61 (s, 3H), 1.60 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 171.1, 138.5, 130.2, 
129.1, 124.0, 70.2, 59.2, 38.8, 25.9, 21.0, 16.8, 14.0; FTIR (Neat Film NaCl) 3423, 2975, 
2923, 2879, 1738, 1671, 1442, 1378, 1232, 1090, 1022, 844 cm-1; HRMS (ESI) m/z 
calc’d for C12H20O3Na [M+Na]+: 235.1305, found 235.1300. 
 
 
Iodo pyrone ester 87.  To a 0 °C solution of allyl acetate 86 (254 mg, 1.20 mmol) 
and pyrone acid 56 (403 mg, 1.44 mmol) in MeCN (12 mL, 0.1 M) was added DCC (297 
mg, 1.44 mmol).  The reaction was allowed to warm to 23 °C and stirred for 1 h.  The 
crude reaction mixture was then flushed through a short pad of celite with additional 
MeCN (15 mL) to remove the insoluble urea byproduct.  Solvent was removed by rotary 
evaporation and purification by column chromatography (EtOAc in hexanes 5%→15% 
on silica) resulted in the isolation of 531 mg (94% yield) of iodo pyrone ester 87 as a 
yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.45 (d, J = 9.7 Hz, 1H), 6.06 (d, J = 9.7 Hz, 
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1H), 5.45–5.38 (m, 1H), 5.33 (tq, J = 7.1, 1.3 Hz, 1H), 4.66 (d, J = 7.2 Hz, 2H), 4.43 (s, 
2H), 3.77 (s, 2H), 2.24–2.02 (m, 7H), 1.70 (s, 3H), 1.64 (s, 3H); 13C NMR (75 MHz, 
CDCl3) δ 171.1, 166.8, 160.5, 158.0, 151.3, 142.8, 130.6, 128.8, 118.0, 116.3, 70.8, 70.3, 
62.7, 42.7, 38.9, 26.0, 21.2, 16.7, 14.1; FTIR (Neat Film NaCl) 2973, 2933, 2854, 1732, 
1607, 1546, 1443, 1376, 1357, 1345, 1230, 1167, 1133, 1063, 1016, 959, 865, 821 cm-1; 
HRMS (ESI) m/z calc’d for C19H23IO6Na [M+Na]+: 497.0432, found 497.0428. 
 
 
Tricyclic acids 88a and 88b.  To a 23 °C solution of iodo pyrone ester 87 (385 mg, 
0.812 mmol) in toluene (4 mL, 0.2 M) in a 250 mL sealed tube was added N,O-
bis(trimethylsilyl)acetamide (BSA) (397 µL, 1.62 mmol) and triethylamine (11.3 µL, 
0.0812 mmol).  The reaction was heated to 110 °C and stirred for 20 min.  The solution 
was then cooled to 23 °C and diluted with toluene (200 mL, 0.004 M), leaving ample 
headspace in the sealed tube to allow for solvent expansion.  The reaction mixture was 
then heated to 100 °C for 7.5 d or until complete as determined by 1H NMR.  The 
reaction mixture was then cooled to 23 °C, a 1% aqueous solution of AcOH was added 
(10 mL), and the reaction was stirred for an additional 2 min.  The reaction was washed 
with an additional 1% aqueous solution of AcOH (3 x 10 mL), and the aqueous phases 
were combined and back extracted with EtOAc (3 x 30 mL), while making sure the pH of 
the aqueous phase remained acidic.  The organics were combined and dried over Na2SO4, 
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and solvent was removed by rotary evaporation.  Purification by column chromatography 
(EtOAc in hexanes with 0.1% AcOH, 17%→25% on silica) gave desired tricycles 88a 
and 88b with a co-eluding impurity (<5% by 1H NMR).  Subsequent recrystallization 
from heptane and EtOAc gave 249 mg (65% yield) of pure tricyclic acids 88a and 88b as 
white solids and a 1:2 mixture of the respective diastereomers (88a and 88b). 
Minor diastereomer 88a: 1H NMR (300 MHz, CDCl3) δ 6.91 (d, J = 6.7 Hz, 1H), 6.34 
(dd, J = 17.4, 11.0 Hz, 1H), 5.17–4.96 (m, 2H), 3.86–3.61 (m, 2H), 3.20 (d, J = 6.8 Hz, 
1H), 2.95 (s, 1H), 2.09 (s, 3H), 2.00–1.37 (m, 5H), 1.37 (s, 3H), 1.11 (s, 3H); 13C NMR 
(75 MHz, CDCl3) δ 174.2, 170.9, 169.7, 140.5, 139.2, 113.5, 98.5, 84.2, 70.0, 60.6, 52.6, 
44.1, 40.3, 40.1, 38.6, 29.9, 20.9, 19.5, 18.3. 
Major diastereomer 88b: 1H NMR (300 MHz, CDCl3) δ 6.91 (d, J = 6.7 Hz, 1H), 6.01 
(dd, J = 17.4, 10.7 Hz, 1H), 5.17–4.96 (m, 2H), 3.86–3.61 (m, 2H), 3.21 (d, J = 6.7 Hz, 
1H), 3.01 (s, 1H), 2.09 (s, 3H), 2.00–1.37 (m, 5H), 1.30 (s, 3H), 1.13 (s, 3H); 13C NMR 
(75 MHz, CDCl3) δ 174.1, 170.9, 169.8, 148.0, 138.9, 111.5, 98.9, 84.1, 70.0, 59.2, 52.5, 
44.0, 40.1, 39.9, 39.5, 38.1, 20.9, 19.5, 18.3. 
FTIR (Neat Film NaCl) 3084, 2977, 2665, 2253, 1733, 1638, 1465, 1438, 1414, 1394, 
1379, 1337, 1315, 1229, 1172, 1120, 1041, 967, 913, 876, 839, 795, 735 cm-1; HRMS 
(Multimode-ESI/APCI) m/z calc’d for C19H24IO6 [M+H]+: 475.0612, found 475.0608. 
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Silyl esters 89a and 89b.  To a 23 °C solution of iodo acids 88a and 88b (115 mg, 
0.243 mmol) in DMF (1.2 mL, 0.2 M) were added sequentially imidazole (99.4 mg, 1.46 
mmol) and TBSCl (147 mg, 0.973 mmol).  The reaction was stirred for 1 h at 23 °C and 
then quenched by the addition of saturated brine (4 mL).  The resulting aqueous phase 
was extracted with a 50% solution of EtOAc in hexanes (3 x 4 mL), after which the 
organics were combined, washed with brine (6 mL), and dried with Na2SO4.  Solvent was 
removed by rotary evaporation and purification by column chromatography (EtOAc in 
hexanes 10%⇒20% on silica) gave 106 mg (74% yield) of silyl esters 89a and 89b as 
white solids and a 1:2 mixture of the respected diastereomers (89a and 89b). 
Minor diastereomer 89a: 1H NMR (300 MHz, CDCl3) δ 6.87 (d, J = 6.7 Hz, 1H), 6.36 
(dd, J = 17.4, 11.0 Hz, 1H), 5.19–4.88 (m, 2H), 3.80–3.63 (m, 2H), 3.14 (d, J = 6.8 Hz, 
1H), 2.85 (s, 1H), 2.07 (s, 3H), 1.91–1.19 (m, 8H), 1.10 (s, 3H), 0.88 (s, 9H), 0.27 (s, 
3H), 0.26 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 170.7, 169.7, 169.1, 141.0, 138.9, 113.2, 
99.2, 84.3, 70.0, 61.8, 52.8, 44.4, 40.5, 39.6, 39.2, 29.8, 25.5, 21.1, 20.91, 19.5, 17.6, -
4.8, -4.8. 
Major diastereomer 89b: 1H NMR (300 MHz, CDCl3) δ 6.87 (d, J = 6.7 Hz, 1H), 6.01 
(dd, J = 17.4, 10.6 Hz, 1H), 5.19–4.88 (m, 2H), 3.80–3.63 (m, 2H), 3.16 (d, J = 6.8 Hz, 
1H), 2.94 (s, 1H), 2.07 (s, 3H), 1.91–1.19 (m, 8H), 1.10 (s, 3H), 0.88 (s, 9H), 0.27 (s, 
3H), 0.24 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 170.7, 169.7, 168.9, 149.0, 138.7, 110.8, 
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99.6, 84.2, 70.0, 60.4, 52.6, 44.3, 40.3, 40.2, 38.5, 25.6, 21.1, 20.9, 19.52, 18.1, 17.6, -
4.7, -4.8. 
FTIR (Neat Film NaCl) 2951, 2930, 2896, 2858, 1760, 1745, 1716, 1472, 1464, 1413, 
1393, 1378, 1364, 1341, 1283, 1250, 1229, 1194, 1173, 1042, 1021, 1007, 984, 968, 939, 
930, 915, 885, 843, 828, 790, 733 cm-1; HRMS (Multimode-ESI/APCI) m/z calc’d for 
C25H38IO6Si [M+H]+: 589.1477, found 589.1496. 
 
 
Basiliolide C (12) and epi-basiliolide C (43).  In a nitrogen filled glovebox, to a 
solution of silyl esters 89a and 89b (13 mg, 0.022 mmol) and Pd(PPh3)4 (28 mg, 0.0242 
mmol) in DMF (220 µL, 0.1 M) was added tributyl(2-methoxyethynyl)stannane (62) (29 
mg, 0.088 mmol).  The reaction was stirred at 30 °C for 15 h at which point another 
equivalent of stannane 62 was added (7.5 mg, 0.022 mmol).  The reaction was stirred for 
an addition 5 h and then additional stannane 62 was added (7.5 mg, 0.022 mmol).  After 
another 4 h of stirring at 30 °C (a total reaction time of 24 h) the reaction was filtered 
through cotton washing with MeCN in order to remove Pd(PPh3)4.  The filtrate was 
further diluted with MeCN (making a total reaction volume of 8 mL) and the reaction 
solution was removed from the glovebox.  pH 7 phosphate buffer (150 µL) was added to 
the crude reaction solution and then stirred at 23 °C for 6 h.  MeCN was then removed by 
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passing a stream of air over the reaction vessel (rotary evaporation could not be 
accomplished without bumping the liquid).  The remaining liquid was diluted with 25% 
saturated brine solution in water (350 µL) and the aqueous phase extracted with EtOAc 
(4 x 750 µL).  The organics were pooled, dried over Na2SO4, and concentrated by rotary 
evaporation.  The crude oil was purified by normal phase HPLC (33% EtOAc in hexanes) 
to yield 0.51 mg (6% yield) of basiliolide C (12) and 0.97 mg (11% yield) of epi-
basiliolide C (43).  The spectroscopic data obtained from synthetic 12 match those 
published from natural sources. 
Basiliolide C (12): 1H NMR (500 MHz, CDCl3) δ 7.00 (dd, J = 17.7, 11.1 Hz, 1H), 
6.05 (dd, J = 6.5, 1.2 Hz, 1H), 5.16 (dd, J = 11.1, 1.4 Hz, 1H), 5.06 (dd, J = 17.7, 1.2 Hz, 
1H), 5.00 (d, J = 1.4 Hz, 1H), 3.73 (s, 3H), 3.73 (d, J = 10.8 Hz, 1H), 3.69 (d, J = 10.8 
Hz, 1H), 3.29 (d, J = 6.5 Hz, 1H), 3.14 (s, 1H), 2.08 (s, 3H), 1.93 (dt, J = 13.5, 3.4 Hz, 
1H), 1.75 (qd, J = 13.5, 3.0 Hz, 1H), 1.64–1.50 (m, 1H), 1.41 (td, J = 13.5, 3.0 Hz, 1H), 
1.32–1.24 (m, 1H), 1.23 (s, 3H), 1.12 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 171.0, 
170.7, 162.4, 157.0, 142.7, 138.6, 123.0, 112.5, 87.0, 79.2, 70.6, 56.6, 53.4, 49.8, 44.8, 
40.3, 38.6, 37.1, 28.7, 21.2, 20.9, 19.8; FTIR (Neat Film NaCl) 3083, 2942, 2873, 2851, 
1766, 1745, 1620, 1464, 1444, 1378, 1334, 1262, 1233, 1199, 1178, 1108, 1038, 1010, 
994, 955, 914, 831, 733 cm-1; HRMS (Multimode-ESI/APCI) m/z calc’d for C22H27O7 
[M+H]+: 403.1751, found 403.1736. 
Epi-basiliolide C (43): 1H NMR (500 MHz, CDCl3) δ 6.04 (dd, J = 6.5, 1.3 Hz, 1H), 
5.80 (dd, J = 17.4, 10.8 Hz, 1H), 5.11–5.03 (m, 2H), 4.98 (d, J = 1.3 Hz, 1H), 3.72 (q, J = 
10.8 Hz, 2H), 3.72 (s, 3H), 3.29 (d, J = 6.5 Hz, 1H), 3.23 (s, 1H), 2.09 (s, 3H), 1.84–1.72 
(m, 1H), 1.70–1.62 (m, 2H), 1.61 (s, 3H), 1.50–1.41 (m, 1H), 1.26 (dd, J = 13.1, 4.9 Hz, 
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1H), 1.16 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 171.0, 170.8, 162.1, 157.0, 146.3, 
138.9, 122.7, 113.2, 87.0, 79.0, 70.6, 56.5, 50.7, 49.7, 44.5, 38.6, 38.3, 37.0, 20.9, 20.7, 
19.9, 19.3; FTIR (Neat Film NaCl) 2931, 1763, 1742, 1666, 1619, 1442, 1377, 1335, 
1228, 1195, 1178, 1113, 1038, 1021, 999, 970, 952, 914, 830, 732 cm-1; HRMS 
(Multimode-ESI/APCI) m/z calc’d for C22H27O7 [M+H]+: 403.1751, found 403.1744. 
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A1.1 SYNTHETIC SUMMARY FOR BASILIOLIDE C AND EPI-
BASILIOLIDE C 
Scheme A1.1.1.  Retrosynthetic analysis for basiliolide C (12) and epi-basiliolide C (43). 
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Scheme A1.1.2.  Syntheses of basiliolide C (12) and epi-basiliolide C (43). 
 
OO
O
O
I
87
O
O
I
OH
O
TBSO
O
H
83
Ph3P
O
OMe
30
C6H6, 60 °C
(41% yield)
TBSO
84
OMe
O
DIBAL–H
Et2O, –78 °C
(89% yield)
TBSO
85
OH
1. Ac2O, pyridine
    0→23 °C
2. TBAF, THF
    0→23 °C
DCC, MeCN
0→23 °C
(94% yield)
(58% yield,
over 2 steps)
56
OAc
BSA, NEt3, PhMe
110→100 °C, 7.5 d
(65% yield,
1:2 dr at C8)
TBSCl, imidazole
DMF, 23 °C
(74% yield)
basiliolide C (12)
OMe
Bu3Sn
O
O
MeO
H
O
O
AcO
O
O
MeO
H
O
O
AcO
Pd(PPh3)4
DMF, 30 °C
(17% yield)
+
epi-basiliolide C (43)
62
HO
O
H
O
O
AcO
I
TBSO
O
H
O
O
AcO
I
88a (C8:  α−Me,  β−vinyl);
88b (C8:  β−Me,  α−vinyl)
89a (C8:  α−Me,  β−vinyl);
89b (C8:  β−Me,  α−vinyl)
HO
86
OAc
1:2 dr
Appendix 2–Comparison of Spectral Data for Synthetic and Reported Basiliolide C, 
as well as Biological Assays for Synthetic Transtaganolide C: Relevant to Chapter 1 
40 
 
 
 
 
APPENDIX 2 
Comparison of Spectral Data for Synthetic and Reported Basiliolide C, 
As well as Biological Assays for Synthetic Transtaganolide C: 
Relevant to Chapter 1 
 
Appendix 2–Comparison of Spectral Data for Synthetic and Reported Basiliolide C, 
as well as Biological Assays for Synthetic Transtaganolide C: Relevant to Chapter 1 
41 
A2.1 COMPARISON OF 1H NMR AND 13C NMR FOR SYNTHETIC AND 
REPORTED BASILIOLIDE C 
Table A2.1.1. Comparison of 1H NMR data for synthetic and reported natural1 basiliolide C (12). 
 
O
O
MeO
H
O
O
O
1
2 11
15
13
5
8
4
14
63 7
10
12
9
18
17 19
16
O20
21
Assignment Synthetic 12 (ppm) Multiplicity, J (Hz)
C2 6.05 6.06 dd, 6.4, 1.1
C3 3.29 3.29 d, 6.4
C4 — — —
C5 1.29 dd, 12.9, 4.6
C6 1.75 1.76 dddd, 13.8, 13.0, 12.9, 2.8
1.64–1.50 1.54 dddd, 13.8, 4.6, 3.9, 2.8
C7 1.93 1.94 ddd, 13.7, 3.9, 2.8
1.41 1.42 ddd, 13.7, 13.0, 2.8
1.32–1.24
C1 — ——
C9 3.14 3.15 s
C10 — — —
C11 7.00 7.00 dd, 17.7, 11.1
C12 5.17 dd, 11.0, 1.0
5.06 5.06 dd, 17.7, 1.0
C13 1.23 1.24 s
C14 1.12 1.12 s
C15 3.73 3.74 d, 10.8
5.16
C8 — ——
Multiplicity, J (Hz)Natural 12 (ppm)
C16 — — —
C17 5.00 5.01 d, 1.1
C18 — — —
C19 — — —
C20 — — —
C21 2.08 2.09 s
3.73 3.74 sOMe
3.69 3.70 d, 10.8
dd, 6.5, 1.2
d, 6.5
—
qd, 13.5, 3.0
m
dt, 13.5, 3.4
td, 13.5, 3.0
m
—
s
—
dd, 17.7, 11.1
dd, 17.7, 1.2
s
s
d, 10.8
dd, 11.1, 1.4
—
—
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—
—
—
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d, 10.8
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Table A2.1.2. Comparison of 13C NMR data for synthetic and reported natural1 basiliolide C (12). 
O
O
MeO
H
O
O
O
1
2 11
15
13
5
8
4
14
63 7
10
12
9
18
17 19
16
O20
21
Assignment Synthetic 12 (ppm)
C2 123.0 122.8
C3 49.8 49.7
C4 37.1 37.0
C5 44.7
C6 21.2 21.1
C7 40.3 40.2
44.8
C1 138.6138.6
C9 53.4 53.3
C10 87.0 86.9
C11 142.7 142.6
C12 112.3
C13 28.7 28.6
C14 19.8 19.6
C15 70.6 70.4
112.5
C8 38.438.6
Natural 12 (ppm)
C16 170.7 170.7
C17 79.2 79.0
C18 157.0 156.9
C19 162.4 162.3
C20 171.0 170.8
C21 20.9 20.7
56.6 56.4OMe
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A2.2 BIOACTIVITY OF SYNTHETIC TRANSTAGANOLIDE C 
Appendino, Muñoz, and coworkers assayed naturally isolated transtaganolide C (9) 
for its effect on calcium mobilization as well as cell viability following exposure to the 
natural product 9.2  To ensure the data obtained was not the result of trace thapsigargin 
(1) contamination in the isolation sample, we sent synthetic transtaganolide C (9) to be 
tested as a control.  Both calcium mobilization (Figure A2.2.1)3 and cell viability (Figure 
A2.2.2)3 assays were consistent with those observed with naturally isolated 
transtaganolide C (9). 
Figure A2.2.1.  A) Thapsigargin (1) and transtaganolide C (9).  B) The effect of synthetic 
transtaganolide C (9) or naturally isolated thapsigargin (1) on calcium mobilization as a function of 
time (arrows indicate the time at which a reagent was added).3 
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Figure A2.2.2.  Percentage of cells still viable after 24 hours of exposure to either synthetic 
transtaganolide C (9) or thapsigargin (1).3 
 
General procedure for calcium mobilization.  Jurkat cells were incubated for 1 h 
at 37 ºC in Tyrode’s salt solution (137 mM  NaCl, 2.7 mM KCl, 1.8 mM CaCl2, 1.0 mM 
MgCl2, 0.4 mM NaH2PO4, 12.0 mM NaHCO3, 5.6 mM  D-glucose) containing 5 µM 
Indo1-AM (Invitrogen) for 30 min at 37 °C in the dark.  Cells were then harvested, 
washed three times with buffer to remove extracellular Indo-1 dye, readjusted to 106 
cells/mL in the appropriate buffer, and analyzed in a spectrofluorimeter operated in the 
ratio mode (Hitachi F-2500 model, Hitachi Ltd.) under continuous stirring and at a 
constant temperature of 37 ºC using a water-jacketed device.  After 5 min for 
accommodation to equilibrate temperatures, samples were excited at 338 nm and 
emission was collected at 405 and 485 nm, corresponding to the fluorescence emitted by 
Ca2+-bound and free Indo-1, respectively.  [Ca2+]i was calculated using the ratio values 
between bound- and free-Indo-1 fluorescence, and assuming an Indo-1 Kd for Ca2+ of 
0.23 µM.  Maximum and minimum ratio values for calculations were determined by the 
addition at the end of the measurements of 10 µM ionomycin.  [Ca2+]i changes are 
presented as changes in the ratio of bound-to-free calcium (340 nm/380 nm).3 
General procedure for cell viability.  For cytotoxicity analysis, Jurkat cells were 
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transtaganolide C (9) or thapsigargin (1) at the indicated concentrations (μM) for 24 
hours.  Samples were then diluted with 300 μL of PBS and incubated for 1 min at 23 °C 
in the presence of propidium iodine (10 μg/ml).  After incubation, cells were immediately 
analyzed by flow cytometry.  The results are represented as the percentage of viability 
considering 100% viability for the untreated cells.3 
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Figure A3.1.2 infrared spectrum (Thin Film, NaCl) of compound 84. 
Figure A3.1.3 13C NMR (75 MHz, CDCl3) of compound 84. 
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Figure A3.2.2 infrared spectrum (Thin Film, NaCl) of compound 85. 
Figure A3.2.3 13C NMR (75 MHz, CDCl3) of compound 85. 
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Figure A3.3.2 infrared spectrum (Thin Film, NaCl) of compound 85.5. 
Figure A3.3.3 13C NMR (75 MHz, CDCl3) of compound 85.5. 
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Figure A3.4.2 infrared spectrum (Thin Film, NaCl) of compound 86. 
Figure A3.4.3 13C NMR (75 MHz, CDCl3) of compound 86. 
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Figure A3.5.2 infrared spectrum (Thin Film, NaCl) of compound 87. 
Figure A3.5.3 13C NMR (75 MHz, CDCl3) of compound 87. 
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Figure A3.6.2 infrared spectrum (Thin Film, NaCl) of compound 88a and 88b. 
Figure A3.6.3 13C NMR (75 MHz, CDCl3) of compound 88a and 88b. 
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Figure A3.7.2 infrared spectrum (Thin Film, NaCl) of compound 89a and 89b. 
Figure A3.7.3 13C NMR (75 MHz, CDCl3) of compound 89a and 89b. 
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Figure A3.8.2 infrared spectrum (Thin Film, NaCl) of basiliolide C (12). 
Figure A3.8.3 13C NMR (125 MHz, CDCl3) of basiliolide C (12). 
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Figure A3.9.2 infrared spectrum (Thin Film, NaCl) of epi-basiliolide C (43). 
Figure A3.9.3 13C NMR (125 MHz, CDCl3) of epi-basiliolide C (43). 
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CHAPTER 2 
Total Syntheses of (–)-Transtaganolide A, (+)-Transtaganolide B, 
(+)-Transtaganolide C, and (–)-Transtaganolide D and Biosynthetic 
Implications 
 
2.1 INTRODUCTION 
Enticed by the opportunity to prepare structurally novel and biologically relevant 
molecules, our group undertook extensive synthetic efforts that resulted in the 
development of a general strategy for the total syntheses of several transtaganolide1 
natural products (Figure 2.1.1, 9–11 ansd 42).2  Integral to this approach was an Ireland–
Claisen rearrangement/intramolecular pyrone Diels–Alder cyclization (ICR/DA) cascade3 
that furnished the stereochemically complex, tricyclic cores (92) in a single step from 
monocyclic, achiral precursors (91).  Additionally, a formal [5+2] annulation process 
forged the formidable C-ring (Scheme 2.1.1).2  While concise and modular, our initial 
approach fell short of achieving two key goals: 1) the preparation of enantioenriched 
products and 2) the synthesis of transtaganolides A (7) and B (8), the most complex 
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members of the natural product family.  Transtaganolides A (7) and B (8) are unique 
within their class due to their lack of an oxabicyclo[2.2.2]octene structural motif (Figure 
2.1.1, 7 and 8 vs. 9–11 and 42). In its place is a fused γ-lactone (E ring, 7 and 8), bridged 
by an ether linkage (D-ring) that contorts the pentacyclic core into a compact, caged 
structure (Figure 2.1.1 and Scheme 2.2.1, see boxed insert).  Strategies to overcome these 
synthetic challenges are presented herein, culminating in the enantioselective total 
syntheses of (–)-transtaganolide A (7) and (+)-transtaganolide B (8), which previously 
had eluded total synthesis.  Furthermore, (–)-transtaganolide C (9) and (+)-
transtaganolide D (10), which were previously prepared as racemates, have now been 
synthesized asymmetrically.  The absolute configurations of these compounds are also 
disclosed and discussed within the context of existing biosynthetic hypotheses.3b, 4 
Figure 2.1.1.  Transtaganolide and basiliolide natural products (7–11 and 42). 
 
Scheme 2.1.1.  General synthetic strategy. 
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2.2 RETROSYNTHETIC ANALYSIS 
Retrosynthetically, transtaganolides A (7) and B (8) could derive from iodo tetracycle 
93 by application of our [5+2] annulation strategy (Scheme 2.2.1).2  We envisioned that 
the tetracyclic core (93) could in turn arise from a translactonization/acetalization 
reaction of aldehyde-hydrate 94.  Tricycle 94 could be derived from an enantiospecific 
ICR/DA cascade of monocyclic precursor 95 with the requisite aldehyde oxidation state. 
Scheme 2.2.1.  Retrosynthetic analysis for the asymmetric construction of transtaganolides A (7) and 
B (8). 
 
In a similar fashion to that of transtaganolides A and B (7 and 8), enantioenriched 
transtaganolides C and D (9 and 10) could be prepared from tricycle 96, which could 
derive from a pyrone ester 97 by a stereocontrolled ICR/DA cascade reaction (Scheme 
2.2.2). 
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Scheme 2.2.2.  Retrosynthetic analysis for the asymmetric construction of transtaganolides C (9) and 
D (10). 
 
2.3 ENANTIOSELECTIVE TOTAL SYNTHESES OF TRANSTAGANOLIDES 
C AND D 
Our studies began with the application of this retrosynthetic analysis to 
transtaganolides C (9) and D (10) (Scheme 2.2.2).5  To impart asymmetry we turned to 
the early work of Ireland and co-workers.6  They demonstrated the efficient employment 
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treatment with stannane 62 and Pd(PPh3)4 yielded (+)-transtaganolide C (9) and (–)-
transtaganolide D (10). 
Scheme 2.3.1.  Enantioselective total syntheses of transtaganolides C and D (9 and 10). 
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2.4 SYNTHETIC STRATEGIES FOR THE TOTAL SYNTHESES OF 
TRANSTAGANOLIDES A AND B 
Having established the feasibility of the chiral geraniol derivative approach to setting 
the critical absolute stereochemistry in this series of natural products, we sought to 
prepare the transtaganolide A (7) and B (8) novel frameworks.  The most apparent path to 
this goal relies on the utilization of a chiral (Z)-enal such as 101 in our ICR/DA 
cyclization cascade to produce aldehydes 103a and 103b, which are predisposed by 
proximity to undergo the desired ring-chain tautomerism upon hydration (Scheme 2.4.1).  
However, we found that (Z)-enal 101 was challenging to prepare and configurationally 
unstable under myriad reaction conditions.8 
Scheme 2.4.1.  Initial attempts at preparing the tricyclic cores of transtaganolides A and B (103a and 
103b). 
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stable aldehyde surrogate.  Initial studies focused on preparing protected alcohol 109, 
which could be oxidized to the aldehyde following the ICR/DA cascade (Scheme 2.4.2).  
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Wadsworth–Emmons reaction of known γ,δ-unsaturated aldehyde 839 to form (Z)-
methylenoate 105 in 71% yield and excellent diastereoselectivity.10  DIBAL reduction of 
methylenoate 105 proceeded at –78 °C in 95% yield.  Acetate protection of alcohol 106 
followed by TBS deprotection furnished alcohol 108 in 67% yield over the two steps.  
Finally, coupling of alcohol 108 to iodo-acid 56 gave ICR/DA cascade substrate 109 in 
89% yield.  Upon submitting pyrone 109 to our standard ICR/DA cascade conditions 
formed tricycles 110a and 110b in a combined 54% yield and 2:1 dr, respectively.  
Cleavage of the acetate protecting group gave a mixture of alcohols 111a and 111b along 
with the translactonized products 112a and 112b.  For the purposes of characterization, 
the crude mixture could be stirred with Amberlyst 15 in Et2O to give solely the 
translactonized products 112a and 112b in 47% yield over the two steps.  Unfortunately 
all attempts to oxidize either alcohols 111a and 111b or the translactonized products 
112a and 112b proved fruitless and therefore we required a different approach to the 
transtaganolide A and B (7 and 8) natural product syntheses. 
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Scheme 2.4.2.  Studies for the transtaganolide A and B (7 and 8) tetracyclic core via protected 
alcohol 109. 
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with no loss of diastereoselectivity.  Subsequent TBAF deprotection of the TBS 
protecting group formed alcohol 114 in 77% yield.  Lastly, coupling to iodo-acid 56 
formed the desired ICR/DA substrate 115 in 75% yield.  Unfortunately, pyrone 115 did 
not successfully undergo the ICR/DA cascade.  For pyrone 115, the Ireland–Claisen 
rearrangement proceeded smoothly, forming silylesters 116a and 116b, but under the 
reaction conditions, even after one month of heating, no appreciable Diels–Alder product 
117a and 117b could be observed. 
Scheme 2.4.3.  Studies for the transtaganolide A and B (7 and 8) tetracyclic core via Weinreb amide 
115. 
 
Since the Weinreb amide bearing pyrone 117 was not a viable substrate for our 
ICR/DA cascade, we decided to attempt the ICR/DA with ester 119 and envisioned a 
HO
O
H
O
OI
TBSO THF, –20 °C
(92% yield)
OMeO
TBSO
113
NO
OMe
O
N
MeO
O
O
I
116a (C8: β−Me,  α−vinyl)
116b (C8: α−Me,  β−vinyl)
OTMSO
O
N
OMe
N
H
OMe
  •HCl,
i-prMgCl,
105
>25:1 Z:E
HO
114
NO
OMe
DCC, MeCN
0 °C
(75% yield)
O O
OH
O
I
56
O
O
I
115
TBAF
THF, 0 °C
(77% yield)
O
O
NO
OMe
BSA (2 equiv)
NEt3 (10 mol %)
PhMe, 100 ºC
117a (C8: β−Me,  α−vinyl)
117b (C8: α−Me,  β−vinyl)
8 8
Chapter 2–Total Syntheses of (–)-Transtaganolide A, (+)-Transtaganolide B, 
(+)-Transtaganolide C, and (–)-Transtaganolide D and Biosynthetic Implications 
75 
single hydride reduction to the aldehyde (Scheme 2.4.4).  Once again, the forward 
synthesis began with (Z)-methyl enoate 105.  Deprotection to form alcohol 118 
proceeded in 92% yield and subsequent coupling to iodo-acid 56 furnished the ICR/DA 
substrate 119 in 84% yield.  Submission of pyrone 119 to our standard ICR/DA cascade 
conditions for 13 days furnished tricycles 120a and 120b in a combined 69% yield and a 
2:1 mixture of diastereomers, respectively.  To our delight, single hydride reduction of 
tricycles 120a and 120b was accomplished at low temperature with DIBAL.  The crude 
aldehyde products 103a and 103b then underwent the desired translactonization event 
with an appropriate acid catalyst (i.e., Amberlyst 15) to form the transtaganolide A and B 
tetracyclic cores 121a and 121b in 47% yield over the two steps.  Having been able to 
successfully synthesize the transtaganolide A and B tetracyclic cores 121a and 121b, we 
turned our attentions toward accomplishing this feat asymmetrically. 
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Scheme 2.4.4.  Studies for the transtaganolide A and B (7 and 8) tetracyclic core via methylester 
119. 
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the Horner–Wadsworth–Emmons reaction allowed for formation of (Z)-methylenoate 125 
in 93% yield and excellent Z:E selectivity.10  Acetate deprotection of (Z)-methylenoate 
125 afforded alcohol 126 in 78% yield.  Efficient coupling of alcohol 126 to acid 56 
yielded the ICR/DA cascade substrate, pyrone ester 127.  Gratifyingly, prolonged heating 
of ester 127 in toluene with N,O-bis(trimethylsilyl)acetamide (BSA) in the presence of a 
catalytic amount of triethylamine afforded diastereomeric tricycles 128a and 128b in a 
combined 62% yield and as a 3:1 mixture of C8 diastereomers, respectively. 
Scheme 2.5.1.  Syntheses of enantioenriched tricyclic cores of transtaganolides A and B (128a and 
128b). 
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Remarkably, brief exposure of acids 128a and 128b to an excess of DIBAL-H at low 
temperature followed by careful quenching with acetic acid resulted in smooth, 
chemoselective ester reduction to furnish corresponding aldehydes 129a and 129b 
(Scheme 2.5.2).  Upon exposure of the crude aldehydes 129a and 129b to aqueous HBF4, 
the desired translactonization/acetalization proceeded and proteodesilylation occurred in 
one pot to yield caged tetracycles 121a and 121b.  Transient protection of the free acids 
(121a and 121b) as the TBS-esters (130a and 130b) in 67% yield, followed by 
application of our [5+2] annulation technology, allowed for the enantioselective 
syntheses of (+)-transtaganolide B (8) and (–)-transtaganolide A (7) in 35% combined 
yield and good optical purity. 
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Scheme 2.5.2.  Enantioselective total syntheses of transtaganolides A and B (7 and 8). 
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2.6 BIOSYNTHETIC IMPLICATIONS AND STEREOCHEMICAL 
ANALYSIS OF THE ENANTIOSELECTIVE TOTAL SYNTHESES OF 
TRANSTAGANOLIDES C AND D 
Recently, Johansson and co-workers have proposed that co-isolated basiliopyrone 3 is 
the direct biosynthetic precursor of transtaganolides C (9) and D (10) (Scheme 2.6.1).3b, 4  
They suggest that a rare naturally-occurring ester-enolate-Claisen rearrangement is 
responsible for the production of optically-pure transtaganolides. Enzymatically 
controlled Claisen processes are particularly uncommon, but are known, as in Chorismate 
mutase.13  Under this scenario, and assuming that the C9 proton is relatively acidic due to 
the withdrawing nature of the pyrone, it could be anticipated that an enzymatic and 
presumably enantioselective14 rearrangement would produce optically pure C9 
diastereomers 28 (with absolute stereocontrol at C8), while a non-enzymatically 
governed process would likely result in a racemic mixture of C9 diastereomers.  The 
demonstrated propensity of these systems to undergo diastereoselective Diels–Alder 
rearrangements under allylic strain control15 would lead to pseudo-enantiomeric 
transtaganolides C (9) and D (10).  Having prepared enantioenriched transtaganolides A–
D (7–10) via an analogous, synthetic enantioselective Ireland–Claisen rearrangement, we 
believe that determination of the absolute stereochemistries of the synthetic 
transtaganolides could provide insight into this biosynthetic hypothesis. 
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Scheme 2.6.1.  Johansson’s biosynthetic proposal. 
 
Hoppe has previously established the absolute stereochemistry of geraniol derivatives 
such as 99 prepared by (–)-sparteine mediated deprotonation as the (R)-enantiomer 
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and E-132.14  These proposed reaction pathways result in the formation of diastereomeric 
intermediates 100a/128a and 100b/128b. 
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Scheme 2.6.2.  Analysis of chiral silane directed ICR/DA cascade (where pyr = iodo pyrone). 
 
Acid 100a was converted to the corresponding methyl ester (133) by treatment with 
diazomethane, and anomalous dispersion analysis of a single crystal confirmed the 
hypothesized stereochemistry of 133 (Scheme 2.6.3).17  As 100a was advanced to (+)-
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transtaganolide C, we unambiguously assign its absolute structure as 9 (Scheme 2.3.1). 
Furthermore, by analogy we assigned (–)-transtaganolide D as 10 (Scheme 2.3.1), (–)-
transtaganolide A as 7, and (+)-transtaganolide B as 8 (Scheme 2.5.2). 
Scheme 2.6.3.  Determination of the absolute stereochemistry of intermediate 100a. 
 
The optical rotations obtained from synthetic and natural transtaganolides A–D (7–
10) are depicted in Table 2.6.1.1, 18  Interestingly, the synthetic transtaganolides uniformly 
rotate plane polarized light to a much greater extent than their naturally occurring 
counterparts.19  As demonstrated by our synthetic efforts, the Ireland–Claisen/Diels–
Alder cascade of prenylated pyrones similar to basiliopyrone (3) is a facile process: the 
metabolites may be biosynthetically derived from basiliopyrone (3), but without action of 
an enzymatic Claisen rearrangement. 
Table 2.6.1.  Comparison of the optical rotations of synthetic and natural transtaganolides A–D (7–
10). 
 
Furthermore, while the naturally occurring C8 diastereomeric pairs (e.g., 
transtaganolides C (9) and D (10)) rotate plane-polarized light with the same sign, the 
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samples derived from a synthetic, enantioselective Ireland–Claisen rearrangement rotate 
light with opposite sign (Table 2.6.1).  This data does not support the action of an 
enzymatic enolate-Claisen rearrangement, as metabolites resulting from this pathway 
would likely have analogous rotations to the synthetic transtaganolides (Scheme 2.6.1). 
Comparison of the natural compounds to the synthetic counterparts by chiral phase 
chromatography is needed before conclusions about the stereochemistry and 
enantiopurity of this series of natural products can be drawn.20  Unfortunately, it appears 
that there are no available samples of natural 7–10 for thorough comparison.  At this 
juncture, however, our optical data strongly suggest that basiliopyrone (3) is not a 
Claisenase substrate in the biosynthesis of transtaganolides C and D (9 and 10).  As 
previously proposed by Massanet and co-workers, basiliopyrone (3) can instead be 
viewed as a decomposition product of epoxide 24 or oxepine 27, which can be derived 
from co-isolated 7-O-geranylscopoletin (2) by oxidation (Scheme 2.6.4).4  Furthermore, 
these high energy intermediates (24 and 27) could undergo a series of non-enzymatic, 
pericyclic transformations to produce the natural products. 
Chapter 2–Total Syntheses of (–)-Transtaganolide A, (+)-Transtaganolide B, 
(+)-Transtaganolide C, and (–)-Transtaganolide D and Biosynthetic Implications 
85 
Scheme 2.6.4.  Proposed biosynthesis of basiliopyrone (3). 
 
2.7 CONCLUSION 
In conclusion, enantioenriched transtaganolides A–D (7–10) have been prepared by 
Ireland–Claisen/Diels–Alder cascade of chiral pyrone esters 97 or 127 that proceed with 
excellent stereofidelity.  Remarkably, all of the titled natural products were prepared in 
ten steps or less from a simple chiral geraniol derivative 99.  Single crystal X-ray 
diffraction studies of a synthetic intermediate have unambiguously determined the 
absolute stereochemistry of (+)-transtaganolide C (9).  By inference, the absolute 
stereochemistries of (–)-transtaganolide D (10), (–)-transtaganolide A (7), and (+)-
transtaganolide B (8) have been proposed.  Finally, analysis of optical rotation data does 
not support the role of a putative Claisenase in the biosynthesis of the transtaganolides. 
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2.8 EXPERIMENTAL SECTION 
2.8.1 MATERIALS AND METHODS 
Unless otherwise stated, reactions were performed in flame-dried glassware under an 
argon or nitrogen atmosphere using dry deoxygenated solvents.  Solvents were dried by 
passage through an activated alumina column under argon.  Chemicals were purchased 
from Sigma-Aldrich Chemical Company and used as received.  Pd(PPh3)4 was prepared 
using known methods.  Thin layer chromatography (TLC), both preparatory and 
analytical, was performed using E. Merck silica gel 60 F254 precoated plates (0.25 mm) 
and visualized by UV fluorescence quenching, p-anisaldehyde, I2, or KMnO4 staining. 
Analytical super critical fluid (SFC) chromatography was performed using a Thar SFC 
and either Chiralpak IA or AD-H columns.  Preparatory SFC was performed with a Jasco 
SFC and a prep AD-H column (21 x 250 mm, 5mic part# 19445).   ICN Silica gel 
(particle size 0.032–0.063 mm) was used for flash chromatography.  1H NMR and 13C 
NMR spectra were recorded on a Varian Mercury 300 (at 300 MHz) or on a Varian Unity 
Inova 500 (at 500 MHz).  1H NMR spectra are reported relative to CDCl3 (7.26 ppm).  
Data for 1H NMR spectra are reported as follows: chemical shift (ppm), multiplicity, 
coupling constant (Hz), and integration.  Multiplicities are reported as follows: s = 
singlet, d = doublet, t = triplet, q = quartet, sept. = septet, m = multiplet, bs = broad 
singlet, bm = broad multiplet.  13C NMR spectra are reported relative to CDCl3 (77.16 
ppm).  FTIR spectra were recorded on a Perkin Elmer SpectrumBX spectrometer and are 
reported in frequency of absorption (cm-1).  HRMS were acquired using an Agilent 6200 
Series TOF with an Agilent G1978A Multimode source in electrospray ionization (ESI), 
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atmospheric pressure chemical ionization (APCI), or multimode-ESI/APCI.  
Crystallographic data were obtained from the Caltech X-Ray Diffraction Facility. 
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2.8.2 PREPARATIVE PROCEDURES 
 
Enantioenriched allyl silane 99.  To a 23 °C solution of known diisopropyl geraniol 
carbamate6a (98, 519 mg, 1.84 mmol) in toluene (9.2 mL, 0.2M) was added freshly 
distilled (–)-sparteine (635 µL, 2.76 mmol) and TMSCl (352 µL, 2.76 mmol).  The 
solution was then cooled to –78 °C and a solution of 2.5M n-BuLi in hexanes (1.1 mL, 
2.76 mmol) was added dropwise.  The reaction was allowed to stir at –78 °C for 3 h.  The 
reaction was then quenched at –78 °C by slow addition of MeOH (250 µL) and allowed 
to warm to 23 °C.  The reaction was washed with saturated NH4Cl (2 x 10 mL).  Aqueous 
layers were combined and back extracted with Et2O (3 x 20 mL).  The combined organics 
were than washed with saturated brine (20 mL), dried over MgSO4, and concentrated by 
rotary evaporation.  This crude oil could be taken on without further purification.  
Purification, if desired, was done via column chromatography (EtOAc in hexanes 
2%→10% on silica) to yield 602 mg (92% yield) of allyl silane 134 as a colorless oil. 
Allyl silane 134 (2.36 g, 6.7 mmol) was dissolved in THF (67 mL, 0.1M with respect 
to substrate) and hexanes (40 mL, 1.0 M with respect to DIBAL-H) and cooled to 0 °C.  
To this 0 °C solution was slowly added neat DIBAL-H (7.1 mL, 40.2 mmol) dropwise.  
After the addition, the reaction was warmed to 23 °C and stirred for 6 h.  The reaction 
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was then cooled to 0 °C and slowly quenched with saturated aqueous Rochelle’s salt (35 
mL) with vigorous stirring.  After addition of Rochelle’s salt, the reaction was allowed to 
warm to 23 °C and celite (10 g) was added.  The suspension was vigorously stirred for 
another 5 min and then filtered through a small pad of celite.  The organic layer was 
collected, washed with saturated brine (35 mL), dried over MgSO4, and concentrated by 
rotary evaporation.  The crude oil could be taken on without further purification. If 
desired, purification was accomplished by column chromatography (EtOAc in hexanes 
2%→20% on silica) to yield 1.38 g (91% yield) of colorless oil 99.  [α]
€ 
D
20 = +69.71 (c 
1.00 in CHCl3).  Enantiomeric excess (ee) was determined for 97 inferred for 99.  All 
other spectral data matches the literature.7a 
 
 
Pyrone ester 97.  To a solution of enantioenriched geraniol derivative 99 (202 mg, 
0.89 mmol) in MeCN (9 mL, 0.1 M) at 0 °C was added sequentially pyrone acid 56 (300 
mg, 1.07 mmol) and DCC (221 mg, 1.07 mmol).  After 20 min at 0 °C, the reaction was 
filtered through a small pad of celite washing with MeCN.  The filtrate was collected and 
concentrated by rotary evaporation and the crude oil was purified by column 
chromatography (EtOAc in hexanes 2%→10% on silica) to yield 384 mg (88% yield) of 
ICR/DA precursor 97 as a colorless oil; 1H NMR (500 MHz, CDCl3) δ 7.46 (d, J = 9.7 
Hz, 1H), 6.06 (d, J = 9.7 Hz, 1H), 5.42 (d, J = 10.4 Hz, 1H), 5.14 (dq, J = 10.4, 1.2 Hz, 
HO
SiMe3
99
90% ee
DCC, MeCN
0 °C
(88% yield)
O O
OH
O
I
56
O
O
I
97
O O SiMe3
Chapter 2–Total Syntheses of (–)-Transtaganolide A, (+)-Transtaganolide B, 
(+)-Transtaganolide C, and (–)-Transtaganolide D and Biosynthetic Implications 
90 
1H), 5.04 (tm, J = 6.2, 1H), 3.76 (s, 2H), 2.16 – 2.00 (m, 4H), 1.66 (d, J = 1.4 Hz, 6H), 
1.59 (d, J = 1.2 Hz, 3H), 0.01 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 166.6, 160.6, 
158.6, 151.4, 138.0, 131.8, 124.1, 120.9, 116.1, 70.5, 69.7, 43.1, 40.0, 26.6, 25.9, 17.9, 
17.0, –3.7; FTIR (Neat Film NaCl) 2959, 2923, 2854, 1741, 1607, 1546, 1445, 1404, 
1382, 1336, 1293, 1273, 1249, 1206, 1170, 1134, 1062, 1016, 960, 908, 842, 819, 750 
cm-1; HRMS (Multimode-ESI/APCI) m/z calc’d for C20H28IO4Si [M–H]–: 487.0807, 
found 487.0821. 
90% ee; SFC conditions: 3.0% IPA, 2.5mL/min, AD-H column, tR (min): major = 
7.02, minor = 7.79.  A portion of this material was then separated by preparatory chiral 
SFC to obtain >99% ee material; [α]
€ 
D
20 = +69.71 (c 1.00, CHCl3, >99% ee). 
Figure 2.8.1.  Racemic SFC trace of compound 97. 
 
Figure 2.8.2.  Enantioenriched SFC trace of compound 97. 
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Vinyl silanes 100a and 100b.  To a 23 °C solution of pyrone ester 97 (384 mg, 0.79 
mmol) in toluene (4 mL, 0.2M) in a 500 mL sealed tube was added N,O-
bis(trimethylsilyl)acetamide (BSA) (384 µL, 1.58 mmol) and NEt3 (11 µL, 0.08 mmol).  
The reaction mixture was heated to 110 °C and stirred for 20 min.  The solution was then 
cooled to 23 °C and diluted with toluene (450 mL), leaving ample headspace in the 
sealed tube to allow for solvent expansion.  The reaction mixture was then re-heated to 
100 °C and stirred for 4 d until complete as determined by NMR analysis.  The reaction 
mixture was then cooled to 23 °C and 0.02% HCl(aq) (20 mL) was added, after which the 
reaction mixture was stirred vigorously for 1 min.  The organic phase was then separated 
and washed with 0.02% HCl(aq) (3 x 25 mL), making sure the aqueous phase remained 
acidic.  The aqueous phases were then combined and back extracted with ethyl acetate (3 
x 30 mL) and all organic phases were combined, dried with Na2SO4, and concentrated by 
rotary evaporation.  The crude oil was purified by column chromatography (Et2O in 
hexanes with 0.1% AcOH, 10%→20% on silica) to yield 294 mg (77% yield) of a 3:1 
diastereomeric mixture of ICR/DA products 100a and 100b as white solids. 
Major (100a): 1H NMR (300 MHz, CDCl3) δ 6.94 (d, J = 6.9 Hz, 1H), 6.12 (d, J = 
18.9 Hz, 1H), 5.64 (d, J = 18.9 Hz, 1H), 3.01 (s, 1H), 2.97 (d, J = 6.9 Hz, 1H), 1.72–1.21 
(m, 5H), 1.28 (s, 3H), 1.08 (s, 3H), 1.00 (s, 3H), 0.07 (s, 9H); 13C NMR (125 MHz, 
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CDCl3) δ 173.6, 170.8, 155.4, 140.2, 125.3, 98.0, 84.7, 59.3, 56.7, 48.1, 41.3, 38.2, 36.9, 
29.9, 24.6, 20.8, 18.5, –1.0. 
Minor (100b): 1H NMR (300 MHz, CDCl3) δ 6.94 (d, J = 6.8 Hz, 1H), 6.44 (d, J = 
19.2 Hz, 1H), 5.68 (d, J = 19.2 Hz, 1H), 2.95 (d, J = 6.8 Hz, 1H), 2.95 (s, 1H) 1.96 (dt, J 
= 13.5, 3.1 Hz, 2H), 1.72–1.21 (m, 3H), 1.31 (s, 3H), 1.04 (s, 3H), 0.99 (s, 3H), 0.06 (s, 
9H); 13C NMR (125 MHz, CDCl3) δ 173.4, 169.9, 148.0, 140.5, 127.8, 97.5, 84.8, 61.2, 
56.8, 47.9, 40.5, 38.1, 37.0, 29.7, 24.6, 20.7, 18.5, –1.1. 
FTIR (Neat Film NaCl) 3075, 3014, 2955, 2671, 2545, 1755, 1713, 1612, 1464, 1455, 
1415, 1397, 1386, 1373, 1338, 1286, 1246, 1218, 1174, 1133, 1103, 1048, 1016, 990, 
967, 932, 903, 867, 838, 796, 757 cm-1; HRMS (Multimode-ESI/APCI) m/z calc’d for 
C20H30IO4Si [M+H]+: 489.0953, found 489.0952; [α]
€ 
D
20 = +13.28 (c 2.00, CHCl3, 90% ee 
of 100a, 81% ee of 100b); SFC conditions: 15.0% IPA, 2.5 mL/min, IA column, tR(min): 
100a) major = 4.85, minor = 5.64; 100b) minor = 4.05, major = 6.05. 
Figure 2.8.3.  Racemic SFC trace of compounds 100a and 100b. 
 
Chapter 2–Total Syntheses of (–)-Transtaganolide A, (+)-Transtaganolide B, 
(+)-Transtaganolide C, and (–)-Transtaganolide D and Biosynthetic Implications 
93 
Figure 2.8.4.  Enantioenriched SFC trace of compounds 100a and 100b. 
 
 
 
Iodo acids 58a and 58b.  To a 23 °C solution of vinyl silanes 100a and 100b (36.5 
mg, 0.075 mmol) in MeCN (1.5 mL, 0.05M) was added HBF4(aq) (48% w/w, 75 µL, 0.60 
mmol).  The reaction was stirred for 4.5 h and then diluted with ethyl acetate (15 mL).  
The organic layer was then washed with 0.02% HCl(aq) (3 x 5 mL).  The aqueous phases 
were combined and back extracted with ethyl acetate (3 x 5 mL).  The combined organic 
phases were dried over Na2SO4 and concentrated by rotary evaporation.  Purification by 
column chromatography (EtOAc in hexanes with 0.1% AcOH, 5%→30% on silica) 
yielded 27.5 mg (89% yield) of a 4:1 diastereomeric mixture of the desilylated tricycles 
58a and 58b as white solids.  [α]
€ 
D
20  = +42.73 (c 1.00 in CHCl3).  All other spectral data 
matches the literature.2 
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TBS-esters 63a and 63b.  To a 23 °C solution of iodo acids 58a and 58b (46 mg, 
0.11 mmol,) in DMF (300 µL, 0.35M) were added sequentially imidazole (76 mg, 1.1 
mmol) and TBSCl (84 mg, 0.55 mmol).  The reaction was warmed to 40 °C and then 
stirred for 12 h.  The solution was then diluted with saturated brine (1 mL) and extracted 
with Et2O/hexane (1:1) (3 x 2 mL).  The combined organic extracts were washed with 
saturated aqueous KHSO4 (1 mL) and then with saturated brine (3 x 1 mL).  The 
combined organics were dried over Na2SO4, and concentrated by rotary evaporation.  The 
crude oil was purified by column chromatography (EtOAc in hexanes 10%→50% on 
silica) to yield 39 mg (66% yield) of a 4:1 mixture of diastereomers 63a and 63b as white 
powders.  [α]
€ 
D
20  = +41.42 (c 1.00 in CHCl3).  All other spectral data matches the 
literature.2 
 
 
Transtaganolides C and D (9 and 10).  In a nitrogen filled glovebox, to a solution of 
esters 63a and 63b (13 mg, 0.026 mmol) and Pd(PPh3)4 (33 mg, 0.029 mmol) in DMF 
HO O
O
O
H
I
HO O
O
O
H
I
TBSCl, imidazole
   DMF, 40 °C, 12 h
(66% yield)
+
58a 58b
58a and 58b = 4:1 dr
O OTBS
O
O
H
I
O OTBS
O
O
H
I
+
63a 63b
63a and 63b = 4:1 dr
(+)-transtaganolide C
(9)
Pd(PPh3)4, DMF
30 °C, 14 h;
then  pH 7 buffer
(31% yield)
OMe
Bu3Sn 62
O
O
MeO
H
O
O
(–)-transtaganolide D
(10)
O
O
MeO
H
O
O
9 and 10 = 2:1 dr
+
O OTBS
O
O
H
I
O OTBS
O
O
H
I
+
63a 63b
63a and 63b = 4:1 dr
Chapter 2–Total Syntheses of (–)-Transtaganolide A, (+)-Transtaganolide B, 
(+)-Transtaganolide C, and (–)-Transtaganolide D and Biosynthetic Implications 
95 
(260 µL, 0.1 M) was added tributyl(2-methoxyethynyl)stannane (62) (34 mg, 0.104 
mmol). The reaction was stirred at 30 °C for 14 h.  The reaction mixture was then filtered 
through a Kimwipe plug with Et2O (1.0 mL) (this removes a large excess of the 
undissolved Pd(PPh3)4) and removed from the glovebox.  Outside of the glovebox, the 
added Et2O was removed by rotary evaporation, and the reaction was diluted with MeCN 
(15 mL).  To this solution was then added pH 7 phosphate buffer (200 µL) and the 
reaction was stirred vigorously at 23 °C for 2 h.  Upon completion, MeCN was removed 
by rotary evaporation and the remaining aqueous solution was diluted with EtOAc (4 
mL).  This was then washed with water (3 x 1 mL) and the combined aqueous washes 
were back extracted with EtOAc (2 x 1 mL).  All organics were pooled, dried with 
Na2SO4, and concentrated by rotary evaporation. The crude oil was purified by normal 
phase HPLC to yield 1.7 mg (20% yield) of transtaganolide C (9) and 0.9 mg (11% yield) 
of transtaganolide D (10) as white powders. 
Transtaganolide C (9): 1H NMR (500 MHz, CDCl3) δ 6.07 (dd, J = 1.5, 6.5 Hz, 1H), 
5.80 (dd, J = 11.0, 17.5 Hz, 1H), 5.07 (d, J = 17.5 Hz, 1H), 5.03 (d, J = 11.0 Hz, 1H), 
5.00 (d, J = 1.5 Hz, 1H), 3.71 (s, 3H), 3.23 (s, 1H), 3.06 (d, J = 6.5 Hz, 1H), 1.71–1.63 
(m, 3H), 1.60 (s, 3H), 1.44 (m, 1H), 1.30 (m, 1H), 1.08 (s, 3H), 0.97 (s, 3H); 13C NMR 
(125 MHz, CDCl3) δ 171.8, 162.3, 156.7, 146.5, 138.0, 123.6, 112.8, 87.3, 79.3, 56.3, 
53.8, 50.6, 48.1, 38.4, 38.3, 33.3, 29.9, 24.8, 19.9, 19.2; FTIR (Neat Film NaCl) 2965, 
2928, 2872, 1791, 1761, 1668, 1619, 1456, 1334, 1267, 1233, 1178, 1115, 970, 954, 828 
cm-1; HRMS (Multimode-ESI/APCI) m/z calc’d for C20H24O5 [M+H]+: 345.1697, found 
345.1703; [α]
€ 
D
20 = +120.73 (c 0.42, CHCl3, 96% ee); SFC conditions: 8.0% IPA, 2.5 
mL/min, AD-H column, tR(min): major = 12.19, minor = 13.15. 
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Figure 2.8.5.  Racemic SFC trace of transtaganolide C (9). 
 
Figure 2.8.6.  Enantioenriched SFC trace of transtaganolide C (9). 
 
Transtaganolide D (10): 1H NMR (500 MHz, CDCl3) δ 7.00 (dd, J = 11.0, 17.5 Hz, 
1H), 6.09 (dd, J = 1.0, 6.5 Hz, 1H), 5.15 (dd, J = 1.0, 11.0 Hz, 1H), 5.05 (dd, J = 1.0, 
17.5 Hz, 1H), 5.02 (d, J = 1.0 Hz, 1H), 3.73 (s, 3H), 3.13 (s, 1H), 3.06 (d, J = 6.5 Hz, 
1H), 1.91 (dt, J = 3.5, 13.5 Hz, 1H), 1.64 (dquint, J = 3.0, 13.5 Hz, 1H), 1.58 (m, 1H), 
1.39 (dt, J = 3.5, 13.5 Hz, 1H), 1.33 (dd, J = 4.5, 13.5 Hz, 1H), 1.22 (s, 3H), 1.04 (s, 3H), 
0.97 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 171.7, 162.6, 156.7, 142.9, 137.7, 123.9, 
112.1, 87.3, 79.4, 56.3, 54.0, 53.3, 48.4, 40.5, 38.4, 33.3, 29.9, 28.5, 24.8, 20.5; FTIR 
(Neat Film NaCl) 2964, 2929, 2872, 1764, 1760, 1738, 1667, 1620, 1467, 1334, 1267, 
1235, 1195, 1177, 1106, 1009, 954, 827 cm-1; HRMS (Multimode-ESI/APCI) m/z calc’d 
for C20H24O5 [M+H]+: 345.1697, found 345.1698; [α]
€ 
D
20  = –51.55 (c 0.17, CHCl3,        
92% ee); SFC conditions: 6.0% IPA, 2.5 mL/min, AD-H column, tR(min): minor = 25.49, 
major = 28.77. 
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Figure 2.8.7.  Racemic SFC trace of transtaganolide D (10). 
 
Figure 2.8.8.  Enantioenriched SFC trace of transtaganolide D (10). 
 
 
 
(Z)-methylenoate 105.  To a –78 °C solution of KHMDS (2.92 g, 14.6 mmol) in 
THF (170 mL) was added a solution of phosphonate reagent 104 (4.46 g, 13.4 mmol) and 
18-crown-6 (6.45 g, 24.4 mmol) in THF (50 mL).  After stirring the reaction mixture for 
10 min at –78 °C, a solution of aldehyde 83 (2.96 g, 12.2 mmol) in THF (50 mL) was 
added.  This brings the total volume of THF to 270 mL, which is a 0.05M solution with 
respect to the Still-Gennari Reagent 104.  The reaction was stirred at –78 °C for 20 min 
and then quenched with a saturated NH4Cl solution (100 mL) at –78 °C.  After allowing 
the reaction mixture to warm to 23 °C, the organic layer was washed with saturated 
NH4Cl (2 x 100 mL).  Aqueous layers were combined and back extracted with Et2O (2 x 
TBSO
O
H
83 O
P
O
O OMe
O
F3CF3C 104
KHMDS
18-crown-6
THF, –78 °C
(71% yield)
105
>25:1 Z:E
TBSO
O OMe
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150 mL).  The combined organic layers were washed with saturated brine (300 mL), 
dried over MgSO4, and concentrated by rotary evaporation.  Purification was 
accomplished by column chromatography (EtOAc in hexanes 2%→10% on silica) to 
yield 2.72 g (71% yield) >25:1, Z:E of enoate 105 as a colorless oil; 1H NMR (500 MHz, 
CDCl3) δ 5.92 (tq, J = 7.3, 1.5 Hz, 1H), 5.32 (tq, J = 6.3, 1.3 Hz, 1H), 4.18 (dq, J = 6.3, 
0.9 Hz, 2H), 3.73 (s, 3H), 2.61–2.55 (m, 2H), 2.11–2.07 (m, 2H), 1.88 (q, J = 1.5 Hz, 
3H), 1.62 (d, J = 1.3 Hz, 3H), 0.89 (s, 9H), 0.06 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 
168.6, 143.0, 136.2, 127.1, 125.2, 60.4, 51.4, 39.1, 27.8, 26.1, 20.8, 18.5, 16.3, –4.9; 
FTIR (Neat Film NaCl) 2953, 2930, 2896, 2857, 1721, 1671, 1648, 1472, 1461, 1435, 
1383, 1362, 1254, 1214, 1197, 1130, 1106, 1087, 1065, 1006, 837, 776 cm-1; HRMS 
(ESI) m/z calc’d for C17H32O3SiNa [M+Na]+: 335.2020, found 335.2013. 
 
 
Alcohol 106.  To a –78 °C solution of (Z)-methylenoate 105 (1.76 g, 5.63 mmol) in 
Et2O (28 mL, 0.2M) was added DIBAL–H (2.50 mL, 14.1 mmol) dropwise.  The reaction 
mixture was then stirred at –78 °C for 45 min.  The reaction mixture was then slowly 
quenched by the dropwise addition of saturated aqueous Rochelle’s salt (20 mL) at –78 
°C.  The reaction was then allowed to warm to ambient temperature and stirred 
vigorously for 1 h.  The aqueous layer was separated from the organics and extracted 
with Et2O (4 x 15).  The organics were combined and dried over MgSO4.  Solvent was 
evaporated by rotary evaporation and purification by column chromatography (EtOAc in 
105
>25:1 Z:E
TBSO
O OMe
DIBAL–H
Et2O, –78 °C
(95% yield) 106
TBSO
OH
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hexanes 3.5%→15% on silica) resulted in the isolation of 1.52 g (95% yield) of alcohol 
106 as a colorless oil; 1H NMR (300 MHz, CDCl3) δ 5.30–5.20 (m, 2H), 4.16 (dq, J = 
6.5, 0.8 Hz, 2H), 4.07 (s, 2H), 2.16 (q, J = 7.5, 2H), 2.00 (t, J = 7.3, 2H), 1.78 (q, J = 1.2 
Hz, 3H), 1.62 (d, J = 1.4 Hz, 3H), 0.90 (s, 9H), 0.07 (s, 6H); 13C NMR (75 MHz, CDCl3) 
δ 136.7, 135.2, 127.4, 125.0, 61.5, 60.3, 39.4, 26.1, 25.8, 21.3, 18.6, 16.5, –5.0; FTIR 
(Neat Film NaCl) 3346, 2956, 2930, 2885, 2857, 1472, 1463, 1382, 1361, 1255, 1110, 
1066, 1006, 836, 814, 776 cm-1; HRMS (ESI) m/z calc’d for C16H32O2SiNa [M+Na]+: 
307.2064, found 307.2070. 
 
 
Acetate 107.  To a 0 °C solution of alcohol 106 (473 mg, 1.66 mmol) in pyridine (3.5 
mL, 0.5 M) was added acetic anhydride (780 µL, 8.32 mmol) dropwise.  The reaction 
was then warmed to ambient temperature and stirred for 3 h.  Following reaction 
completion the mixture was diluted with Et2O (25 mL) and washed with saturated 
aqueous CuSO4 (2 x 10 mL), saturated aqueous NaHCO3 (2 x 10 mL), saturated aqueous 
CuSO4 (1 x 10 mL), and lastly saturated brine (1 x 15 mL).  The organic mixture was 
then dried over MgSO4, concentrated by rotary evaporation, and purified by column 
chromatography (EtOAc in hexanes 1% on silica) to give 466 mg (86% yield) of acetate 
107 as a colorless oil; 1H NMR (300 MHz, CDCl3) δ 5.41–5.35 (m, 1H), 5.30 (tq, J = 6.3, 
1.3 Hz, 1H), 4.57 (s, 2H), 4.18 (dq, J = 6.3, 0.9 Hz, 2H), 2.19 (q, J = 7.3 Hz, 2H), 2.07 (s, 
3H), 2.06–1.98 (m, 2H), 1.74 (q, J = 1.3 Hz, 3H), 1.61 (d, J = 1.3 Hz, 3H), 0.90 (s, 9H), 
106
TBSO
OH
Ac2O
pyridine
0→23 °C
(86% yield)
107
TBSO
OAc
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0.07 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 171.3, 136.3, 130.4, 130.1, 125.1, 63.3, 60.4, 
39.6, 26.2, 26.1, 21.6, 21.1, 18.6, 16.4, –4.9; FTIR (Neat Film NaCl) 2951, 2929, 2856, 
1740, 1472, 1457, 1381, 1363, 1230, 1110, 1065, 1024, 982, 835, 775 cm-1; HRMS (ESI) 
m/z calc’d for C18H34O3SiH [M+H]+: 327.2350, found 327.2348. 
 
 
Alcohol 108.  To a 0 °C solution of acetate 107 (312 mg, 0.955 mmol) in THF (5 mL, 
0.2 M) was added a 1 M solution of TBAF in THF (1.45 mL, 1.45 mmol).  The reaction 
mixture was then stirred at 0 °C at for 2 h.  After 2 h the reaction appeared to have 
stalled, so another equiv of 1 M TBAF solution (1 mL, 1 mmol) was added and the 
reaction stirred at 0 °C for an additional hour.  The reaction mixture was quenched at 0 
°C by the addition of saturated aqueous NH4Cl (5 mL) and then allowed to warm to 
ambient temperature.  The aqueous phase was then extracted with Et2O (3 x 5 mL), the 
organics were combined, and subsequently washed with saturated brine (1 x 20 mL).  The 
organics were then dried over MgSO4, concentrated by rotary evaporation, and purified 
by column chromatography (EtOAc in hexanes 5%→20% on silica) to give 159 mg (78% 
yield) of alcohol 108 as a colorless oil; 1H NMR (300 MHz, CDCl3) δ 5.45–5.30 (m, 2H), 
4.56 (s, 2H), 4.13 (d, J = 6.9 Hz, 2H), 2.19 (q, J = 7.4 Hz, 2H), 2.06 (s, 3H), 2.08–2.00 
(m, 2H), 1.73 (s, 3H), 1.65 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 171.3, 139.0, 130.2, 
130.2, 124.0, 63.3, 59.4, 39.5, 26.1, 21.5, 21.1, 16.4; FTIR (Neat Film NaCl) 3420, 2972, 
2922, 2858, 1734, 1672, 1448, 1368, 1233, 1100, 1022, 955, 916 cm-1; HRMS (ESI) m/z 
calc’d for C12H20O3Na [M+Na]+: 235.1305, found 235.1296. 
107
TBSO
OAc
TBAF, THF
0 °C, 3h
(78% yield) 108
HO
OAc
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Pyrone ester 109.  To a 0 °C solution of alcohol 108 (173 mg, 814 mmol) in MeCN 
(8.15 mL, 0.1M) was added sequentially iodo-acid 56 (274 mg, 0.977 mmol) and DCC 
(202 mg, 0.977 mmol).  The reaction mixture was stirred at 0 °C for 30 min.  The still 
cold reaction was then filtered through a small pad of celite with MeCN to remove excess 
urea byproduct.  The organics were then concentrated by rotary evaporation and purified 
by column chromatography (EtOAc in hexanes 6%→12% on silica) to give 344 mg (89% 
yield) of pyrone ester 109 as a yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.46 (d, J = 9.7 
Hz, 1H), 6.07 (d, J = 9.7 Hz, 1H), 5.38–5.30 (m, 2H), 4.66 (d, J = 7.2 Hz, 2H), 4.56 (s, 
2H), 3.77 (s, 2H), 2.19 (q, J = 7.0 Hz, 2H), 2.10–2.02 (m, 2H) 2.06 (s, 3H), 1.74 (d, J = 
1.4 Hz, 3H), 1.69 (dd, J = 1.4, 0.6 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ 171.3, 166.8, 
160.5, 158.0, 151.4, 142.7, 130.4, 129.9, 118.1, 116.3, 70.8, 63.2, 62.7, 42.7, 39.5, 26.0, 
21.6, 21.1, 16.7; FTIR (Neat Film NaCl) 2966, 2937, 2853, 1732, 1606, 1548, 1445, 
1372, 1344, 1328, 1277, 1234, 1165, 1133, 1063, 1016, 959, 867, 821, 767, 728 cm-1; 
HRMS (ESI) m/z calc’d for C19H23IO6Na [M+Na]+: 497.0432, found 497.0413. 
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Tricycles 110a and 110b.  To a 23 °C solution of pyrone ester 109 (93 mg, 0.197 
mmol) in toluene (1.21 mL, 0.17 M) in a 100 mL sealed tube was added BSA (118 µL, 
0.484 mmol) and NEt3 (3.4 µL, 0.024 mmol).  The reaction mixture was heated to 110 °C 
and stirred for 20 min.  The mixture was then cooled to 23 °C and diluted with toluene 
(75 mL).  The reaction mixture was then re-heated to 100 °C and stirred for 6 d until 
completion, which was determined after monitoring by NMR.  The reaction mixture was 
then cooled to 23 °C, a 1% aqueous solution of AcOH was added (5 mL), and the 
reaction was stirred for an additional 2 min.  The reaction was washed with a 1% aqueous 
solution of AcOH (3 x 20 mL), and the aqueous phases were combined and back 
extracted with EtOAc (3 x 30 mL), while making sure the pH of the aqueous phase 
remained acidic.  The organics were combined, dried over Na2SO4 and solvent was 
removed by rotary evaporation.  Purification by column chromatography (EtOAc in 
hexanes with 0.1% AcOH, 17%→25% on silica) to give 51 mg (54% yield) of a 2:1 
mixture of ICR/DA diastereomers 110a and 110b as a white solid. 
Major (110a): 1H NMR (300 MHz, CDCl3) δ 6.95 (d, J = 7.0 Hz, 1H), 6.00 (dd, J = 
17.5, 10.6 Hz, 1H), 5.13–5.00 (m, 2H), 4.03 (dd, J = 100.4, 11.5 Hz, 2H), 3.30 (d, J = 7.0 
Hz, 1H), 3.00 (s, 1H), 2.08 (s, 3H), 2.02–1.33 (m, 5H), 1.30 (s, 3H), 1.02 (s, 3H); 13C 
O
O
I
109
O O
AcO
BSA (2 equiv)
NEt3 (10 mol %)
PhMe, 100 ºC
6 d
(54% yield)
HO O
O
O
H
I
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110b (C8: α−Me,  β−vinyl)
110a and 110b = 2:1 dr
OAc
Chapter 2–Total Syntheses of (–)-Transtaganolide A, (+)-Transtaganolide B, 
(+)-Transtaganolide C, and (–)-Transtaganolide D and Biosynthetic Implications 
103 
NMR (125 MHz, CDCl3) δ 173.0, 170.7, 169.8, 147.9, 139.5, 111.8, 99.2, 84.3, 67.7, 
59.3, 51.8, 48.8, 40.0, 39.9, 38.2, 24.8, 20.9, 19.0, 18.4. 
Minor (110b): 1H NMR (300 MHz, CDCl3) δ 6.95 (d, J = 7.0 Hz, 1H), 6.32 (dd, J = 
17.5, 11.0 Hz, 1H), 5.13–5.00 (m, 2H), 4.20–3.81 (m, 2H), 3.29 (d, J = 6.9 Hz, 1H), 2.94 
(s, 1H), 2.07 (s, 3H), 2.02–1.33 (m, 5H), 1.36 (s, 3H), 1.01 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ 173.1, 170.7, 169.8, 140.4, 139.9, 113.8, 98.7, 84.5, 67.7, 60.8, 51.9, 48.8, 
40.2, 39.5, 38.6, 29.9, 20.9, 19.0, 18.4. 
FTIR (Neat Film NaCl) 3084, 2970, 2932, 2668, 1746, 1455, 1377, 1338, 1315, 1234, 
1173, 1124, 1047, 1019, 967, 914, 839, 800, 733 cm-1; HRMS (Multimode-ESI/APCI) 
m/z calc’d for C19H23IO6H [M+H]+: 475.0612, found 475.0595. 
 
 
Tricycles 112a and 112b.  To a 0 °C solution of tricycles 110a and 110b (24 mg, 
0.051 mmol) in MeOH (2.5 mL, 0.02 M) was added K2CO3 (30 mg, 0.024 mmol).  The 
reaction mixture was then stirred for 2 h at 0 °C.  Upon completion of the desired 
deprotection, the reaction mixture was quenched at 0 °C by the dropwise addition of 
glacial AcOH until the solution had become acidic, as was ascertained by pH paper.  
Once acidic, the reaction mixture was concentrated by rotary evaporation to remove the 
MeOH, and then re-dissolved in EtOAc (5 mL).  The organic solution was then washed 
HO O
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I
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with a 1% aqueous solution of AcOH (3 x 5 mL), and the aqueous phases were combined 
and back extracted with EtOAc (2 x 15 mL), while making sure the pH of the aqueous 
phase remained acidic.  The organics were combined, dried over Na2SO4 and solvent was 
removed by rotary evaporation to give a crude mixture of alcohols 111a and 111b along 
with translactonized products 112a and 112b.  For the purposes of characterization, the 
crude mixture of 111a, 111b, 112a, and 112b was dissolved in Et2O (3 mL) and stirred at 
23 °C over Amberlyst 15 (30 mg) for 12 h.  This allowed for complete conversion of 
alcohols 111a and 111b to the translactonized products 112a and 112b.  The reaction 
mixture was then filtered through a short pad of celite to remove the Amberlyst 15 resin 
with EtOAc.  Solvent was removed by rotary evaporation and subsequent purification by 
column chromatography (EtOAc in hexanes with 0.1% AcOH, 17%→25% on silica) to 
give 10 mg (47% yield) of a 2:1 mixture of tricycles 112a and 112b as a white solid. 
Major (112a): 1H NMR (300 MHz, CDCl3) δ 6.74 (d, J = 7.3 Hz, 1H), 5.91 (dd, J = 
17.3, 10.8 Hz, 1H), 5.60 (bs, 1H), 5.05–4.95 (m, 3H), 3.89 (d, J = 9.0 Hz, 1H), 2.98 (d, J 
= 7.2 Hz, 1H), 2.55 (s, 1H), 2.20–1.74 (m, 2H), 1.72–1.40 (m, 3H), 1.28 (s, 3H), 1.25 (s, 
3H); 13C NMR (125 MHz, CDCl3) δ 179.6, 176.1, 148.1, 136.3, 111.8, 109.8, 76.1, 74.8, 
59.7, 53.4, 51.2, 41.1, 38.8, 38.7, 29.8, 20.0, 19.5. 
Minor (112b): 1H NMR (300 MHz, CDCl3) δ 6.76 (d, J = 7.7 Hz, 1H), 6.44 (dd, J = 
17.6, 10.8 Hz, 1H), 5.60 (bs, 1H), 5.08–4.94 (m, 3H), 3.87 (d, J = 9.1 Hz, 1H), 2.98 (d, J 
= 7.2 Hz, 1H), 2.53 (s, 1H), 2.20–1.74 (m, 2H), 1.72–1.40 (m, 3H), 1.31 (s, 3H), 1.28 (s, 
3H); 13C NMR (125 MHz, CDCl3) δ 179.8, 176.1, 141.7, 136.7, 113.4, 109.5, 76.1, 74.9, 
61.8, 53.4, 51.8, 40.8, 40.3, 38.8, 29.9, 28.5, 19.5. 
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FTIR (Neat Film NaCl) 3362, 3083, 2962, 2923, 2877, 1760, 1690, 1460, 1397, 1379, 
1307, 1245, 1205, 1173, 1150, 1090, 1061, 1033, 986, 909, 826, 731 cm-1; HRMS 
(Multimode-ESI/APCI) m/z calc’d for C17H21IO5Na [M+Na]+: 455.0326, found 455.0323. 
 
 
Weinreb amide 113.  To a –20 °C solution of (Z)-methylenoate 105 (340 mg, 1.09 
mmol) in THF (11 mL, 0.1 M) was added sequentially N,O-dimethylhydroxyamine 
hydrochloride (165 mg, 1.69 mmol) and the slow addition of 2 M isopropylmagnesium 
chloride solution in THF (1.63 mL, 3.26 mmol) dropwise.  The reaction mixture was then 
warmed to 0 °C and stirred for 3 h.  The reaction was then quenched with saturated 
aqueous NH4Cl (2.6 mL) at 0 °C and allowed to warm to ambient temperature.  Upon 
reaching 23 °C, water was added (10 mL) and the aqueous phase separated and back 
extracted with Et2O (4 x 15 mL).  The organics were combined, washed with saturated 
brine (40 mL), dried over Na2SO4, and concentrated by rotary evaporation.  Purification 
was accomplished by column chromatography (EtOAc in hexanes 2.5%→10% on silica) 
to give 340 mg (92% yield) of Weinreb amide 113 as a colorless oil; 1H NMR (500 MHz, 
CDCl3) δ 5.39 (tq, J = 7.3, 1.6 Hz, 1H), 5.29 (tq, J = 6.3, 1.3 Hz, 1H), 4.17 (d, J = 6.3 Hz, 
2H), 3.65 (bs, 3H), 3.23 (s, 3H), 2.13 (q, J = 7.8, 7.4 Hz, 2H), 2.08–2.02 (m, 2H), 1.88 (s, 
3H), 1.59 (s, 3H), 0.89 (s, 9H), 0.05 (s, 6H); 13C NMR (125 MHz, CDCl3) δ 172.0, 136.0, 
131.5, 129.7, 124.9, 61.5, 60.2, 38.9, 32.1, 27.8, 26.0, 20.0, 18.4, 16.2, -5.1; FTIR (Neat 
Film NaCl) 2955, 2930, 2897, 2857, 1652, 1472, 1462, 1414, 1382, 1255, 1180, 1111, 
TBSO THF, –20 °C
(92% yield)
OMeO
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1088, 1063, 1004, 836, 776 cm-1; HRMS (ESI) m/z calc’d for C18H35NO3SiNa [M+Na]+: 
364.2278, found 364.2283. 
 
 
Alcohol 114.  To a 0 °C solution of Weinreb amide 113 (217 mg, 0.635 mmol) in 
THF (6.35 mL, 0.1 M) was slowly added a 1 M TBAF solution in THF (1.27 mL, 1.27 
mmol).  The reaction mixture was then stirred at 0 °C for 4 h.  After the reaction had 
gone to completion, saturated aqueous NH4Cl (1 mL) was added at 0 °C and the reaction 
was warmed to ambient temperature.  Water (4 mL) was then added, the aqueous phase 
was separated from the organics, and the aqueous phase was back extracted with EtOAc 
(3 x 6 mL).  The organics were combined, washed with saturated brine (15 mL), dried 
over Na2SO4, and concentrated by rotary evaporation.  Purification was accomplished by 
column chromatography (EtOAc in hexanes 17% → hexanes in EtOAc 20% on silica) to 
give 111 mg (77% yield) of alcohol 114 as a colorless oil; 1H NMR (300 MHz, CDCl3) δ 
5.42–5.33 (bm, 2H), 4.10 (d, J = 7.1 Hz, 2H), 3.65 (bs, 3H), 3.22 (s, 1H), 2.18–1.98 (m, 
5H), 1.89 (s, 3H), 1.64 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 172.0, 137.5, 131.4, 
129.4, 124.5, 61.5, 58.7, 38.6, 31.9, 27.9, 19.9, 16.1; FTIR (Neat Film NaCl) 3420, 2970, 
2935, 2856, 1633, 1440, 1384, 1346, 1325, 1180, 1150, 1103, 1079, 997, 898, 845, 752 
cm-1; HRMS (ESI) m/z calc’d for C12H21NO3Na [M+Na]+: 250.1414, found 250.1405. 
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Pyrone 115.  To a 0 °C solution of alcohol 114 (92 mg, 0.405 mmol) in MeCN (4 
mL, 0.1M) was added sequentially iodo-acid 56 (136 mg, 0.486 mmol) and DCC (100 
mg, 0.486 mmol).  The reaction was stirred at 0 °C for 30 min.  The still cold reaction 
was then filtered through a small pad of celite with MeCN to remove excess urea 
byproduct.  The solution was then concentrated by rotary evaporation and purified by 
column chromatography (EtOAc in hexanes 20%→35% on silica) to give 149 mg (75% 
yield) of pyrone 115 as a yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.46 (d, J = 9.7 Hz, 
1H), 6.07 (d, J = 9.7 Hz, 1H), 5.41–5.29 (bm, 2H), 4.65 (d, J = 7.1 Hz, 2H), 3.77 (s, 2H), 
3.66 (bs, 3H), 3.23 (s, 3H), 2.20–2.05 (m, 5H), 1.89 (s, 3H), 1.69 (s, 3H); 13C NMR (126 
MHz, CDCl3) δ 166.6, 160.3, 157.8, 151.3, 142.4, 131.9, 129.2, 118.0, 116.1, 70.7, 62.5, 
61.6, 42.6, 38.9, 27.7, 20.1, 16.5; FTIR (Neat Film NaCl) 2969, 2934, 2853, 1742, 1641, 
1608, 1546, 1452, 1383, 1344, 1327, 1278, 1205, 1169, 1133, 1088, 1064, 1017, 994, 
926, 868, 823, 752 cm-1; HRMS (Multimode-ESI/APCI) m/z calc’d for C19H24INO6H 
[M+H]+: 490.0721, found 490.0761. 
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Attempt at tricycle 117a and 117b.  To a 23 °C solution of pyrone 115 (44 mg, 0.09 
mmol) in toluene (450 µL, 0.2 M) in a 50 mL sealed tube was added BSA (44 µL, 0.18 
mmol) and NEt3 (1.0 µL, 0.007 mmol).  The reaction mixture was heated to 110 °C and 
stirred for  20 min to form Ireland–Claisen products 116a and 116b.  The mixture was 
then cooled to 23 °C and diluted with toluene (30 mL).  The reaction mixture was then 
re-heated to    100 °C and stirred indefinitely, and no Diels–Alder product 117a and 117b 
could be observed by NMR even after one month of heating at 100 °C. 
 
 
Alcohol 118.  To a 0 °C solution of (Z)-methylenoate 105 (108 mg, 0.346 mmol) in 
THF (3.5 mL, 0.1 M) was added dropwise a 1 M solution of TBAF in THF (415 µL, 
0.415).  The reaction was stirred at 0 °C for 2 h.  After 2 h more 1 M solution of TBAF in 
THF (200 µL, 0.200 mmol) was added and the reaction was stirred for 1 h at 0 °C.  The 
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reaction was quenched by the addition of water (3 mL) at 0 °C and the mixture was 
stirred and allowed to warm to ambient temperature.  The aqueous phase was separated 
and back extracted with Et2O (3 x 2 mL) and the organics were combined.  The combined 
organics were washed with saturated brine (8 mL), concentrated by rotary evaporation, 
and purified by column chromatography (EtOAc in hexanes 5%→20% on silica) to give 
63 mg (92% yield) of alcohol 118 as a singly isomeric colorless oil; 1H NMR (300 MHz, 
CDCl3) δ 5.91 (tq, J = 7.3, 1.5 Hz, 1H), 5.42 (tp, J = 6.8, 1.3 Hz, 1H), 4.15 (d, J = 6.9 Hz, 
2H), 3.73 (s, 3H), 2.63–2.54 (m, 2H), 2.11 (td, J = 7.6, 1.0 Hz, 2H), 1.89 (q, J = 1.4 Hz, 
3H), 1.67 (dd, J = 1.4, 0.6 Hz, 3H); 13C NMR (125 MHz, CDCl3) δ 168.6, 142.5, 139.0, 
127.4, 124.2, 59.5, 51.4, 39.1, 27.8, 20.8, 16.3; FTIR (Neat Film NaCl) 3365, 2951, 2917, 
2853, 1704, 1651, 1457, 1362, 1196, 1128, 1085, 1015, 881, 822, 772 cm-1; HRMS (ESI) 
m/z calc’d for C11H18O3H [M+H]+: 199.1329, found 199.1331. 
 
 
Pyrone ester 119.  To a 0 °C solution of alcohol 118 (198 mg, 1.00 mmol) in MeCN 
(10 mL, 0.1 M) was added sequentially iodo-acid 56 (337 mg, 1.20 mmol) and DCC (248 
mg, 1.20 mmol).  The reaction mixture was stirred at 0 °C for 30 min.  The still cold 
reaction was then filtered through a small pad of celite with MeCN to remove excess urea 
byproduct.  The organics were then concentrated by rotary evaporation and purified by 
column chromatography (EtOAc in hexanes 9%→12% on silica) to give 386 mg (84% 
HO
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(84% yield)
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yield) of pyrone ester 119 as a yellow oil; 1H NMR (300 MHz, CDCl3) δ 7.46 (d, J = 9.7 
Hz, 1H), 6.07 (d, J = 9.7 Hz, 1H), 5.90 (tq, J = 7.3, 1.5 Hz, 1H), 5.35 (tq, J = 7.1, 1.4 Hz, 
1H), 4.67 (d, J = 7.1 Hz, 2H), 3.77 (s, 2H), 3.73 (s, 3H), 2.59 (q, J = 7.6 Hz, 2H), 2.13 (t, 
J = 7.6 Hz, 2H), 1.89 (s, 3H), 1.71 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 168.4, 166.8, 
160.5, 158.1, 151.4, 142.7, 142.5, 127.4, 118.2, 116.3, 70.8, 62.7, 51.4, 42.7, 39.0, 27.7, 
20.8, 16.6; FTIR (Neat Film NaCl) 3080, 3054, 2975, 2950, 2925, 2857, 1731, 1606, 
1548, 1446, 1403, 1367, 1347, 1277, 1243, 1205, 1163, 1131, 1087, 1063, 1045, 1016, 
962, 867, 821, 770, 727 cm-1; HRMS (ESI) m/z calc’d for C18H21IO6H [M+H]+: 461.0456, 
found 461.0444. 
 
 
Tricyclic acids 120a and 120b.  To a 23 °C solution of pyrone ester 119 (218 mg, 
0.474 mmol) in toluene (2.03 mL, 0.233 M) in a 500 mL sealed tube was added BSA 
(231 µL, 0.948 mmol) and NEt3 (5.00 µL, 0.047 mmol).  The reaction mixture was 
heated to 110 °C and stirred for 20 min.  The mixture was then cooled to 23 °C and 
diluted with toluene (250 mL).  The reaction mixture was then re-heated to 100 °C and 
stirred for 13 d, until completion, which was determined after monitoring by NMR.  The 
reaction mixture was then cooled to 23 °C and 0.02% HCl(aq) (20 mL) was added and the 
mixture stirred vigorously for 1 min.  The organic phase was then separated and washed 
with 0.02% HCl(aq) (3 x 25 mL).  Aqueous phases were then combined and back extracted 
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with ethyl acetate (3 x 30 mL).  The organic phases were combined, dried with Na2SO4, 
and concentrated by rotary evaporation.  The crude oil was purified by column 
chromatography (EtOAc in hexanes with 0.1% AcOH, 5%→30% on silica) to yield 151 
mg (69% yield) of a 2:1 mixture of ICR/DA diastereomers 120a and 120b as a white 
solid. It is important to note that compounds 120a and 120b, and all subsequent 
compounds: 103a, 103b, 121a, and 121b have very poor solubility in most common 
organic solvents excluding EtOAc.  Therefore all transfers of products 120a, 120b, 103a, 
103b, 121a, and 121b should be accomplished using EtOAc and vessels should be 
repeatedly washed. 
Major (120a): 1H NMR (500 MHz, CDCl3) δ 6.95 (d, J = 7.0 Hz, 1H), 5.99 (dd, J = 
17.2, 10.8 Hz, 1H), 5.09–4.99 (m, 2H), 3.73 (s, 3H), 3.36 (d, J = 7.0 Hz, 1H), 2.95 (s, 
1H), 1.90–1.38 (m, 5H), 1.28 (s, 3H), 1.26 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 173.5, 
173.0, 168.9, 147.8, 139.7, 111.8, 99.9, 83.7, 59.2, 52.7, 51.4, 49.5, 49.2, 40.2, 38.0, 24.5, 
20.7, 18.6. 
Minor (120b): 1H NMR (500 MHz, CDCl3) δ 6.95 (d, J = 7.0 Hz, 1H), 6.34 (dd, J = 
17.4, 11.0 Hz, 1H), 5.09–4.99 (m, 2H), 3.71 (s, 3H), 3.36 (d, J = 7.0 Hz, 1H), 2.90 (s, 
1H), 1.90–1.38 (m, 5H), 1.35 (s, 3H), 1.26 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 173.4, 
173.0, 168.8, 140.3, 140.0, 113.9, 99.4, 83.9, 60.7, 52.7, 51.5, 49.7, 49.3, 39.6, 38.6, 29.6, 
24.5, 20.8. 
FTIR (Neat Film NaCl) 3083, 2950, 1770, 1732, 1713, 1456, 1434, 1413, 1381, 1309, 
1277, 1237, 1165, 1115, 969, 934, 911, 872, 731 cm-1; HRMS (Multimode-ESI/APCI) 
m/z calc’d for C18H21IO6Na [M+Na]+: 483.0275, found 483.0261. 
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Tetracyclic acetals 121a and 121b.  It is important to note that the selective single 
hydride reduction of the methyl esters of tricyclic acids 120a and 120b was only made 
possible using a glass cannula, as it allows for the precise temperature control necessary 
to effect the transformation on such a complex molecule bearing many electrophilic 
carbonyl functionalities (Figure 2.8.9).  A solution of acids 120a and 120b (25 mg, 0.055 
mmol) in toluene (550 µL, 0.1M) was stirred in the receiving chamber of the glass 
cannula at –78 °C (the entire glass cannula is placed in a –78 °C bath submerging both 
chambers and the cannula itself).  A freshly made 1M solution of DIBAL-H (270 µL, 
0.270 mmol) in toluene was added to the addition chamber of the glass cannula, further 
diluted with toluene (500 µL), and stirred at –78 °C.  Once both solutions and the entire 
glass cannula were sufficiently cooled, the –78 °C solution of DIBAL-H was slowly 
added to acids 120a and 120b dropwise.  The reaction was stirred for 10 min and then 
slowly quenched by a –78 °C solution of AcOH (100 µL) in toluene (1.5 mL) via the 
addition chamber of the glass cannula.  Once complete, the reaction vessel was removed 
from the –78 °C bath, allowed to warm to 23 °C, and then diluted with ethyl acetate (10 
mL).  The solution was washed with a 1% aqueous solution of AcOH (3 x 2 mL) and the 
aqueous phases were combined and back extracted with ethyl acetate (2 x 2 mL).  All 
organic phases were pooled, dried over Na2SO4, and concentrated by rotary evaporation 
120a and 120b = 2:1 dr
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to give 21 mg (90% crude yield) of the desired aldehydes 103a and 103b as an orange-
brown solid.  103a and 103b were used immediately in the following step without further 
purification. 
Figure 2.8.9.  Reaction schematic for the single hydride reduction of tricyclic acids 120a and 120b 
using a glass cannula. 
 
To a 23 °C solution of the crude aldehyde products 103a and 103b (21 mg, 0.049 
mmol) in benzene (10 mL, 0.005 M) was added Amberlyst 15 (25 mg).  The reaction was 
stirred for at 23 °C for 3 h and then filtered through a small pad of celite with EtOAc to 
remove the Amberlyst 15 resin.  The organics were then washed with pH 2–3 water 
(0.02% HCl solution) (3 x 3 mL), and the aqueous phases were back extracted with ethyl 
acetate (2 x 6 mL).  All organics were combined, dried over Na2SO4, and concentrated by 
rotary evaporation. Purification was accomplished by column chromatography (EtOAc in 
hexanes with 0.1% AcOH, 5%→30% on silica) to yield 11 mg (47% yield over two 
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steps) of a 2:1 mixture of the reduced, cyclized, and diastereomers 121a and 121b as a 
yellow solid. 
Major (121a): 1H NMR (500 MHz, CDCl3) δ 6.69 (d, J = 5.8 Hz, 1H), 6.03 (dd, J = 
17.3, 10.8 Hz, 1H), 5.75 (s, 1H), 5.10 (d, J = 10.8 Hz, 1H), 5.04 (d, J = 17.4 Hz, 1H), 
3.08 (d, J = 5.9 Hz, 1H), 2.92 (s, 1H), 2.21–2.14 (m, 1H), 1.97–1.38 (m, 4H), 1.36 (s, 
3H), 1.19 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 173.1, 169.5, 147.1, 136.1, 112.3, 
108.9, 107.3, 87.1, 61.5, 54.7, 49.1, 48.8, 39.7, 36.2, 20.1, 18.8, 15.9. 
Minor (121b): 1H NMR (500 MHz, CDCl3) δ 6.69 (d, J = 5.9 Hz, 1H), 6.07 (dd, J = 
17.5, 11.1 Hz, 1H), 5.67 (s, 1H), 5.12 (d, J = 11.1 Hz, 1H), 5.08 (d, J = 17.5 Hz, 1H), 
3.07 (d, J = 5.9 Hz, 1H), 2.88 (s, 1H), 2.21–2.14 (m, 1H), 1.97–1.38 (m, 4H), 1.36 (s, 
3H), 1.33 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 173.2, 169.7, 139.5, 136.3, 114.6, 
108.8, 107.0, 87.1, 63.1, 54.7, 49.3, 48.8, 39.4, 36.3, 29.6, 20.0, 15.8. 
FTIR (Neat Film NaCl) 3300, 3077, 3007, 2958, 2933, 2873, 1785, 1748, 1708, 1456, 
1375, 1286, 1239, 1217, 1199, 1182, 1157, 1115, 1083, 1046, 1034, 992, 964, 957, 910, 
895, 873, 829, 814, 796, 752 cm-1; HRMS (Multimode-ESI/APCI) m/z calc’d for 
C17H20IO5 [M+H]+: 431.0350 found 431.0359; [α]  = +18.71 (c 0.94 in CHCl3). 
 
 
Allyl acetate 122.  To a 0 °C solution of 99 (256 mg, 1.13 mmol) in pyridine (11 mL, 
0.1M) was added acetic anhydride (534 µL, 5.65 mmol).  The reaction was allowed to 
warm to 23 °C and was stirred for 6 h.  The solution was then diluted with ethyl acetate 
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(30 mL) and quenched with saturated NaHCO3 (10 mL).  The organic layer was washed 
with saturated aqueous CuSO4 (4 x 10 mL) until the dark blue color no longer persisted in 
the aqueous phase.  This was followed by another saturated NaHCO3 wash (10 mL), a 
brine wash (10 mL), and then drying over MgSO4.  Concentration by rotary evaporation 
gave a crude, colorless oil, which could be taken on without further purification.  
Purification, if desired, was by column chromatography (EtOAc in hexanes 2→10% on 
silica) to yield 260 mg (86% yield) of allyl acetate 122 as a colorless oil; 1H NMR (300 
MHz, CDCl3) δ 5.42 (d, J = 10.4 Hz, 1H), 5.16 (dm J = 10.4 Hz, 1H), 5.10–5.00 (m, 1H), 
2.18–1.94 (m, 7H), 1.66 (s, 6H), 1.59 (s, 3H), 0.02 (s, 9H); 13C NMR (125 MHz, CDCl3) 
δ 171.1, 137.0, 131.7, 124.2, 121.7, 67.6, 40.0, 26.6, 25.9, 21.4, 17.9, 17.0, –3.7; FTIR 
(Neat Film NaCl) 2962, 2927, 2856, 1737, 1443, 1368, 1290, 1248, 1237, 1158, 1109, 
1014, 957, 842, 750 cm-1; HRMS (ESI) m/z calc’d for C15H29O2Si [M]+: 268.1859, found 
268.1863; [α]
€ 
D
20 = +49.50 (c 1.00 in CHCl3). 
 
 
Epoxide 123.  To a –78 °C solution of allyl acetate 122 (260 mg, 0.97 mmol) in 
CH2Cl2 (10 mL, 0.1M) was added m-CPBA (max 77% by weight) (240 mg, 1.07 mmol).  
The reaction was warmed to 0 °C and stirred for 30 min until complete, as determined by 
TLC analysis. The reaction was quenched with 10% aqueous Na2SO3 (5 mL) at 0 °C.  
The organic layer was then separated from the aqueous and washed again with 10% 
Na2SO3 (5 mL).  The combined aqueous layers were then combined and back extracted 
with CH2Cl2 (3 x 10 mL).  The combined organic layers were washed with saturated 
m-CPBA, CH2Cl2
–78→0 °C
(78% yield)
AcO
SiMe3
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AcO
SiMe3
123
O
Chapter 2–Total Syntheses of (–)-Transtaganolide A, (+)-Transtaganolide B, 
(+)-Transtaganolide C, and (–)-Transtaganolide D and Biosynthetic Implications 
116 
NaHCO3 (15 mL), brine (15 mL), and dried over MgSO4.  Concentration by rotary 
evaporation gave a crude oil, which was purified by column chromatography (EtOAc in 
hexanes 2%→10% on silica) to yield 215 mg (78% yield) of 123 as a colorless oil and a 
1:1 mixture of diastereomers; 1H NMR (500 MHz, CDCl3) δ 5.40 (d, J = 10.3 Hz, 1H), 
5.21 (d, J = 10.3, 1H), 2.69 (td, J = 6.5, 5.3 Hz, 1H), 2.24–2.05 (m, 2H), 2.02 (s, 3H), 
1.71–2.05 (m, 3H), 1.68–1.56 (m, 2H), 1.30–1.24 (m, 6H), 0.02 (s, 9H); 13C NMR (125 
MHz, CDCl3) δ 171.04, 171.02, 136.3, 136.2, 122.2, 122.1, 67.4, 64.1, 58.49, 58.48, 
36.64, 36.56, 27.7, 27.5, 25.03, 25.00, 21.3, 18.9, 18.8, 17.1, 16.9, –3.6; FTIR (Neat Film 
NaCl) 2960, 2928, 1736, 1732, 1446, 1377, 1369, 1323, 1291, 1248, 1238, 1123, 1046, 
1015, 958, 842, 795, 751, 718 cm-1; HRMS (ESI) m/z calc’d for C15H28O3SiNa [M+Na]+: 
307.1700, found 307.1706; [α]
€ 
D
20  = +34.03 (c 1.00 in CHCl3). 
 
 
Aldehyde 124.  To a solution of epoxide 123 (244 mg, 0.86 mmol) in THF (8.6 mL, 
0.1M) and water (4.8 mL, 0.18M) at 0 °C was added periodic acid (391 mg, 1.72 mmol).  
The reaction was stirred for 7 h, diluted with Et2O (25 mL), and quenched with saturated 
NaHCO3 (10 mL).  The aqueous layer was then separated from the organic and back 
extracted with Et2O (2 x 10 mL).  The combined organics were washed with saturated 
brine (3 x 15 mL), dried over MgSO4, and concentrated by rotary evaporation.  
Purification by column chromatography (EtOAc in hexanes 5%→25% on silica) yielded 
161 mg (77% yield) of aldehyde 124 as a colorless oil; 1H NMR (300 MHz, CDCl3) δ 
periodic acid
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9.74 (t, J = 1.7 Hz, 1H), 5.37 (d, J = 10.3 Hz, 1H), 5.18 (d, J = 10.3, 1H), 2.58–2.47 (m, 
2H), 2.41–2.28 (m, 2H), 2.01 (s, 3H), 1.68 (s, 3H), 0.00 (s, 9H); 13C NMR (75 MHz, 
CDCl3) δ 202.1, 171.0, 134.9, 122.7, 67.3, 42.2, 32.0, 21.3, 17.1, –3.7; FTIR (Neat Film 
NaCl) 3432, 2958, 2902, 2823, 2720, 2479, 2113, 1732, 1415, 1368, 1291, 1248, 1142, 
1115, 1046, 1016, 958, 842, 769, 752, 718 cm-1; HRMS (ESI) m/z calc’d for 
C12H22O3SiNa [M+Na]+: 265.1230, found 265.1232; [α]
€ 
D
20 = +41.93 (c 1.00 in CHCl3). 
 
 
(Z)-Enone 125.  To a –78 °C solution of KHMDS (35 mg, 0.18 mmol) in THF (2 
mL) was added a solution of phosphonate reagent 104 (53.5 mg, 0.16 mmol) and 18-
crown-6 (193.5 mg, 0.73 mmol) in THF (600 µL).  After stirring the reaction mixture for 
10 min at –78 °C, a solution of aldehyde 124 (35.5 mg, 0.15 mmol) in THF (600 µL) was 
added.  This brings the total volume of THF to 3.2 mL, which is a 0.05M solution with 
respect to the Still-Gennari Reagent 104.  The reaction was stirred at –78 °C for 20 min 
and then quenched with a saturated NH4Cl solution (1 mL) at –78 °C.  After allowing the 
reaction mixture to warm to 23 °C, it was diluted with Et2O (10 mL) and washed with 
saturated NH4Cl (1 x 3 mL).  Aqueous layers were combined and back extracted with 
Et2O (2 x 3 mL).  The combined organic layers were washed with saturated brine (10 
mL), dried over MgSO4, and concentrated by rotary evaporation.  Purification was 
accomplished by column chromatography (EtOAc in hexanes 2%→10% on silica) to 
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O OMe
O
F3CF3C 104
AcO
O
SiMe3
124
H
KHMDS
18-crown-6
THF, –78 °C
(93% yield)
AcO
SiMe3
125
>25:1 Z:E
OMeO
Chapter 2–Total Syntheses of (–)-Transtaganolide A, (+)-Transtaganolide B, 
(+)-Transtaganolide C, and (–)-Transtaganolide D and Biosynthetic Implications 
118 
yield 42.5 mg (93% yield) >25:1, Z:E of enone 125 as a colorless oil; 1H NMR (300 
MHz, CDCl3) δ 5.88 (t, J = 7.2 Hz, 1H), 5.39 (d, J = 10.3 Hz, 1H), 5.17 (d, J = 10.5 Hz, 
1H), 3.72 (s, 3H), 2.58 (q, J = 7.5 Hz, 2H), 2.11 (t, J = 7.3 Hz, 2H), 2.02 (s, 3H), 1.88–
1.85  (m, 3H), 1.67–1.66 (m, 3H), 0.01 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 168.4, 
143.0, 136.3, 127.2, 122.3, 67.4, 51.3, 39.4, 27.9, 21.3, 20.8, 16.9, –3.7; FTIR (Neat Film 
NaCl) 2954, 2928, 2855, 1722, 1649, 1453, 1434, 1368, 1289, 1248, 1238, 1199, 1131, 
1104, 1085, 1015, 958, 842, 769, 751 cm-1; HRMS (ESI) m/z calc’d for C16H28O4SiNa 
[M+Na]+: 335.1649, found 335.1648; [α]
€ 
D
20 = +49.43 (c 1.00 in CHCl3). 
 
 
Alcohol 126.  To a 23 °C solution of (Z)-enone 125 (143 mg, 0.46 mmol) in MeOH 
(10 mL, 0.05M) was added K2CO3 (32 mg, 0.23 mmol). The resulting suspension was 
then stirred for 2.5 d until complete deprotection was observed by TLC.  Following 
completion, the reaction was diluted with Et2O (100 mL) and washed with water (2 x 75 
mL).  The combined aqueous washes were back extracted with Et2O (3 x 75 mL).  The 
organic phases were combined, washed with saturated brine (100 mL), dried over 
MgSO4, and concentrated by rotary evaporation.  Purification was accomplished by 
column chromatography (EtOAc in hexanes 5%→10% on silica) to yield 96 mg (78%) of 
>25:1, Z:E of alcohol 126 as a colorless oil; 1H NMR (300 MHz, CDCl3) δ 5.89 (t, J = 
7.3 Hz, 1H), 5.27 (d, J = 10.1 Hz, 1H), 4.16 (d, J = 10.1 Hz, 1H), 3.71 (s, 3H), 2.63–2.52 
(m, 2H), 2.11 (t, J = 7.3 Hz, 2H), 1.88–1.84 (m, 3H), 1.58 (d, J = 1.2 Hz, 3H), 0.01 (s, 
AcO
SiMe3
O OMe
MeOH, K2CO3
(78% yield)
125
>25:1 Z:E
HO
SiMe3
O OMe
126
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9H); 13C NMR (75 MHz, CDCl3) δ 168.5, 142.9, 134.3, 127.2, 126.9, 64.5, 51.4, 39.5, 
28.0, 20.8, 16.7, –4.0; FTIR (Neat Film NaCl) 3424, 2953, 2928, 2854, 1719, 1648, 
1454, 1437, 1382, 1366, 1331, 1246, 1198, 1129, 1083, 1032, 978, 856, 841, 791, 749 
cm-1; HRMS (ESI) m/z calc’d for C14H26O3SiNa [M+Na]+: 293.1543, found 293.1538; [α]
€ 
D
20  = +56.83 (c 1.00 in CHCl3). 
 
 
Pyrone ester 127.  To a 0 °C solution of alcohol 126 (297 mg, 1.10 mmol) in MeCN 
(11mL, 0.1M) were added sequentially pyrone acid 56 (339 mg, 1.21 mmol) and DCC 
(250 mg, 1.21 mmol).  After 20 min at 0 °C the reaction was filtered through a short pad 
of celite, washing with MeCN.  The filtrate was collected and concentrated by rotary 
evaporation.  The crude oil was purified by column chromatography (EtOAc in hexanes 
2%→10% on silica) to yield 534 mg (91% yield) of pyrone ester 127 as a yellow oil; 1H 
NMR (300 MHz, CDCl3) δ 7.46 (d, J = 9.7 Hz, 1H), 6.06 (d, J = 9.7 Hz, 1H), 5.88 (t, J = 
7.2 Hz, 1H), 5.41 (d, J = 10.4 Hz, 1H), 5.16 (d, J = 10.4 Hz, 1H), 3.76 (s, 2H), 3.73 (s, 
3H), 2.59 (td, J = 7.3, 7.2 Hz, 2H), 2.13 (t, J = 7.3 Hz, 2H), 1.87 (d, J = 1.4 Hz, 3H), 1.67 
(d, J = 1.3 Hz, 3H), 0.01 (s, 9H); 13C NMR (75 MHz, CDCl3) δ 166.6, 160.5, 158.5, 
151.4, 142.9, 137.3, 127.2, 121.5, 116.1, 70.5, 69.6, 51.4, 43.1, 39.4, 27.9, 20.9, 16.9, –
3.7; FTIR (Neat Film NaCl) 2953, 2923, 2854, 1742, 1648, 1607, 1546, 1451, 1434, 
1405, 1382, 1365, 1336, 1249, 1202, 1172, 1131, 1085, 1062, 1016, 960, 842, 764, 751, 
DCC, MeCN
0 °C
(91% yield)
O O
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O
I
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729 cm-1; HRMS (Multimode-ESI/APCI) m/z calc’d for C21H28IO6Si [M–H]–: 531.0705, 
found 531.0712; [α]
€ 
D
20  = +17.79 (c 1.00 in CHCl3). 
 
 
Vinyl silane 128a and 128b.  To a 23 °C solution of pyrone ester 127 (298 mg, 0.56 
mmol) in toluene (2.8 mL, 0.2M) in a 500 mL sealed tube was added BSA (274 µL, 1.12 
mmol) and NEt3 (8 µL, 0.06 mmol).  The reaction mixture was heated to 110 °C and 
stirred for 20 min.  The mixture was then cooled to 23 °C and diluted with toluene (450 
mL), leaving ample headspace in the sealed tube to allow for solvent expansion.  The 
reaction mixture was then re-heated to 100 °C and stirred for 19 d, until completion, 
which was determined after monitoring by NMR.  The reaction mixture was then cooled 
to 23 °C and 0.02% HCl(aq) (20 mL) was added and the mixture stirred vigorously for 1 
min.  The organic phase was then separated and washed with 0.02% HCl(aq) (3 x 25 mL).  
Aqueous phases were then combined and back extracted with ethyl acetate (3 x 30 mL).  
The organic phases were combined, dried with Na2SO4, and concentrated by rotary 
evaporation.  The crude oil was purified by column chromatography (EtOAc in hexanes 
with 0.1% AcOH, 5%→30% on silica) to yield 186 mg (62% yield) of a 3:1 mixture of 
ICR/DA diastereomers 128a and 128b as a yellow solid.  It is important to note that 
compounds 128a and 128b, and all subsequent compounds 129a, 129b, 121a, 121b, 
130a, 130b, 7, and 8 have very poor solubility in most common organic solvents 
O
O
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excluding EtOAc.  Therefore all transfers of products 128a, 128b, 129a, 129b, 121a, 
121b, 130a, 130b, 7, and 8 should be accomplished using EtOAc and vessels should be 
repeatedly washed. 
Major (128a): 1H NMR (500 MHz, CDCl3) δ 6.96 (d, J = 7.0 Hz, 1H), 6.09 (d, J = 
18.8 Hz, 1H), 5.64 (d, J = 18.8 Hz, 1H), 3.74 (s, 3H), 3.36 (d, J = 7.0 Hz, 1H), 2.96 (s, 
1H), 1.98–1.36 (m, 5H), 1.27 (s, 6H), 0.06 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 173.5, 
172.1, 168.9, 154.9, 139.8, 125.8, 99.8, 83.8, 59.2, 52.7, 51.5, 49.5, 49.2, 41.4, 37.9, 24.6, 
20.8, 18.7, –1.0. 
Minor (128b): 1H NMR (500 MHz, CDCl3) δ 6.95 (d, J = 6.9 Hz, 1H), 6.41 (d, J = 
19.1 Hz, 1H), 5.64 (d, J = 19.1 Hz, 1H), 3.70 (s, 3H), 3.34 (d, J = 7.1 Hz, 1H), 2.91 (s, 
1H), 1.98–1.36 (m, 5H), 1.30 (s, 3H), 1.25 (s, 3H), 0.06 (s, 9H); 13C NMR (125 MHz, 
CDCl3) δ 173.3, 171.9, 168.0, 147.5, 140.1, 128.1, 99.2, 83.9, 61.2, 52.5, 51.5, 49.6, 
49.0, 40.6, 37.6, 29.6, 24.6, 20.7, –1.1. 
FTIR (Neat Film NaCl) 3077, 2952, 1773, 1736, 1611, 1492, 1459, 1453, 1382, 1309, 
1276, 1247, 1184, 1161, 1122, 1047, 1019, 989, 970, 935, 870, 838, 783, 754 cm-1; 
HRMS (Multimode-ESI/APCI) m/z calc’d for C21H30IO6Si [M+H]+: 533.0851, found 
533.0847; [α]
€ 
D
20 = +10.47 (c 1.00 in CHCl3). 
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Tetracyclic acetals 121a and 121b.  It is important to note that the selective single 
hydride reduction of the methyl esters of vinyl silanes 128a and 128b was only made 
possible using a glass cannula, as it allows for the precise temperature control necessary 
to effect the transformation on such a complex molecule bearing many electrophilic 
carbonyl functionalities (Figure 2.8.9).  A solution of vinyl silanes 128a and 128b (31 
mg, 0.06 mmol) in toluene (600 µL, 0.1M) was stirred in the receiving chamber of the 
glass cannula at –78 °C (the entire glass cannula is placed in a –78 °C bath submerging 
both chambers and the cannula itself).  A freshly made 1M solution of DIBAL-H (300 
µL, 0.30 mmol) in toluene was added to the addition chamber of the glass cannula, 
further diluted with toluene (500 µL), and stirred at –78 °C.  Once both solutions and the 
entire glass cannula were sufficiently cooled, the –78 °C solution of DIBAL-H was 
slowly added to vinyl silanes 128a and 128b dropwise.  The reaction was stirred for 10 
min and then slowly quenched by a –78 °C solution of AcOH (100 µL) in toluene (2 mL) 
via the addition chamber of the glass cannula.  Once complete, the reaction vessel was 
removed from the –78 °C bath, allowed to warm to 23 °C, and then diluted with ethyl 
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acetate (10 mL).  The solution was washed with a 1% aqueous solution of AcOH (3 x 2 
mL) and the aqueous phases were combined and back extracted with ethyl acetate (2 x 2 
mL).  All organic phases were pooled, dried over Na2SO4, and concentrated by rotary 
evaporation to give the desired aldehydes 129a and 129b as an orange-brown solid.  129a 
and 129b were used immediately in the following step without further purification. 
To a 23 °C solution of the crude aldehyde products (129a and 129b) in MeCN      
(150 µL, 0.4M assuming quantitative yield from the reduction) was added aqueous HBF4 
(48% w/w, 100 µL, 0.78 mmol).  The reaction was stirred at 23 °C for 8 h and then 
diluted with ethyl acetate (5 mL).  This was washed with pH 2–3 water (0.02% HCl 
solution) (3 x 1 mL), and the aqueous phases were back extracted with ethyl acetate (2 x 
1 mL).  All organics were combined, dried over Na2SO4, and concentrated by rotary 
evaporation. Purification was accomplished by column chromatography (EtOAc in 
hexanes with 0.1% AcOH, 5%→30% on silica) to yield 15 mg (57% yield over two 
steps) of a 3:1 mixture of the reduced, cyclized, and desilylated diastereomers 121a and 
121b as a yellow solid. 
Major (121a): 1H NMR (500 MHz, CDCl3) δ 6.69 (d, J = 5.8 Hz, 1H), 6.03 (dd, J = 
17.3, 10.8 Hz, 1H), 5.75 (s, 1H), 5.10 (d, J = 10.8 Hz, 1H), 5.04 (d, J = 17.4 Hz, 1H), 
3.08 (d, J = 5.9 Hz, 1H), 2.92 (s, 1H), 2.21–2.14 (m, 1H), 1.97–1.38 (m, 4H), 1.36 (s, 
3H), 1.19 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 173.1, 169.5, 147.1, 136.1, 112.3, 
108.9, 107.3, 87.1, 61.5, 54.7, 49.1, 48.8, 39.7, 36.2, 20.1, 18.8, 15.9. 
Minor (121b): 1H NMR (500 MHz, CDCl3) δ 6.69 (d, J = 5.9 Hz, 1H), 6.07 (dd, J = 
17.5, 11.1 Hz, 1H), 5.67 (s, 1H), 5.12 (d, J = 11.1 Hz, 1H), 5.08 (d, J = 17.5 Hz, 1H), 
3.07 (d, J = 5.9 Hz, 1H), 2.88 (s, 1H), 2.21–2.14 (m, 1H), 1.97–1.38 (m, 4H), 1.36 (s, 
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3H), 1.33 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 173.2, 169.7, 139.5, 136.3, 114.6, 
108.8, 107.0, 87.1, 63.1, 54.7, 49.3, 48.8, 39.4, 36.3, 29.6, 20.0, 15.8. 
FTIR (Neat Film NaCl) 3300, 3077, 3007, 2958, 2933, 2873, 1785, 1748, 1708, 1456, 
1375, 1286, 1239, 1217, 1199, 1182, 1157, 1115, 1083, 1046, 1034, 992, 964, 957, 910, 
895, 873, 829, 814, 796, 752 cm-1; HRMS (Multimode-ESI/APCI) m/z calc’d for 
C17H20IO5 [M+H]+: 431.0350 found 431.0359; [α]
€ 
D
20  = +18.71 (c 0.94 in CHCl3). 
 
 
TBS-ester 130a and 130b. To a 23 °C solution of acetals 121a and 121b (15 mg, 
0.034 mmol) in DMF (600 µL, 0.055M) were added sequentially imidazole (14 mg, 0.21 
mmol) and TBSCl (21 mg, 0.14 mmol).  The reaction was stirred at 23 °C for 2 h.  The 
reaction mixture was then diluted with saturated brine (2 mL) and extracted with 
EtOAc/hexanes (1:1) (4 x 3 mL).  The combined organic extracts were washed with 
saturated aqueous NaHCO3 (3 mL) and then with brine (2 x 3 mL).  The combined 
organics were dried over Na2SO4 and concentrated by rotary evaporation.  The crude oil 
was purified by column chromatography (EtOAc in hexanes 10%→50% on silica) to 
yield 12.5 mg (67% yield) of a 4:1 mixture of diastereomers 130a and 130b as a white 
solid. 
Major (130a): 1H NMR (500 MHz, CDCl3) δ 6.61 (d, J = 6.0 Hz, 1H), 6.00 (dd, J = 
17.4, 10.7 Hz, 1H), 5.68 (s, 1H), 4.99 (d, J = 10.7 Hz, 1H), 4.98 (d, J = 17.4 Hz, 1H), 
TBSCl, imidazole
   DMF, 23 °C, 2 h
(67% yield)
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2.98 (dd, J = 6.0, 0.8 Hz, 1H), 2.80 (s, 1H), 2.08–2.00 (m, 1H), 1.90–1.35 (m, 4H), 1.29 
(s, 3H), 1.18 (s, 3H), 0.92 (s, 9H), 0.31 (s, 3H), 0.25 (s, 3H); 13C NMR (125 MHz, 
CDCl3) δ 174.4, 169.7, 149.2, 135.4, 110.9, 110.0, 109.8, 87.0, 61.1, 55.1, 49.5, 48.7, 
40.0, 37.4, 25.7, 20.6, 18.2, 17.7, 16.0, –4.7. 
Minor (130b): 1H NMR (500 MHz, CDCl3) δ 6.61 (d, J = 6.1 Hz, 1H), 6.26 (dd, J = 
17.6, 11.0 Hz, 1H), 5.58 (s, 1H), 5.03 (dd, J = 11.0, 1.1 Hz, 1H), 4.97 (dd, J = 17.6, 1.1 
Hz, 1H), 2.96 (dd, J = 6.1, 0.9 Hz, 1H), 2.72 (s, 1H), 2.08–2.00 (m, 1H), 1.90–1.35 (m, 
4H), 1.32 (s, 3H), 1.26 (s, 3H), 0.93 (s, 9H), 0.31 (s, 3H), 0.25 (s, 3H); 13C NMR (125 
MHz, CDCl3) δ 174.5, 169.9, 141.4, 135.6, 112.8, 109.9, 109.4, 87.0, 62.6, 55.1, 49.6, 
48.9, 39.6, 37.7, 30.4, 25.6, 20.6, 17.6, 15.9, –4.8. 
FTIR (Neat Film NaCl) 3083, 2930, 2857, 1784, 1716, 1638, 1601, 1471, 1463, 1413, 
1390, 1362, 1338, 1317, 1282, 1250, 1235, 1222, 1196, 1183, 1160, 1144, 1115, 1084, 
1049, 1036, 1000, 960, 942, 908, 895, 884, 868, 843, 828, 816, 787, 752 cm-1; HRMS 
(Multimode-ESI/APCI) m/z calc’d for C23H34IO5Si [M+H]+: 545.1215, found 545.1218; 
[α]
€ 
D
20 = +49.09 (c 1.00 in CHCl3). 
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Transtaganolides B and A (8 and 7).  In a nitrogen filled glovebox, to a solution of 
TBS-esters 130a and 130b (9 mg, 0.0165 mmol) and Pd(PPh3)4 (21 mg, 0.018 mmol) in 
DMF (165 µL, 0.1M) was added tributyl(2-methoxyethynyl)stannane (62) (22 mg, 0.066 
mmol). The heterogeneous reaction mixture was vigorously stirred at 31 °C for 7.5 h. The 
reaction mixture was then filtered through a Kimwipe with MeCN (1.5 mL) (this removes 
a large excess of the undissolved Pd(PPh3)4) and removed from the glovebox.  pH 7 
phosphate buffer (75 µL) was added to the MeCN solution, which was then vigorously 
stirred for 36 h.  The reaction was then concentrated by rotary evaporation, so as to 
remove some of the copious amounts of MeCN, and then diluted with EtOAc (2 mL).  
This was then washed with water (3 x 750 µL) and the combined aqueous washes were 
back extracted with EtOAc (2 x 750 µL).  All organics were pooled, dried with Na2SO4, 
and concentrated by rotary evaporation. The crude oil was purified by normal phase 
HPLC to yield 1.5 mg (25% yield) of transtaganolide B (8) and 0.6 mg (10% yield) of 
transtaganolide A (7) as white powders. 
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Transtaganolide B (8): 1H NMR (500 MHz, CDCl3) δ 5.80 (dd, J = 17.4, 10.8 Hz, 
1H), 5.65 (t, 0.8 Hz, 1H), 5.58 (dd, J = 6.0, 1.1 Hz, 1H), 5.05 (dd, J = 17.4, 0.6 Hz, 1H), 
5.02 (d, J = 10.8, 0.6 Hz, 1H), 4.96 (t, 0.8 Hz, 1H), 3.68 (s, 3H), 3.12 (dt, J = 6.0, 0.9 Hz, 
1H), 3.08 (s, 1H), 1.94 (dd, J = 12.3, 6.3 Hz, 1H), 1.72 (ddt, J = 13.1, 6.3, 3.3 Hz, 1H), 
1.63 (ddd, J = 13.1, 3.9, 2.7 Hz, 1H), 1.55 (s, 3H), 1.55–1.35 (m, 2H), 1.33 (s, 3H); 13C 
NMR (125 MHz, CDCl3) δ 175.6, 163.8, 154.5, 146.7, 144.2, 119.4, 112.7, 109.8, 87.7, 
84.4, 56.5, 51.6, 49.8, 49.5, 48.8, 38.1, 37.0, 20.1, 19.4, 15.9; FTIR (Neat Film NaCl) 
2948, 2931, 2874, 2855, 1782, 1668, 1447, 1372, 1348, 1324, 1296, 1252, 1237, 1167, 
1109, 1059, 1024, 999, 966, 912, 897, 843, 812, 736 cm-1; HRMS (Multimode-
ESI/APCI) m/z calc’d for C20H21O6 [M–H]–: 357.1344, found 357.1356; [α]
€ 
D
20  = +207.93 
(c 0.15, CHCl3, 81% ee); SFC conditions: 30% IPA, 2.5 mL/min, AD-H column, tR(min): 
major = 2.83, minor = 4.68. 
Figure 2.8.10.  Racemic SFC trace of transtaganolide B (8). 
 
Figure 2.8.11.  Enantioenriched SFC trace of transtaganolide B (8). 
 
Transtaganolide A (7): 1H NMR (500 MHz, CDCl3) δ 6.90 (dd, J = 17.9, 11.1 Hz, 
1H), 5.62 (s, 1H), 5.60 (dd, J = 5.9, 1.0 Hz, 1H), 5.12 (ddd, J = 11.1, 1.1, 0.6 Hz, 1H), 
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5.03 (dd, J = 17.9, 1.1 Hz, 1H), 4.98 (s, 1H), 3.70 (s, 3H), 3.11 (dt, J = 5.9, 0.8 Hz, 1H), 
2.98 (s, 1H), 1.95 (dd, J = 12.3, 6.3 Hz, 1H), 1.83 (ddd, J = 12.9, 3.7, 2.6 Hz, 1H), 1.60–
1.30 (m, 3H), 1.30 (s, 3H), 1.22 (s, 3H); 13C NMR (125 MHz, CDCl3) δ 175.6, 164.1, 
154.5, 143.9, 143.8, 119.6, 111.8, 109.8, 87.6, 84.5, 56.5, 52.8, 51.6, 49.7, 48.8, 39.4, 
38.3, 28.6, 20.1, 15.8; FTIR (Neat Film NaCl) 2963, 2922, 2852, 1780, 1670, 1453, 1348, 
1323, 1259, 1236, 1167, 1113, 1058, 1021m 999, 973, 959, 921, 840, 808, 731 cm-1; 
HRMS (Multimode-ESI/APCI) m/z calc’d for C20H21O6 [M–H]–: 357.1344, found 
357.1356; [α]
€ 
D
20 = –98.76 (c 0.06, CHCl3, 90% ee); SFC conditions: 30% IPA, 2.5 
mL/min, AD-H column, tR(min): minor = 3.20, major = 4.97. 
Figure 2.8.12.  Racemic SFC trace of transtaganolide A (7). 
 
Figure 2.8.13.  Enantioenriched SFC trace of transtaganolide A (7). 
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Methyl esters 133 and 135:  Diazomethane in a solution of Et2O was added 
dropwise to a 0.1M solution of the acids 100a and 100b at 0 °C.  This was done using 
flame polished pipettes, glassware containing no ground glass joints, and open top to 
avoid detonation.  The diazomethane was added until the yellow color of diazomethane 
persisted in the reaction solution.  The reaction was then stirred for an additional 35 min, 
until the lemon-lime color faded, and all unreacted diazomethane had evaporated into the 
well-ventilated hood.  The reaction was then concentrated by rotary evacuation and 
purified by preparatory HPLC, to separate diastereomers 133 and 135.  The major 
diastereomer (133) was crystallized by slow evaporation from pentanes in order to obtain 
crystals suitable for X-ray diffraction. 
Major (133): 1H NMR (500 MHz, CDCl3) δ 6.92 (d, J = 6.8 Hz, 1H), 6.10 (d, J = 
18.9 Hz, 1H), 5.59 (d, J = 18.9 Hz, 1H), 3.61 (s, 3H), 2.97 (s, 1H), 2.94 (d, J = 6.8 Hz, 
1H), 1.70–1.40 (m, 4H), 1.34 (dd, J = 12.0, 5.3 Hz, 1H), 1.23 (s, 3H), 1.08 (s, 3H), 1.00 
(s, 3H), 0.08 (s, 9H); 13C NMR (125 MHz, CDCl3) δ 171.0, 169.3, 156.1, 140.3, 124.5, 
98.0, 84.7, 59.0, 56.9, 51.2, 48.3, 41.5, 38.2, 37.0, 30.0, 24.7, 20.9, 18.4, –0.9; FTIR 
(Neat Film NaCl) 2953, 2923, 2848, 1746, 1612, 1464, 1454, 1392, 1386, 1365, 1352, 
1302, 1246, 1209, 1196, 1167, 1141, 1052, 1011, 993, 976, 965, 939, 868, 838, 796, 756 
cm-1; HRMS (Multimode-ESI/APCI) m/z calc’d for C21H32IO4Si [M+H]+: 503.1109 found 
503.1113; [α]
€ 
D
20 = +34.50 (c 0.24 in CHCl3); MP: 125–130 ºC. 
CH2N2
133
MeO O
O
OI
8
4
SiMe3
H
100a
HO O
O
OI
8
4
SiMe3
H
135
MeO O
O
OI
8
4
SiMe3
H
+
100b
HO O
O
OI
8
4
SiMe3
H
+
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Minor (135): 1H NMR (500 MHz, CDCl3) δ 6.89 (d, J = 6.8 Hz, 1H), 6.48 (d, J = 
19.2 Hz, 1H), 5.57 (d, J = 19.2 Hz, 1H), 3.68 (s, 3H), 2.90 (d, J = 6.8 Hz, 1H), 2.87 (s, 
1H), 1.96 (dt, J = 13.7, 3.4 Hz, 1H), 1.66–1.51 (m, 2H), 1.41 (td, J = 13.5, 3.4 Hz, 1H), 
1.34 (dd, J = 12.6, 5.0 Hz, 1H), 1.27 (s, 3H), 1.02 (s, 3H), 0.97 (s, 3H), 0.06 (s, 9H); 13C 
NMR (125 MHz, CDCl3) δ 170.4, 169.6, 148.9, 140.4, 126.6, 110.1, 97.7, 84.5, 61.1, 
57.0, 51.7, 48.3, 40.8, 38.3, 37.2, 30.0, 24.6, 20.9, –1.1; FTIR (Neat Film NaCl) 2952, 
2893, 1760, 1745, 1608, 1455, 1435, 1394, 1372, 1354, 1304, 1246, 1224, 1190, 1168, 
1149, 1137, 1102, 1047, 1012, 994, 955, 869, 838, 799, 755, 737, 727 cm-1; HRMS 
(Multimode-ESI/APCI) m/z calc’d for C21H32IO4Si [M+H]+: 503.1109 found 503.1119; 
[α]
€ 
D
20 = –82.77 (c 0.37 in CHCl3). 
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(19) Subsequent to submission of this manuscript Prof. Giovanni Appendino 
generously provided our group with an authentic sample of the structurally, and 
presumably biosynthetically, related basiliolide B (11).17  Comparison to racemic 
synthetic basiliolide B (see ref. 16b) by chiral phase chromatography clearly 
demonstrated that naturally occurring basiliolide B is enantiopure upon isolation. 
Furthermore, consistent in magnitude with the enantioenriched synthetic 
transtaganolides, the specific rotation of natural basiliolide B was measured as     
–173° (0.24 c). 
(20) Extensive efforts were made to obtain authentic samples of 7–10 from the 
isolation chemists to no avail. 
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A4.1 SYNTHETIC SUMMARY FOR (+)-TRANSTAGANOLIDE C AND (–)-
TRANSTAGANOLIDE D 
Scheme 4.1.1.  Retrosynthetic analysis for (+)-transtaganolide C (9) and (–)-transtaganolide D (10). 
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Scheme 4.1.2.  Syntheses of (+)-transtaganolide C (9) and (–)-transtaganolide D (10). 
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A4.2 SYNTHETIC SUMMARY FOR (–)-TRANSTAGANOLIDE A AND (+)-
TRANSTAGANOLIDE B 
Scheme 4.2.1.  Retrosynthetic analysis for (–)-transtaganolide A (7) and (+)-transtaganolide B (8). 
 
O
H H
O O
O
O
MeO
4
8
C
[5 + 2]
OMe
Bu3Sn 62
RO O
O
O
94a
I
8
4
HO
OH
translactonization/
acetalization
ICR/DA
O
O O
O
I
95
4
8
SiMe3
D
A B
H
RO OI
93a
O
H H
O O
8
4
E
(+)-transtaganolide B (8)
O
H H
O O
O
O
MeO
4
8
C
D
A B
E
(–)-transtaganolide A (7)
RO OI
93b
O
H H
O O
8
4
+
+
RO O
O
O
94b
I
8
4
HO
OH
H
H
O
+
Appendix 4–Synthetic Summary for (–)-Transtaganolide A, (+)-Transtaganolide B, 
(+)-Transtaganolide C, and (–)-Transtaganolide D: Relevant to Chapter 2 
138 
Scheme 4.2.2.  First attempt to synthesize (±)-transtaganolide A and B (7–8) tetracyclic core via 
protected alcohol 109. 
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Scheme 4.2.3.  Second attempt to synthesize (±)-transtaganolide A and B (7–8) tetracyclic core via 
Weinreb amide 115. 
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Scheme 4.2.4.  Third attempt to synthesize (±)-transtaganolide A and B (7–8) tetracyclic core via 
methylester 119. 
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Scheme 4.2.5.  Forward syntheses of (–)-transtaganolide A (7) and (+)-transtaganolide B (8). 
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Scheme 4.2.6.  Continued forward syntheses of (–)-transtaganolide A (7) and (+)-transtaganolide B 
(8). 
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A5.1 COMPARISON OF 1H NMR AND 13C NMR FOR SYNTHETIC AND 
REPORTED TRANSTAGANOLIDE A 
Table A5.1.1. Comparison of 1H NMR data for synthetic and reported natural1 transtaganolide A (7). 
 
1
2
11
15
13
5
8
4 14
63 7
10
12
9
18
17
19
16
Assignment Synthetic 7 (ppm) Multiplicity, J (Hz)
C2 5.60 5.60 dd, 5.9, 1.1
C3 3.11 3.11 d, 6.0
C4 — — —
C5 1.96 dd, 12.1, 6.2
C6 1.60–1.30 1.60 dddd, 13.3, 6.2, 2.7, 2.2
1.60–1.30 1.47 dddd, 13.3, 13.3, 12.3, 2.3
C7 1.60–1.30 1.39 ddd, 13.3, 13.3, 2.7
1.83 1.82 ddd, 12.7, 3.7, 2.3
1.95
C1 — ——
C9 2.98 2.99 s
C10 — — —
C11 4.98 4.99 bs
C12 — —
C13 — — —
C14 1.30 1.30 s
C15 5.62 5.61 s
—
C8 — ——
Multiplicity, J (Hz)Natural 7 (ppm)
C16 6.90 6.89 dd, 17.9, 11.2
C17 5.12 5.11 ddt, 11.1, 1.1, 0.6
C18 1.22 1.22 s
3.70 3.70 sOMe
dd, 5.9, 1.0
dt, 5.9, 0.8
—
m
m
m
ddd, 12.9, 3.7, 2.6
dd, 12.3, 6.3
—
s
—
s
—
s
s
—
—
dd, 17.9, 11.1
ddd, 11.1, 1.1, 0.6
s
s
O
H H
O O
O
O
MeO
5.03 5.03 dd, 17.8, 1.1dd, 17.9, 1.1
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Table A5.1.2. Comparison of 13C NMR data for synthetic and reported natural1 transtaganolide A 
(7). 
 
  
Assignment Synthetic 7 (ppm)
C2 119.6 119.4
C3 51.6 51.3
C4 48.8 48.6
C5 49.4
C6 20.1 19.9
C7 39.4 39.1
49.7
C1 143.7143.8
C9 52.8 52.5
C10 87.6 87.5
C11 84.5 84.1
C12 154.4
C13 175.6 175.5
C14 15.8 15.6
C15 109.8 109.6
154.5
C8 38.138.3
Natural 7 (ppm)
C16 143.9 143.7
C17 111.8 111.5
C18 28.6 28.3
C19 164.1 164.0
56.5 56.3OMe
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A5.2 COMPARISON OF 1H NMR AND 13C NMR FOR SYNTHETIC AND 
REPORTED TRANSTAGANOLIDE B 
Table A5.2.1. Comparison of 1H NMR data for synthetic and reported natural1 transtaganolide B (8). 
 
 
1
2
11
15
13
5
8
4 14
63 7
10
12
9
18
17
19
16
Assignment Synthetic 8 (ppm) Multiplicity, J (Hz)
C2 5.58 5.58 dd, 6.0, 1.1
C3 3.12 3.12 dt, 6.0, 0.9
C4 — — —
C5 1.95 dd, 12.1, 6.3
C6 1.72 1.73 dddd, 12.9, 6.2, 3.7, 2.5
1.55–1.35 1.51 dddd, 13.0, 13.0, 13.0, 2.4
C7 1.55–1.35 1.43 ddd, 13.3, 11.9, 2.3
1.63 1.63 ddd, 13.3, 3.7, 2.3
1.94
C1 — ——
C9 3.08 3.09 s
C10 — — —
C11 4.96 4.97 t, 0.8
C12 — —
C13 — — —
C14 1.33 1.33 s
C15 5.65 5.66 t, 0.7
—
C8 — ——
Multiplicity, J (Hz)Natural 8 (ppm)
C16 5.80 5.81 dd, 17.4, 10.8
C17 5.05 5.09 dd, 10.8, 0.7
C18 1.55 1.55 s
3.68 3.68 sOMe
dd, 6.0, 1.1
dt, 6.0, 0.9
—
ddt, 13.1, 6.3, 3.3
m
m
ddd, 13.1, 3.9, 2.7
dd, 12.3, 6.3
—
s
—
t, 0.8
—
s
t, 0.8
—
—
dd, 17.4, 10.8
dd, 17.4, 0.6
s
s
O
H H
O O
O
O
MeO
5.02 5.06 dd, 17.4, 0.7dd, 10.8, 0.6
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Table A5.2.2. Comparison of 13C NMR data for synthetic and reported natural1 transtaganolide B 
(8). 
 
Assignment Synthetic 8 (ppm)
C2 119.4 119.2
C3 51.6 51.4
C4 48.8 48.6
C5 49.3
C6 19.4 19.2
C7 37.0 36.8
49.5
C1 144.0144.2
C9 49.8 49.6
C10 87.7 87.5
C11 84.4 84.2
C12 154.3
C13 175.6 175.5
C14 15.9 15.7
C15 109.8 109.6
154.5
C8 37.938.1
Natural 8 (ppm)
C16 146.7 146.5
C17 112.7 112.5
C18 20.1 19.9
C19 163.8 163.7
56.5 56.3OMe
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A5.3 COMPARISON OF 1H NMR AND 13C NMR FOR SYNTHETIC AND 
REPORTED TRANSTAGANOLIDE C 
Table A5.3.1. Comparison of 1H NMR data for synthetic and reported natural1 transtaganolide C (9). 
 
O
O
MeO
H
O
O1
2 16
15
18
5
8
4
14
63 7
10
17
9
12
11 19
13
Assignment Synthetic 9 (ppm) Multiplicity, J (Hz)
C2 6.07 6.08 dd, 6.5, 1.1
C3 3.06 3.07 d, 6.5
C4 — — —
C5 1.30 dd, 11.5, 6.5
C6 1.71–1.63 1.70–1.60 m
1.71–1.63 1.70–1.60 m
C7 1.48–1.39 1.44 ddd, 13.0, 13.0, 3.3
1.71–1.63 1.65 m
1.34–1.27
C1 — ——
C9 3.23 3.24 s
C10 — — —
C11 5.00 5.01 d, 1.1
C12 — —
C13 — —
C14 0.97 0.98 s
C15 1.08 1.09 s
—
C8 — ——
Multiplicity, J (Hz)Natural 9 (ppm)
C16 5.80 5.81 dd, 17.4, 10.8
C17 5.03 5.05 br d, 10.7
C18 1.60 1.61 s
C19 — — —
3.71 3.72 sOMe
dd, 6.5, 1.5
d, 6.5
—
m
m
m
m
m
—
s
—
d, 1.5
s
s
—
—
dd, 17.5, 11.0
d, 11.0
s
—
s
5.07 5.08 br d, 17.4d, 17.5
——
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Table A5.3.2. Comparison of 13C NMR data for synthetic and reported natural1 transtaganolide C 
(9). 
 
Assignment Synthetic 9 (ppm)
C2 123.6 123.5
C3 53.8 53.8
C4 33.3 33.2
C5 47.9
C6 19.9 19.8
C7 38.3 38.3
48.1
C1 131.9138.0
C9 50.6 50.4
C10 87.3 87.4
C11 79.3 79.1
C12 156.7
C13 171.8 172.0
C14 29.9 29.6
C15 24.8 24.8
156.7
C8 38.438.4
Natural 9 (ppm)
C16 146.5 146.5
C17 112.8 112.8
C18 19.2 19.1
C19 162.3 162.5
56.6 56.3OMe
O
O
MeO
H
O
O1
2 16
15
18
5
8
4
14
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17
9
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13
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A5.4 COMPARISON OF 1H NMR AND 13C NMR FOR SYNTHETIC AND 
REPORTED TRANSTAGANOLIDE D 
Table A5.4.1. Comparison of 1H NMR data for synthetic and reported natural1 transtaganolide D 
(10). 
 
O
O
MeO
H
O
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2 16
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18
5
8
4
14
63 7
10
17
9
12
11 19
13
Assignment Synthetic 10 (ppm) Multiplicity, J (Hz)
C2 6.09 6.08 dd, 6.5, 1.2
C3 3.06 3.04 d, 6.6
C4 — — —
C5 1.34 dd, 12.6, 5.3
C6 1.64 1.65–1.53 m
1.59–1.56 1.65–1.53 m
C7 1.39 1.39 ddd, 13.0, 13.0, 3.3
1.91 1.89 ddd, 13.0, 3.3, 3.3
1.33
C1 — ——
C9 3.13 3.14 s
C10 — — —
C11 5.02 5.02 d, 1.1
C12 — —
C13 — — —
C14 0.97 0.96 s
C15 1.04 1.02 s
—
C8 — ——
Multiplicity, J (Hz)Natural 10 (ppm)
C16 7.00 6.98 dd, 17.8, 11.2
C17 5.15 5.11 dd, 11.1, 1.1
C18 1.22 1.21 s
C19 — — —
3.73 3.72 sOMe
dd, 6.5, 1.0
d, 6.5
—
dquint, 13.5, 3.0
m
dt, 13.5, 3.5
dt, 13.5, 3.5
dd, 13.5, 3.5
—
s
—
d, 1.0
s
s
—
—
dd, 17.5, 11.0
dd, 11.0, 1.0
s
—
s
5.05 5.03 dd, 17.8, 1.1dd, 17.5, 1.0
—
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Table A5.4.2. Comparison of 13C NMR data for synthetic and reported natural1 transtaganolide D 
(10). 
 
  
Assignment Synthetic 10 (ppm)
C2 123.9 123.8
C3 54.0 53.9
C4 33.3 33.2
C5 48.2
C6 20.5 20.3
C7 40.5 40.3
48.4
C1 137.5137.7
C9 53.3 53.1
C10 87.3 87.4
C11 79.4 79.2
C12 156.6
C13 171.7 171.9
C14 29.9 29.8
C15 24.8 24.7
156.7
C8 38.338.4
Natural 10 (ppm)
C16 142.9 142.9
C17 112.1 111.9
C18 28.5 28.4
C19 162.6 162.7
56.3 56.3OMe
O
O
MeO
H
O
O1
2 16
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A5.5 CD SPECTRA OF DIFFRACTED CRYSTAL 133 
The circular dichroism (CD) spectra of crystal 133 (in green, Figure A5.5.1) and the 
CD spectra of the bulk material from which crystal 133 was obtained (in red, Figure 
A5.5.1) were compared.  Since crystal 133 was grown from 90% enantiomeric excess 
(ee) material it was possible that crystal 133 could have been the crystallized minor 
enantiomer (135).  Figure A5.5.1 demonstrates that the CD spectra of the bulk material 
(133 and 135) and crystal 133 are quite similar and therefore confirms that crystal 133 is 
representative of the major enantiomer. 
Figure A5.5.1.  CD spectral comparison of diffracted crystal 133 to 90% enantioenriched bulk 
sample of 133 and 135. 
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Figure A6.1.2 infrared spectrum (Thin Film, NaCl) of compound 97. 
Figure A6.1.3 13C NMR (125 MHz, CDCl3) of compound 97. 
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Figure A6.2.2 infrared spectrum (Thin Film, NaCl) of compounds 100a and 100b. 
Figure A6.2.3 13C NMR (125 MHz, CDCl3) of compounds 100a and 100b. 
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Figure A6.3.2 infrared spectrum (Thin Film, NaCl) of transtaganolide C (9). 
Figure A6.3.3 13C NMR (125 MHz, CDCl3) of transtaganolide C (9). 
Appendix 6–Spectra Relevant to Chapter 2 Total Syntheses of (–)-Transtaganolide A, 
(+)-Transtaganolide B, (+)-Transtaganolide C, and (–)-Transtaganolide D 
And Biosynthetic Implications 
161 
 
  
Fi
gu
re
 A
6.4
.1 
1 H
 N
M
R 
(50
0 M
Hz
, C
DC
l 3)
 of
 tr
an
sta
ga
no
lid
e D
 (1
0).
 
(–
)-t
ra
ns
ta
ga
no
lid
e D
(1
0)O
O
M
eO
HOO
Appendix 6–Spectra Relevant to Chapter 2 Total Syntheses of (–)-Transtaganolide A, 
(+)-Transtaganolide B, (+)-Transtaganolide C, and (–)-Transtaganolide D 
And Biosynthetic Implications 
162 
 
  
Figure A6.4.2 infrared spectrum (Thin Film, NaCl) of transtaganolide D (10). 
Figure A6.4.3 13C NMR (125 MHz, CDCl3) of transtaganolide D (10). 
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Figure A6.5.2 infrared spectrum (Thin Film, NaCl) of compound 105. 
Figure A6.5.3 13C NMR (125 MHz, CDCl3) of compound 105. 
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Figure A6.6.2 infrared spectrum (Thin Film, NaCl) of compound 106. 
Figure A6.6.3 13C NMR (75 MHz, CDCl3) of compound 106. 
Appendix 6–Spectra Relevant to Chapter 2 Total Syntheses of (–)-Transtaganolide A, 
(+)-Transtaganolide B, (+)-Transtaganolide C, and (–)-Transtaganolide D 
And Biosynthetic Implications 
167 
0
1
2
3
4
5
6
7
8
9
10
pp
m
 
  
Fi
gu
re
 A
6.7
.1 
1 H
 N
M
R 
30
0 M
Hz
, C
DC
l 3)
 of
 co
mp
ou
nd
 10
7. 
10
7
TB
SO
OA
c
Appendix 6–Spectra Relevant to Chapter 2 Total Syntheses of (–)-Transtaganolide A, 
(+)-Transtaganolide B, (+)-Transtaganolide C, and (–)-Transtaganolide D 
And Biosynthetic Implications 
168 
020406080100120140160180200220
ppm
 
  
Figure A6.7.2 infrared spectrum (Thin Film, NaCl) of compound 107. 
Figure A6.7.3 13C NMR (125 MHz, CDCl3) of compound 107. 
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Figure A6.8.2 infrared spectrum (Thin Film, NaCl) of compound 108. 
Figure A6.8.3 13C NMR (75 MHz, CDCl3) of compound 108. 
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Figure A6.9.2 infrared spectrum (Thin Film, NaCl) of compound 109. 
Figure A6.9.3 13C NMR (75 MHz, CDCl3) of compound 109. 
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Figure A6.10.2 infrared spectrum (Thin Film, NaCl) of compounds 110a and 110b. 
Figure A6.10.3 13C NMR (125 MHz, CDCl3) of compounds 110a and 110b. 
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Figure A6.11.2 infrared spectrum (Thin Film, NaCl) of compounds 112a and 112b. 
Figure A6.11.3 13C NMR (125 MHz, CDCl3) of compounds 112a and 112b. 
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Figure A6.12.2 infrared spectrum (Thin Film, NaCl) of compound 113. 
Figure A6.12.3 13C NMR (125 MHz, CDCl3) of compound 113. 
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Figure A6.13.2 infrared spectrum (Thin Film, NaCl) of compound 114. 
Figure A6.13.3 13C NMR (125 MHz, CDCl3) of compound 114. 
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Figure A6.14.2 infrared spectrum (Thin Film, NaCl) of compound 115. 
Figure A6.14.3 13C NMR (125 MHz, CDCl3) of compound 115. 
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Figure A6.16.2 infrared spectrum (Thin Film, NaCl) of compound 118. 
Figure A6.16.3 13C NMR (125 MHz, CDCl3) of compound 118. 
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Figure A6.17.2 infrared spectrum (Thin Film, NaCl) of compound 119. 
Figure A6.17.3 13C NMR (75 MHz, CDCl3) of compound 119. 
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Figure A6.18.2 infrared spectrum (Thin Film, NaCl) of compounds 120a and 120b. 
Figure A6.18.3 13C NMR (125 MHz, CDCl3) of compounds 120a and 120b. 
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Figure A6.19.2 infrared spectrum (Thin Film, NaCl) of compound 122. 
Figure A6.19.3 13C NMR (75 MHz, CDCl3) of compound 122. 
Appendix 6–Spectra Relevant to Chapter 2 Total Syntheses of (–)-Transtaganolide A, 
(+)-Transtaganolide B, (+)-Transtaganolide C, and (–)-Transtaganolide D 
And Biosynthetic Implications 
192 
 
  
Fi
gu
re
 A
6.2
0.1
 1 H
 N
M
R 
(50
0 M
Hz
, C
DC
l 3)
 of
 co
mp
ou
nd
 12
3. 
Ac
O
Si
M
e 3
12
3
O
Appendix 6–Spectra Relevant to Chapter 2 Total Syntheses of (–)-Transtaganolide A, 
(+)-Transtaganolide B, (+)-Transtaganolide C, and (–)-Transtaganolide D 
And Biosynthetic Implications 
193 
 
  
Figure A6.20.2 infrared spectrum (Thin Film, NaCl) of compound 123. 
Figure A6.20.3 13C NMR (125 MHz, CDCl3) of compound 123. 
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Figure A6.21.2 infrared spectrum (Thin Film, NaCl) of compound 124. 
Figure A6.21.3 13C NMR (75 MHz, CDCl3) of compound 124. 
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Figure A6.22.2 infrared spectrum (Thin Film, NaCl) of compound 125. 
Figure A6.22.3 13C NMR (75 MHz, CDCl3) of compound 125. 
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Figure A6.23.2 infrared spectrum (Thin Film, NaCl) of compound 126. 
Figure A6.23.3 13C NMR (75 MHz, CDCl3) of compound 126. 
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Figure A6.24.2 infrared spectrum (Thin Film, NaCl) of compound 127. 
Figure A6.24.3 13C NMR (125 MHz, CDCl3) of compound 127. 
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Figure A6.25.2 infrared spectrum (Thin Film, NaCl) of compounds 128a and 128b. 
Figure A6.25.3 13C NMR (125 MHz, CDCl3) of compounds 128a and 128b. 
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Figure A6.26.2 infrared spectrum (Thin Film, NaCl) of compounds 121a and 121b. 
Figure A6.26.3 13C NMR (125 MHz, CDCl3) of compounds 121a and 121b. 
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Figure A6.27.2 infrared spectrum (Thin Film, NaCl) of compounds 130a and 130b. 
Figure A6.27.3 13C NMR (125 MHz, CDCl3) of compounds 130a and 130b. 
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Figure A6.28.2 infrared spectrum (Thin Film, NaCl) of transtaganolide B (8). 
Figure A6.28.3 13C NMR (125 MHz, CDCl3) of transtaganolide B (8). 
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Figure A6.29.2 infrared spectrum (Thin Film, NaCl) of transtaganolide A (7). 
Figure A6.29.3 13C NMR (125 MHz, CDCl3) of transtaganolide A (7). 
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Figure A6.30.2 infrared spectrum (Thin Film, NaCl) of compound 133. 
Figure A6.30.3 13C NMR (125 MHz, CDCl3) of compound 133. 
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Figure A6.31.2 infrared spectrum (Thin Film, NaCl) of compound 135. 
Figure A6.31.3 13C NMR (125 MHz, CDCl3) of compound 135. 
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APPENDIX 7 
X-ray Crystallography Reports: 
Relevant to Chapter 2 
 
A7.1 CRYSTAL STRUCTURE ANALYSIS FOR COMPOUND 133 
 
By  Larry Henling  128 Beckman    ext. 2735 
      e-mail: xray@caltech.edu 
 
Contents 
Table A7.1.1.  Crystal data 
Table A7.1.2.  Atomic coordinates 
Table A7.1.3.  Full bond distances and angles 
Table A7.1.4.  Anisotropic displacement parameters 
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Table A7.1.5.  Hydrogen atomic coordinates 
Figure A7.1.1.  Ortep diagram of 133. The crystallographic data have been deposited in the 
Cambridge Database (CCDC) and placed on hold pending further instructions. 
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Table A7.1.1.  Crystal data and structure analysis details for 133. 
Empirical formula  C21 H31 I O4 Si 
Formula weight  502.45 
Crystallization solvent  Hexanes/Pentane  
Crystal shape  block 
Crystal color  colorless  
Crystal size 0.28 x 0.3 x 0.38 mm 
 
 Data Collection  
Preliminary photograph(s)  rotation  
Type of diffractometer  Bruker APEX-II CCD 
Wavelength  0.71073 ≈ MoK 
Data collection temperature  100 K 
Theta range for 9418 reflections used 
in lattice determination  2.69 to 49.27∞ 
Unit cell dimensions a = 7.8106(6) ≈ α = 90∞ 
 b = 9.9557(9) ≈ β = 90∞ 
 c = 29.925(3) ≈ γ  = 90∞ 
Volume 2326.9(3) ≈ 3 
Z 4 
Crystal system  orthorhombic 
Space group  P 21 21 21   (# 19) 
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Density (calculated) 1.434 g/cm3 
F(000) 1024 
Theta range for data collection 2.2 to 51.0∞ 
Completeness to theta = 25.00∞ 99.9%  
Index ranges –16 ≤ h ≤ 8, –21 ≤ k ≤ 21, –61 ≤ l ≤ 65 
Data collection scan type  and scans 
Reflections collected 91039 
Independent reflections 24693 [Rint= 0.0329] 
Reflections > 2σ(I) 22910  
Average σ(I)/(net I) 0.0301 
Absorption coefficient 1.45 mm–1 
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.8799 and 0.8128 
 
 Structure Solution and Refinement  
Primary solution method  dual 
Secondary solution method  difmap 
Hydrogen placement  geom 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 24693 / 0 / 368 
Treatment of hydrogen atoms  refall 
Goodness-of-fit on F2 1.71 
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Final R indices [I>2σ(I), 22910 reflections] R1 = 0.0322, wR2 = 0.0520 
R indices (all data) R1 = 0.0364, wR2 = 0.0525 
Type of weighting scheme used calc 
Weighting scheme used calc w=1/[^2^(Fo^2^)] 
Max shift/error  0.002 
Average shift/error  0.000 
Absolute structure parameter –0.001(5) 
Largest diff. peak and hole 2.58 and –2.43 e∑≈–3 
 
 Programs Used  
Cell refinement   SAINT V8.18C (Bruker-AXS, 2007) 
Data collection   APEX2 2012.2-0 (Bruker-AXS, 2007) 
Data reduction   SAINT V8.18C (Bruker-AXS, 2007) 
Structure solution   SHELXS-97 (Sheldrick, 1990) 
Structure refinement   SHELXL-97 (Sheldrick, 1997) 
Graphics  DIAMOND 3 (Crystal Impact, 1999) 
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Table A7.1.2.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameter         
(Å2 x 103) for 133.  U(eq) is defined as one third of the trace of the orthogonalized Uij tensor 
__________________________________________________________________   
 x  y  z  Ueq 
__________________________________________________________________   
I(1) 3229(1) 3273(1) 1007(1) 15(1) 
Si(1) 8286(1) 9598(1) 296(1) 18(1) 
O(1) 5867(1) 5072(1) 2118(1) 11(1) 
O(2) 5592(1) 4487(1) 2829(1) 19(1) 
O(3) 3205(1) 6242(1) 1658(1) 17(1) 
O(4) 4368(1) 7639(1) 1154(1) 18(1) 
C(1) 6046(1) 4527(1) 1664(1) 10(1) 
C(2) 6004(1) 5727(1) 1341(1) 10(1) 
C(3) 7647(1) 6616(1) 1326(1) 12(1) 
C(4) 9209(1) 5673(1) 1298(1) 17(1) 
C(5) 9286(1) 4665(1) 1680(1) 15(1) 
C(6) 7759(1) 3724(1) 1662(1) 12(1) 
C(7) 7701(1) 2636(1) 2044(1) 13(1) 
C(8) 5895(1) 2726(1) 2272(1) 13(1) 
C(9) 4551(1) 2554(1) 1916(1) 14(1) 
C(10) 4638(1) 3483(1) 1598(1) 12(1) 
C(11) 5751(1) 4138(1) 2445(1) 12(1) 
C(12) 4363(1) 6542(1) 1412(1) 11(1) 
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C(13) 2917(1) 8524(1) 1196(1) 21(1) 
C(14) 7682(1) 7423(1) 893(1) 14(1) 
C(15) 8219(1) 8682(1) 840(1) 17(1) 
C(16) 7633(2) 8455(1) -168(1) 29(1) 
C(17) 6799(3) 11047(2) 328(1) 51(1) 
C(18) 10497(2) 10244(2) 195(1) 31(1) 
C(19) 7776(1) 7534(1) 1736(1) 15(1) 
C(20) 9053(1) 2839(1) 2411(1) 20(1) 
C(21) 7953(1) 1234(1) 1846(1) 20(1) 
__________________________________________________________________   
  
Appendix 7–X-ray Crystallography Reports: Relevant to Chapter 2 223 
Table A7.1.3.  Bond lengths [Å] and angles [°] for 133. 
___________________________________________________________   
I(1)-C(10)  2.0931(7) 
Si(1)-C(15)  1.8650(8) 
Si(1)-C(16)  1.8677(12) 
Si(1)-C(17)  1.8543(14) 
Si(1)-C(18)  1.8672(13) 
O(1)-C(1)  1.4684(9) 
O(1)-C(11)  1.3539(10) 
O(2)-C(11)  1.2063(11) 
O(3)-C(12)  1.2049(10) 
O(4)-C(12)  1.3363(10) 
O(4)-C(13)  1.4404(11) 
C(1)-C(2)  1.5377(11) 
C(1)-C(6)  1.5580(11) 
C(1)-C(10)  1.5261(11) 
C(2)-H(2)  1.015(14) 
C(2)-C(3)  1.5596(10) 
C(2)-C(12)  1.5307(10) 
C(3)-C(4)  1.5419(12) 
C(3)-C(14)  1.5258(11) 
C(3)-C(19)  1.5320(12) 
C(4)-H(4A)  1.008(15) 
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C(4)-H(4B)  0.875(17) 
C(4)-C(5)  1.5223(12) 
C(5)-H(5A)  1.052(15) 
C(5)-H(5B)  0.959(14) 
C(5)-C(6)  1.5178(12) 
C(6)-H(6)  1.030(13) 
C(6)-C(7)  1.5739(12) 
C(7)-C(8)  1.5698(11) 
C(7)-C(20)  1.5367(12) 
C(7)-C(21)  1.5297(13) 
C(8)-H(8)  1.004(16) 
C(8)-C(9)  1.5052(12) 
C(8)-C(11)  1.5022(12) 
C(9)-H(9)  0.930(16) 
C(9)-C(10)  1.3303(11) 
C(13)-H(13A)  0.951(16) 
C(13)-H(13B)  0.993(14) 
C(13)-H(13C)  0.904(18) 
C(14)-H(14)  0.928(14) 
C(14)-C(15)  1.3312(13) 
C(15)-H(15)  0.997(18) 
C(16)-H(16A)  0.915(17) 
C(16)-H(16B)  1.04(2) 
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C(16)-H(16C)  1.020(18) 
C(17)-H(17A)  0.80(3) 
C(17)-H(17B)  1.01(2) 
C(17)-H(17C)  0.99(2) 
C(18)-H(18A)  1.020(18) 
C(18)-H(18B)  0.93(2) 
C(18)-H(18C)  0.88(2) 
C(19)-H(19A)  0.904(15) 
C(19)-H(19B)  0.952(15) 
C(19)-H(19C)  0.886(16) 
C(20)-H(20A)  0.920(16) 
C(20)-H(20B)  0.950(17) 
C(20)-H(20C)  0.924(16) 
C(21)-H(21A)  1.003(14) 
C(21)-H(21B)  0.889(18) 
C(21)-H(21C)  0.987(16) 
C(15)-Si(1)-C(16) 110.06(5) 
C(15)-Si(1)-C(18) 109.60(5) 
C(17)-Si(1)-C(15) 108.59(6) 
C(17)-Si(1)-C(16) 109.91(9) 
C(17)-Si(1)-C(18) 108.64(10) 
C(18)-Si(1)-C(16) 110.01(6) 
C(11)-O(1)-C(1) 114.95(6) 
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C(12)-O(4)-C(13) 116.59(7) 
O(1)-C(1)-C(2) 106.94(6) 
O(1)-C(1)-C(6) 105.89(6) 
O(1)-C(1)-C(10) 107.66(6) 
C(2)-C(1)-C(6) 114.54(6) 
C(10)-C(1)-C(2) 115.60(6) 
C(10)-C(1)-C(6) 105.64(6) 
C(1)-C(2)-H(2) 105.4(8) 
C(1)-C(2)-C(3) 116.17(6) 
C(3)-C(2)-H(2) 107.3(8) 
C(12)-C(2)-C(1) 110.08(6) 
C(12)-C(2)-H(2) 103.7(8) 
C(12)-C(2)-C(3) 113.09(6) 
C(4)-C(3)-C(2) 107.88(7) 
C(14)-C(3)-C(2) 109.73(6) 
C(14)-C(3)-C(4) 105.03(6) 
C(14)-C(3)-C(19) 111.41(7) 
C(19)-C(3)-C(2) 111.72(6) 
C(19)-C(3)-C(4) 110.80(7) 
C(3)-C(4)-H(4A) 109.0(8) 
C(3)-C(4)-H(4B) 108.2(11) 
H(4A)-C(4)-H(4B) 110.6(13) 
C(5)-C(4)-C(3) 113.04(7) 
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C(5)-C(4)-H(4A) 109.2(8) 
C(5)-C(4)-H(4B) 106.8(10) 
C(4)-C(5)-H(5A) 110.4(8) 
C(4)-C(5)-H(5B) 106.8(8) 
H(5A)-C(5)-H(5B) 109.1(12) 
C(6)-C(5)-C(4) 110.45(7) 
C(6)-C(5)-H(5A) 111.9(8) 
C(6)-C(5)-H(5B) 108.1(8) 
C(1)-C(6)-H(6) 106.3(7) 
C(1)-C(6)-C(7) 109.03(6) 
C(5)-C(6)-C(1) 111.02(7) 
C(5)-C(6)-H(6) 108.4(7) 
C(5)-C(6)-C(7) 114.99(7) 
C(7)-C(6)-H(6) 106.6(7) 
C(8)-C(7)-C(6) 107.59(6) 
C(20)-C(7)-C(6) 114.06(7) 
C(20)-C(7)-C(8) 107.40(7) 
C(21)-C(7)-C(6) 110.09(7) 
C(21)-C(7)-C(8) 109.68(7) 
C(21)-C(7)-C(20) 107.94(7) 
C(7)-C(8)-H(8) 110.6(9) 
C(9)-C(8)-C(7) 108.20(6) 
C(9)-C(8)-H(8) 114.9(9) 
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C(11)-C(8)-C(7) 105.71(7) 
C(11)-C(8)-H(8) 109.7(9) 
C(11)-C(8)-C(9) 107.34(7) 
C(8)-C(9)-H(9) 119.6(9) 
C(10)-C(9)-C(8) 113.10(7) 
C(10)-C(9)-H(9) 127.0(9) 
C(1)-C(10)-I(1) 123.83(5) 
C(9)-C(10)-I(1) 120.64(6) 
C(9)-C(10)-C(1) 114.63(7) 
O(1)-C(11)-C(8) 112.82(6) 
O(2)-C(11)-O(1) 119.90(8) 
O(2)-C(11)-C(8) 127.25(8) 
O(3)-C(12)-O(4) 123.87(7) 
O(3)-C(12)-C(2) 125.54(7) 
O(4)-C(12)-C(2) 110.58(6) 
O(4)-C(13)-H(13A) 107.9(10) 
O(4)-C(13)-H(13B) 110.3(8) 
O(4)-C(13)-H(13C) 110.2(12) 
H(13A)-C(13)-H(13B) 109.1(12) 
H(13A)-C(13)-H(13C) 114.6(15) 
H(13B)-C(13)-H(13C) 104.8(14) 
C(3)-C(14)-H(14) 113.4(9) 
C(15)-C(14)-C(3) 127.14(8) 
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C(15)-C(14)-H(14) 119.3(9) 
Si(1)-C(15)-H(15) 116.0(10) 
C(14)-C(15)-Si(1) 125.05(7) 
C(14)-C(15)-H(15) 118.5(10) 
Si(1)-C(16)-H(16A) 108.5(10) 
Si(1)-C(16)-H(16B) 110.7(10) 
Si(1)-C(16)-H(16C) 113.9(11) 
H(16A)-C(16)-H(16B) 106.6(15) 
H(16A)-C(16)-H(16C) 112.0(15) 
H(16B)-C(16)-H(16C) 104.8(15) 
Si(1)-C(17)-H(17A) 105(2) 
Si(1)-C(17)-H(17B) 110.7(13) 
Si(1)-C(17)-H(17C) 103.4(14) 
H(17A)-C(17)-H(17B) 103(2) 
H(17A)-C(17)-H(17C) 126(2) 
H(17B)-C(17)-H(17C) 108.5(18) 
Si(1)-C(18)-H(18A) 111.1(11) 
Si(1)-C(18)-H(18B) 109.9(13) 
Si(1)-C(18)-H(18C) 104.1(16) 
H(18A)-C(18)-H(18B) 109.8(16) 
H(18A)-C(18)-H(18C) 108.5(18) 
H(18B)-C(18)-H(18C) 113(2) 
C(3)-C(19)-H(19A) 112.9(10) 
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C(3)-C(19)-H(19B) 112.8(9) 
C(3)-C(19)-H(19C) 110.1(9) 
H(19A)-C(19)-H(19B) 104.8(13) 
H(19A)-C(19)-H(19C) 105.1(13) 
H(19B)-C(19)-H(19C) 110.7(13) 
C(7)-C(20)-H(20A) 107.2(10) 
C(7)-C(20)-H(20B) 110.3(10) 
C(7)-C(20)-H(20C) 110.6(9) 
H(20A)-C(20)-H(20B) 107.5(13) 
H(20A)-C(20)-H(20C) 111.0(14) 
H(20B)-C(20)-H(20C) 110.3(14) 
C(7)-C(21)-H(21A) 107.9(8) 
C(7)-C(21)-H(21B) 114.7(12) 
C(7)-C(21)-H(21C) 113.7(9) 
H(21A)-C(21)-H(21B) 110.7(12) 
H(21A)-C(21)-H(21C) 109.6(12) 
H(21B)-C(21)-H(21C) 100.0(14) 
___________________________________________________________   
Symmetry transformations used to generate equivalent atoms: 
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Table A7.1.4.  Anisotropic displacement parameters (Å2x 104) for 133.  The anisotropic 
displacement factor exponent takes the form: –2π2 [h2 a*2 U11  + ... + 2 h k a* b* U12] 
_________________________________________________________________  
 U11 U22  U33 U23 U13 U12 
_________________________________________________________________  
I(1) 153(1)  162(1) 141(1)  –20(1) –36(1)  –19(1) 
Si(1) 248(1)  130(1) 151(1)  45(1) 40(1)  16(1) 
O(1) 155(2)  82(2) 85(2)  0(2) 5(2)  6(2) 
O(2) 318(4)  150(3) 106(2)  8(2) 23(2)  13(2) 
O(3) 139(2)  179(3) 181(2)  39(2) 29(2)  33(2) 
O(4) 154(2)  162(3) 233(3)  93(2) 1(2)  34(2) 
C(1) 116(2)  85(3) 86(2)  1(2) –1(2)  3(2) 
C(2) 110(2)  91(3) 94(2)  6(2) –6(2)  –1(2) 
C(3) 120(2)  109(3) 117(3)  16(2) –6(2)  –15(2) 
C(4) 117(3)  181(4) 200(4)  68(3) 24(2)  9(2) 
C(5) 106(3)  166(4) 192(3)  48(3) –7(2)  8(2) 
C(6) 119(2)  112(3) 115(3)  6(2) 5(2)  24(2) 
C(7) 148(3)  98(3) 148(3)  17(2) –11(2)  20(2) 
C(8) 167(3)  90(3) 131(3)  22(2) –1(2)  2(2) 
C(9) 149(3)  98(3) 160(3)  5(2) 2(2)  –15(2) 
C(10) 115(2)  103(3) 128(3)  -4(2) –16(2)  –9(2) 
C(11) 161(3)  103(3) 108(3)  14(2) 5(2)  7(2) 
C(12) 118(2)  99(3) 118(3)  7(2) –19(2)  9(2) 
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C(13) 192(4)  165(4) 271(4)  34(3) –35(3)  58(3) 
C(14) 151(3)  149(3) 115(3)  23(2) 9(2)  –11(2) 
C(15) 237(3)  132(3) 147(3)  26(2) 28(3)  –6(3) 
C(16) 380(6)  294(6) 191(4)  60(4) –41(3)  –109(4) 
C(17) 732(12)  401(8) 403(8)  181(7) 221(8)  366(9) 
C(18) 363(6)  296(6) 274(5)  104(5) –16(4)  –138(5) 
C(19) 190(3)  143(3) 124(3)  8(3) –24(2)  –49(3) 
C(20) 189(3)  211(4) 188(4)  57(3) –58(3)  5(3) 
C(21) 238(4)  119(3) 256(4)  –9(3) 21(3)  51(3) 
_________________________________________________________________  
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Table A7.1.5.  Hydrogen coordinates ( x 103) and isotropic displacement parameters (Å2 x 103) for 
133. 
___________________________________________________________________  
 x  y  z  Uiso 
___________________________________________________________________  
H(2) 585(2) 532(1) 103(1) 16(3) 
H(4A) 917(2) 517(1) 100(1) 18(3) 
H(4B) 1014(2) 616(2) 132(1) 23(4) 
H(5A) 937(2) 517(2) 199(1) 20(3) 
H(5B) 1030(2) 414(1) 164(1) 11(3) 
H(6) 779(2) 321(1) 136(1) 10(3) 
H(8) 581(2) 208(2) 253(1) 24(4) 
H(9) 384(2) 181(2) 192(1) 22(3) 
H(13A) 197(2) 811(2) 105(1) 28(4) 
H(13B) 316(2) 940(1) 105(1) 16(3) 
H(13C) 273(2) 872(2) 149(1) 38(5) 
H(14) 735(2) 693(2) 64(1) 17(3) 
H(15) 848(2) 923(2) 111(1) 37(5) 
H(16A) 657(2) 812(2) –11(1) 30(4) 
H(16B) 845(2) 763(2) –19(1) 40(5) 
H(16C) 768(2) 889(2) –48(1) 42(5) 
H(17A) 587(4) 1072(3) 33(1) 80(10) 
H(17B) 680(3) 1156(2) 4(1) 65(6) 
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H(17C) 731(3) 1162(2) 56(1) 59(6) 
H(18A) 1056(2) 1077(2) –10(1) 37(5) 
H(18B) 1127(3) 953(2) 19(1) 48(6) 
H(18C) 1068(3) 1080(2) 42(1) 58(6) 
H(19A) 875(2) 802(2) 174(1) 22(4) 
H(19B) 777(2) 705(2) 201(1) 23(4) 
H(19C) 694(2) 814(2) 173(1) 21(3) 
H(20A) 885(2) 220(2) 263(1) 23(4) 
H(20B) 892(2) 370(2) 255(1) 25(4) 
H(20C) 1014(2) 275(2) 229(1) 24(4) 
H(21A) 910(2) 121(2) 170(1) 14(3) 
H(21B) 714(2) 98(2) 166(1) 31(4) 
H(21C) 788(2) 50(2) 207(1) 25(4) 
___________________________________________________________________ 
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CHAPTER 3 
Negishi Cross-Coupling of Zinc Methoxyacetylides and Protecting-
Group-Free Total Syntheses of Basiliopyrone 
And Transtaganolides C and D 
3.1 INTRODUCTION 
Having successfully synthesized transtaganolides A–B (7–10, Figure 3.1.1) 
(basiliolide B (11), epi-basiliolide B (42), basiliolide C (12), and epi-basiliolide C (43)) 
by means of a concise general synthetic strategy, we once again revisited this general 
synthetic strategy, aiming to further improve upon it.1  Our approach employed an 
Ireland–Claisen, Diels–Alder cycloaddition cascade (ICR/DA) to build the ABD tricyclic 
core followed by formal [5+2] annulation strategy to build the 7-membered C-ring.  
Although our strategy allowed for rapid assembly of the transtaganolide and basiliolide 
natural products, the key formal [5+2] annulation, which builds the ketene-acetal 
containing 7-membered C-ring, was inefficient, a trend observed in all of our reported 
total syntheses.  Transtaganolides A and B (7 and 8) proceeded in 35% combined yield 
from tetracycles 130a and 130b (Scheme 3.1.1A).  Transtaganolides C and D (9 and 10) 
proceeded in 31% combined yield from tricycles 63a and 63b (Scheme 3.1.1B).  
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Basiliolide B (11) and epi-basiliolide B (42) were formed in 18% combined yield from 
silyl esters 67a and 67b (Scheme 3.1.1C).  Lastly, basiliolide C (12) and epi-basiliolide C 
(43) were formed in 17% combined yield from tricycles 89a and 89b (Scheme 3.1.1D).  
Furthermore, these transformations require stoichiometric palladium and super-
stoichiometric quantities of the organostannane.  To date, similar cross-coupling reactions 
of organostannanes have not been accomplished on substrates of such complexity, and 
few examples are known that utilize stannyl oxy-acetylides.2  Therefore, we sought to 
improve the efficiency of this challenging cross-coupling through improved yield, 
reduced catalyst loading, and reduction or elimination of equivalents of stannane utilized. 
 
Figure 3.1.1.  Transtaganolides and basiliolides (7–12, 42, and 43). 
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Scheme 3.1.1.  A) Cross-coupling to form transtaganolides A and B (7 and 8).  B) Cross-coupling to 
form transtaganolides C and D (9 and 10).  C) Cross-coupling to form basiliolide B (11) and epi-
basiliolide B (42).  D) Cross-coupling to form basiliolide C (12) and epi-basiliolide C (43). 
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3.2 MODEL CROSS-COUPLING REACTIONS OF ZINC 
METHOXYACETYLIDES 
In 1992, Himbert and Löffler reported a palladium-catalyzed cross-coupling of zinc 
alkoxyacetylides to simple aryl iodides.3 Inspired by this precedent, we began 
investigations of palladium catalyzed cross-coupling reactions of a zinc alkoxyacetylide 
to form the characteristic C-ring of the series. 
Synthesis of the precedented zinc alkoxyacetylide (136) proceeded via known 
treatment of 1,1-dimethoxy-2-chloro-acetaldehyde (60) with 3 equivalents of lithium 
diethyl amide to form the putative lithium acetylide 614, which is then trapped as the zinc 
acetylide 136 by the addition of anhydrous zinc chloride (Scheme 3.2.1).  The 
methoxyethynyl zinc chloride (136) was stored at 0 °C as the crude solution and always 
used within hours of preparation.5 
Scheme 3.2.1.  Synthesis of methoxyethynyl zinc chloride (136). 
 
As a model system, Pd-catalyzed coupling of organozinc 136 to iodo-cyclohexene 
(137)6 was evaluated (Table 3.2.1).  Initially, we investigated a variety of bidentate 
ligands, as well as those conditions described by Himbert and Löffler.  Spontaneous 
hydration of the cross-coupled product 138 on work-up yielded methyl ester 139, which 
could be quantified to determine the overall yield of the process.  We found that the 
conditions reported by Himbert and Löffler (Table 3.2.1, entry 1) did not extend readily 
from aryl iodides to vinyl iodides such as iodo-cyclohexene (137).  The use of an N,N–
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ligand, bipyridine (entry 2) as well as a P,N-ligand, H2PHOX (entry 3) resulted in 
approximately 50% consumption of the vinyl iodide 137, giving 0% or 10% yield of the 
product 139, respectively.  This large discrepancy between substrate 137 conversion and 
the calculated of yield 139 is general and attributed to the rapid decomposition of the 
cross-coupled product 138 under the reaction conditions.  Among the diphosphines 
tested, BINAP (entry 4) gave 40% conversion of iodo-cyclohexene (137), but 
unfortunately provided the product 139 in a mere 6% yield.  Dppe (entry 6) was found to 
provide no reactivity, whereas dpp-benzene (entry 5) and dppp (entry 7) gave minimal 
conversions (13% and 22%, respectively) and poor yields (6% and 7%, respectively).  
Lastly dppb (entry 8) and dppf (entry 9) gave the highest yields (13% and 17%, 
respectively) and 100% conversion of iodo-cyclohexene (137).  Although the yields were 
quite low, we were delighted to have found conditions that employ substoichiometric 
quantities of palladium for this challenging cross-coupling reaction. 
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Table 3.2.1. Ligand screen for the cross-coupling of methoxyethynyl zinc chloride (136) and iodo-
cyclohexene (137). 
 
3.3 LIGAND BITE ANGLES AND THE RELATIONSHIP TO 
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In our reported cross-coupling reactions of organostannanes, as well as the studies 
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alkoxy alkynyl moiety.3  We posited that the non-productive polymerization pathway led 
to degradation of the metal methoxyacetylide (i.e., 62 or 136), degradation of the 
intermediate eneyne (e.g., 138), and degradation of the catalyst.  We reasoned that these 
non-productive pathways necessitated stoichiometric quantities of palladium in our [5+2] 
annulation.  Thus, we were pleased to find that dppb and dppf (Table 3.2.1, entry 8 and 9, 
respectively) could accomplish the coupling of organozinc 136 to iodide 137 utilizing 
substoichiometric quantities of palladium. 
The superior reactivity demonstrated by both dppb and dppf were attributed to their 
relatively large bite angles (98° and 96° bite angles, respectively).7  It has been shown 
that bidentate ligands with large bite angles are poor catalysts for ethylene carbonylative 
polymerization reactions,8 which require an inner-sphere cis-geometry of monomers.  We 
therefore envisioned that trans-chelating ligands could improve the efficiency of our 
reaction through the attenuation of acetylide polymerization, the putative catalyst, and 
substrate decomposition pathway.  Thus, we were eager to investigate Xantphos (Table 
3.3.1, entries 9–12) within our reaction manifold, because of its large bite angle (111°) 
and demonstrated propensity for trans-chelation.7, 8 
We probed this hypothesis again through cross-coupling reactions of methoxyethynyl 
zinc chloride (136) and iodo-cyclohexene (137, Table 3.3.1), tabulating the conversion 
and yield as a function of time for dppb (Table 3.3.1, entries 1–4), dppf (entries 5–8), and 
Xantphos (entries 9–12).  Consistent with our hypothesis, dppb and dppf (entries 1–4 and 
5–8 respectively) with similar bite angles of 98° and 96° gave similar yields, 35% and 
31% respectively.  Xantphos (entries 9–12) with a considerably larger bite angle of 111° 
provided the product in 48% yield.  Furthermore, for all three ligand-catalyst frameworks 
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we observed product decomposition by the end of the 4 h window that the reactions were 
monitored, suggesting polymerization was possibly still a competing pathway. 
Table 3.3.1.  Comparing dppb, dppf, and Xantphos as ligands for catalyzing the cross-coupling of 
methoxyethynyl zinc chloride (136) and iodo-cyclohexene (137) as a function of time. 
 
3.4 APPLICATIONS OF ORGANOZINC CROSS-COUPLINGS TO THE 
SYNTHESES OF TRANSTAGANOLIDE NATURAL PRODUCTS 
Having found Xantphos to be optimal for achieving the cross-coupling of acetylide 
136 to vinyl iodide 137, we moved from the model iodide 137 to the tricyclic 
transtaganolide core 63a and 63b.  Unfortunately, our procedure did not readily translate 
to the more complex vinyl iodide (63a and 63b) utilized in the total synthesis (Scheme 
3.4.1A).  Under these conditions we observed minimal substrate consumption and no 
137
entry
Pd2(dba)3
(5 mol%)
ligand
(15 mol%)
(136 , 1.5 equiv)
THF, 30 °C
OMeClZn
O
PPh2 PPh2
Xantphos
ligand conversion (%) a
I
138
OMe
139
OMe
O
2
yield of 139  (%) a
78 35
3 94 29
4 100 26
5 46 3
6 81 30
7 98 31
8 100 29
9 59 40
dppb
Ph2P
Fe
PPh2
Ph2P
dppf
1 21 3
rxn time
1 h
2.5 h
4 h
1 h
2.5 h
4 h
15 min
15 min
15 min
10 87 48
11 91 39
12 96 44
1 h
2.5 h
4 h
H2O
PPh2
a Determined by GC using a tridecane internal standard.
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noticeable product formation; surprisingly, use of stoichiometric palladium loading led to 
trace product formation.  We attribute this poor reactivity to the demanding steric 
environment of the substrate when compared to the simple cyclohexene 137 utilized in 
the model studies.  In an effort to overcome the putative kinetic barrier, we explored 
heating of the reaction mixture. Ultimately, we found that microwave heating (100 °C) 
for short durations (<1 min) led to observable product formation (140a and 140b, 
Scheme 3.4.1B).  However, because of the rapid rate of product 140a and 140b 
decomposition at 100 °C, as well as the very short reaction time, the coupling could not 
be scaled and had poor reproducibility. 
Scheme 3.4.1.  A) Cross-coupling of tricycles 63a and 63b using the palladium Xantphos catalytic 
conditions developed on model cross-couplings to iodo-cyclohexene (137).  B) Cross-coupling of 
tricycles 63a and 63b facilitated by microwave irradiation. 
 
With no clear means to overcome the steric congestion of 63a and 63b, we 
reevaluated our retrosynthetic analysis, noting that prior to the ICR/DA cascade, pyrone 
Pd2(dba)3
(5 mol%)
Xantphos
(12.5 mol%)
(136 , 3  equiv)
THF, 30 °C
TBSO
O
H
O
OI
OMeClZn
O
OTBS
H
O
O
Pd2(dba)3
(10 mol%)
Xantphos
(25 mol%)
(136 , 4 equiv)
THF, µw 100 °C
1 min
TBSO
O
H
O
OI
OMeClZn
OMe
no reaction
63a (C8:  β−Me,  α−vinyl)
63b (C8:  α−Me,  β−vinyl)
A.
63a (C8:  β−Me,  α−vinyl)
63b (C8:  α−Me,  β−vinyl)
140a (C8:  β−Me,  α−vinyl)
140b (C8:  α−Me,  β−vinyl)
B.
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ester 57 bears a heteroaromatic iodine far more accessible for cross-coupling (Scheme 
3.4.2).  To our delight, palladium catalyzed cross-coupling of ICR/DA precursor 57 and 
methoxyacetylide 136 proceeded in 19% yield.  Furthermore, we were pleased to find 
that the eneyne 141 could be purified by silica column chromatography without hydration 
or decomposition. 
Scheme 3.4.2.  Retrosynthetic Analysis illuminates a viable cross-coupling substrate pyrone ester 57. 
 
With a viable cross-coupling partner in pyrone 57, we proceeded with optimization of 
the reaction conditions.  Initial optimization was accomplished in a nitrogen filled 
glovebox at 50 °C (Table 3.4.1).  We investigated organozinc 136 equivalents, catalyst 
loading, and concentration as they pertain to yield of the cross-coupled product 141 as a 
function of time.  First off, more equivalents of organozinc (comparing entries 1–6 to 
entries 7–12) gave much higher yields.  Lower catalyst loading (comparing entries 1–6 to 
entries 13–18) gave longer reaction times and lower yields.  And lastly, lower 
concentration (comparing entries 13–18 to entries 19–24) greatly reduced the overall 
efficacy of the transformation, cutting the yield in half.  Furthermore, as was observed in 
previous cross-coupling reactions, the cross-coupled product 141 decomposes under the 
reaction conditions. 
OO
O
O
I
Pd2(dba)3
(10 mol%)
Xantphos
(20 mol%)
(136 , 2.0 equiv)
THF, 30 °C
(19% yield)
OMeClZn
TBSO
O
H
O
OI
ICR/DA
63a (C8:  β−Me,  α−vinyl)
63b (C8:  α−Me,  β−vinyl)
57
OO
O
O
141
OMe
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Table 3.4.1.  Comparing methoxyethynyl zinc chloride (136) equivalents, catalyst loading, and 
concentration as they effect the cross-coupling reaction at 50 °C of organozinc 136 and pyrone 57 
as a function of time. 
 
In our second optimization screen, reactions were performed at 40 °C (Table 3.4.2).  
3.0 equivalents of organozinc 136 (entries 4–6) gave higher yields than 2.0 equivalents 
(entries 1–3).  Lower catalyst loadings (comparing entries 7–12 to entries 1–6) gave 
lower yields similar to experiments executed at 50 °C (Table 3.4.1).  Furthermore, when 
comparing reactions carried out at 40 °C (Table 3.4.2, entries 1–3) to those conducted at 
entry
Pd2(dba)3
Xantphos
136 , THF
50 °C
time
OMeClZn
equiv 136 concentration
1 2.0 0.05 M
a Determined by SFC using diphenylether internal standard.  b SFC failed and no data could be collected 
at the time point.  Resubmission was not a viable option as SFC sample would degrade over time.
OO
O
O
I
57
OO
O
O
141
OMe
time yield of 141  (%) a
15 min 46
2 2.0 0.05 M 30 min 35
3 2.0 0.05 M 45 min —b
4 2.0 0.05 M 1 h 31
5 2.0 0.05 M 1.5 h 22
6 2.0 0.05 M 2.5 h 12
7 1.2 0.05 M 15 min 21
8 1.2 0.05 M 30 min 12
9 1.2 0.05 M 45 min 15
10 1.2 0.05 M 1 h —b
11 1.2 0.05 M 1.5 h 4
12 1.2 0.05 M 2.5 h 0
mol% Pd2(dba)3
10
10
10
10
10
10
10
10
10
10
10
10
mol% Xantphos
20
20
20
20
20
20
20
20
20
20
20
20
13 2.0 0.05 M 15 min 38
14 2.0 0.05 M 30 min 39
15 2.0 0.05 M 45 min 27
16 2.0 0.05 M 1 h —b
17 2.0 0.05 M 1.5 h 25
18 2.0 0.05 M 2.5 h —b
5
5
5
5
5
5
10
10
10
10
10
10
19 2.0 0.02 M 15 min 20
20 2.0 0.02 M 30 min 21
21 2.0 0.02 M 45 min 17
22 2.0 0.02 M 1 h 16
23 2.0 0.02 M 1.5 h 15
24 2.0 0.02 M 2.5 h —b
5
5
5
5
5
5
10
10
10
10
10
10
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50 °C (Table 3.4.1, entries 1–6), reactions times were slower, as expected, and yields 
only slightly differed.  For this reason, all remaining cross-coupling reactions were 
executed at 50 °C for substrate 57. 
Table 3.4.2.  Comparing methoxyethynyl zinc chloride (136) equivalents and catalyst loading as 
they effect the cross-coupling reaction at 40 °C of organozinc 136 and pyrone 57 as a function of 
time. 
 
Having accomplished two rounds of optimization for the cross-coupling reaction of 
pyrone 57 and methoxyethynyl zinc chloride (136), we applied what we had learned from 
the optimization and performed the cross-coupling on a larger scale (Scheme 3.4.3).  To 
our delight, using 10 mol% Pd2(dba)3, 20 mol% Xantphos, and 3.5 equivalents of 
methoxyacetylide 136, we formed product 141 in 25 min of 50 °C heating in 61% yield, 
as determined by SFC and 44% isolated yield.  The discrepancy between the 61% yield 
entry
Pd2(dba)3
Xantphos
136
THF (0.05M)
40 °C, time
OMeClZn
equiv 136
1 2.0
a Determined by SFC using diphenylether internal standard.
OO
O
O
I
57
OO
O
O
141
OMe
time yield of 141  (%) a
15 min 29
2 2.0 30 min 42
3 2.0 1 h 32
mol% Pd2(dba)3
10
10
10
mol% Xantphos
20
20
20
4 3.0 15 min 37
5 3.0 30 min 52
6 3.0 1 h 35
10
10
10
20
20
20
7 2.0 15 min 22
8 2.0 30 min 27
9 2.0 1 h 27
5
5
5
10
10
10
10 3.0 15 min 27
11 3.0 30 min 34
12 3.0 1 h 28
5
5
5
10
10
10
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as determined by SFC and the 44% isolated yield was not unexpected.  Even though 
eneyne 141 could be isolated by column chromatography, it was clear that product 141 
decomposed over time, and therefore we expected to observe some decomposition during 
purification.  
Scheme 3.4.3.  Cross-coupling of pyrone 57 and methoxyethynyl zinc chloride (136) using our 
optimized reaction conditions. 
 
3.5 PROTECTING-GROUP-FREE SYNTHESES OF BASILIOPYRONE 
AND TRANSTAGANOLIDES C AND D 
Having developed an acceptable method for the palladium catalyzed Negishi cross-
coupling of methoxyethynyl zinc chloride (136) and pyrone ester 57, we could 
successfully form eneyne 141, which could be taken on to transtaganolides C and D (9 
and 10) as well as basiliopyrone (3).  If desired, eneyne 141 could be hydrated by 
treatment with aqueous sulfuric acid in acetonitrile to cleanly furnish basiliopyrone (3) in 
40% yield (Scheme 3.5.1).  The total synthesis of basiliopyrone (3) required seven steps 
(longest linear sequence) from commercially available material. 
OO
O
O
I
Pd2(dba)3
(10 mol%)
Xantphos
(20 mol%)
(136 , 3.5 equiv)
THF, 50 °C
25 min
OMeClZn
57
OO
O
O
141
SFC yield: 61%
isolated yield: 44%
OMe
Chapter 3–Negishi Cross-Coupling of Zinc Methoxyacetylides and Protecting- 
Group-Free Total Syntheses of Basiliopyrone and Transtaganolides C and D 
248 
Scheme 3.5.1.  Acid catalyzed hydration of 141 allows for the formation of basiliopyrone (3). 
 
Finally, minor modification of our reported ICR/DA cascade conditions allowed 
direct access to transtaganolides C and D (9 and 10) in a single step from the alkynyl 
pyrone ester 141 as a 2:1 mixture of diastereomers in 14% combined yield (Scheme 
3.5.2).  Because of the thermal instability of the substrate (141) the cascade was 
performed at a lower temperature (70 °C) than our standard conditions and in a nitrogen 
filled glovebox to ensure the absolute exclusion of adventitious water.  Furthermore, the 
Ireland–Claisen step of the cascade proceeded smoothly, but the Ireland–Claisen products 
(142a and 142b) we found to be unstable and prone to decomposition.  Nevertheless, we 
were satisfied to observe the successful [4+2] cycloaddition of a substrate (142a or 142b) 
bearing an electron-donating methoxy alkynyl moiety on the pyrone ring (all prior pyrone 
Diels-Alder cycloadditions had required electron-withdrawing substituents).  While low 
yielding, this one-pot procedure forms three rings, two all-carbon quaternary centers, and 
four tertiary stereocenters from a simple monocyclic, achiral precursor (141).  Finally, the 
success of this cascade process further implicates the Ireland–Claisen/Diels–Alder 
sequence as a potential biosynthetic route. 
OO
O
O
141
OMe
OO
O
O
basiliopyrone (3)
O
MeO
MeCN, 1 M
H2SO4 (aq)
 
23 °C, 24 h
(40% yield)
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Scheme 3.5.2.  A one-pot synthesis of transtaganolides C and D (9 and 10) from alkynyl pyrone 
141. 
 
3.6 CONCLUSION 
In conclusion, we have improved our previously disclosed [5+2] annulation of 
methoxy acetyl stannane 62 by obviating the need for organotin reagents and developing 
a complimentary Negishi cross-coupling of methoxyacetylide 136.  This methodology, 
which employs catalytic quantities of a Xantphos palladium complex, was used to furnish 
the alkynyl pyrone ester 141.  The cross-coupled product 141 could be hydrated to 
furnish basiliopyrone (3) or, to our delight, transformed in a single step cascade process 
into transtaganolides C and D (9 and 10). 
 
 
OO
O
O
141
OMe
O
O
MeO
H
O
O
transtaganolide C 
(9)
BSA (2.5 equiv)
NEt3 (10 mol%)
PhMe, 70 °C
2.75 h
O
O
MeO
H
O
O
transtaganolide D 
(10)
+
2:1 mixture of
diastereomers
OTMSO
O
O
142a
OMe
+
OTMSO
O
O
142b
OMe
PhMe, 70 °C
5.25 days;
then MeCN, pH 7
phosphate buffer
23 °C, 3 h
(14% yield)
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3.7 EXPERIMENTAL SECTION 
3.7.1 Materials and Methods 
Unless otherwise stated, reactions were performed in flame-dried glassware under an 
argon or nitrogen atmosphere using dry deoxygenated solvents.  Solvents were dried by 
passage through an activated alumina column under argon.  Chemicals were purchased 
from Sigma-Aldrich Chemical Company and used as received.  Pd(PPh3)4 was prepared 
using known methods.  Thin layer chromatography (TLC), both preparatory and 
analytical, was performed using E. Merck silica gel 60 F254 precoated plates (0.25 mm) 
and visualized by UV fluorescence quenching, p-anisaldehyde, I2, or KMnO4 staining. 
Analytical super critical fluid (SFC) chromatography was performed using a Thar SFC 
and either Chiralpak IA or AD-H columns.  Preparatory SFC was performed with a Jasco 
SFC and a prep AD-H column (21 x 250 mm, 5mic part# 19445).   ICN Silica gel 
(particle size 0.032–0.063 mm) was used for flash chromatography.  1H NMR and 13C 
NMR spectra were recorded on a Varian Mercury 300 (at 300 MHz) or on a Varian Unity 
Inova 500 (at 500 MHz).  1H NMR spectra are reported relative to CDCl3 (7.26 ppm).  
Data for 1H NMR spectra are reported as follows: chemical shift (ppm), multiplicity, 
coupling constant (Hz), and integration.  Multiplicities are reported as follows: s = 
singlet, d = doublet, t = triplet, q = quartet, sept. = septet, m = multiplet, bs = broad 
singlet, bm = broad multiplet.  13C NMR spectra are reported relative to CDCl3 (77.16 
ppm).  FTIR spectra were recorded on a Perkin Elmer SpectrumBX spectrometer and are 
reported in frequency of absorption (cm-1).  HRMS were acquired using an Agilent 6200 
Series TOF with an Agilent G1978A Multimode source in electrospray ionization (ESI), 
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atmospheric pressure chemical ionization (APCI), or multimode-ESI/APCI.  
Crystallographic data were obtained from the Caltech X-Ray Diffraction Facility. 
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3.7.2 PREPARATIVE PROCEDURES 
 
 
Methoxyethynyl zinc chloride (136).  In a nitrogen glovebox, to a 0 °C solution of 
HNEt2 (807 µL, 7.8 mmol) in THF (4.25 mL) was added a 2.5 M solution of n-BuLi in 
hexanes (2.72 mL, 6.8 mmol).  The reaction was stirred for 25 min at 0 °C at which point 
1,1-dimethoxy-2-chloro-acetaldehyde (60) was added (228 µL, 2.0 mmol).  The reaction 
was stirred at 0 °C and the formation of white precipitate was observed.  After 2 h of 
stirring at 0 °C, anhydrous zinc chloride was added (300 mg, 2.2 mmol), and the reaction 
was stirred for another 15 min at 0 °C or until all the zinc chloride had dissolved.  The 
resulting 0.25 M solution of methoxyethynyl zinc chloride (136) in THF was kept at 0 
°C, in the glovebox, and used, as is, within hours of its generation. 
 
 
Methyl 2-(cyclohex-1-en-1-yl)acetate (139).  General Procedure: In a nitrogen filled 
glovebox were combined Pd2(dba)3 (1.4 mg, 1.5 µmol), Xantphos (2.6 mg, 4.5 µmol), 
and THF (180 µL) in a glass vial.  The reaction mixture was stirred for 30 min at 30 °C.  
Then a 1 M solution of known iodo-cyclohexene6 (137) in THF (30 µL, 0.030 mmol), 
LiNEt2
(3 equiv)
THF
0 °C, 2 h
OMe
ClZn
136
Cl
H
OMeMeO
60
OMe
Li
61
ZnCl2
(1 equiv)
0 °C, 20 min
137
Pd2(dba)3
(5 mol%)
ligand
(15 mol%)
(136 , 1.5 equiv)
THF, 30 °C, 3 h
OMeClZn
I
138
OMe
139
OMe
O
H2O
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internal standard tridecane (6 µL, 0.025 mmol), and freshly made 0.05 M 
methoxyethynyl zinc chloride (136) solution (90 µL, 0.045 mmol) were added 
sequentially and the solution was stirred at 30 °C.  Aliquots (5 µL) were taken from the 
reaction solution at 15 min, 1 h, 2.5 h, and 4.5 h.  Aliquots were diluted with Et2O, 
pushed through a short pad of silica, and then injected on GC for analysis.  Yields of 
methyl ester 139 and consumption of vinyl iodide 137 were then quantified.  All spectral 
data for 139 match the literature.9 
 
 
(E)-3,7-dimethylocta-2,6-dien-1-yl 2-(5-(methoxyethynyl)-2-oxo-2H-pyran-6-
yl)acetate (141).  In a nitrogen filled glovebox, a solution of Pd2(dba)3 (18.8 mg, 0.0205 
mmol) and Xantphos (23.8 mg, 0.0411 mmol) in THF (900 µL) was stirred at 40 °C for 
25 min.  Following the catalyst pre-stir, 57 (85.6 mg, 0.206 mmol) was added as a 
solution in THF (350 µL) with internal standard diphenylether (37.1 mg, 0.218 mmol).  
This was subsequently followed by the addition of freshly generated 0.25 M solution of 
methoxyethynyl zinc chloride (136) (2.9 mL, 0.719 mmol).  The resulting 0.05 M 
reaction solution was heated to 50 °C and stirred for 25 min.  The reaction mixture was 
then immediately removed from heat, diluted with 0 °C THF (12 mL), removed from the 
OO
O
O
I
Pd2(dba)3
(10 mol%)
Xantphos
(20 mol%)
(136 , 3.5 equiv)
THF, 50 °C
25 min
OMeClZn
57
OO
O
O
141
SFC yield: 61%
isolated yield: 44%
OMe
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glovebox, and flushed through a short pad of silica, eluding with a 30% solution of Et2O 
in hexanes (150 mL).  A small aliquot was then shot on SFC for analysis.  Solvent was 
then removed by rotary evaporation and purified by column chromatography (EtOAc in a 
50% solution of CH2Cl2 in hexanes 1%→2% on silica) to give 31 mg (44% isolated yield, 
61% SFC yield) of 141 as a reddish, yellow oil; 1H NMR (500 MHz, CDCl3) δ  7.23 (d, J 
= 9.6 Hz, 1H), 6.20 (d, J = 9.6 Hz, 1H), 5.32 (tq, J = 7.1, 1.3 Hz, 1H), 5.08–5.04 (m, 1H), 
4.65 (d, J = 7.2 Hz, 2H), 3.96 (s, 3H), 3.71 (s, 2H), 2.13–1.98 (m, 4H), 1.69 (s, 3H), 1.67 
(s, 3H), 1.59 (s, 3H); 13C NMR (125 MHz, CDCl3) δ  167.6, 160.8, 159.9, 146.8, 143.2, 
132.0, 123.8, 117.8, 114.5, 104.4, 103.5, 66.4, 62.6, 39.6, 38.8, 31.8, 26.4, 25.8, 17.8, 
16.6; FTIR (Neat Film NaCl) 2926, 2856, 2271, 1742, 1634, 1548, 1446, 1418, 1377, 
1347, 1318, 1294, 1238, 1208, 1167, 1134, 1064, 1040, 969, 895, 870, 826 cm–1; HRMS 
(Multimode-ESI/APCI) m/z calc’d for C20H25O5 [M+H]+: 345.1697, found 345.1701. 
 
 
Basiliopyrone (3).  To a 23 °C solution of 141 (19 mg, 0.055 mmol) in MeCN (2 
mL) was added a 1M solution of H2SO4 in water (500 µL).  The reaction mixture was 
then stirred at 23 °C for 24 h.  After the reaction had gone to completion, the mixture was 
slowly quenched with a saturated solution of NaHCO3 (5 mL), such that the reaction 
mixture was no longer acidic.  The solution was then extracted with EtOAc (4x 8 mL).  
OO
O
O
141
OMe
OO
O
O
basiliopyrone (3)
O
MeO
MeCN, 1 M
H2SO4 (aq)
 
23 °C, 24 h
(40% yield)
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The organics were combined and sequentially washed with saturated NaHCO3 solution 
(25 mL), saturated brine solution (25 mL), and then once again with saturated NaHCO3 
solution (25 mL), and saturated brine solution (25 mL).  The organics were then dried 
over Na2SO4 and solvent was removed by rotary evaporation.  Purification by column 
chromatography (EtOAc in hexanes 10%→25% on silica) yielded 8.1 mg (40% yield) of 
basiliopyrone (3) as a pale yellow oil.  The spectroscopic data obtained from synthetic 3 
match those published from natural sources; 1H NMR (300 MHz, CDCl3) δ 7.27 (d, J = 
9.9 Hz, 1H), 6.27 (d, J = 9.5 Hz, 1H), 5.31 (tq, J = 7.2, 1.3 Hz, 1H), 5.10–5.04 (m, 1H), 
4.64 (d, J = 7.2 Hz, 2H), 3.71 (s, 3H), 3.59 (s, 2H), 3.35 (s, 2H), 2.16–1.98 (m, 4H), 1.69 
(s, 3H), 1.68 (s, 3H), 1.60 (s, 3H); 13C NMR (125 MHz, CDCl3) δ  170.3, 167.5, 161.3, 
155.8, 146.4, 143.4, 132.0, 123.9, 117.8, 115.3, 111.1, 62.9, 52.5, 39.7, 37.7, 34.9, 26.5, 
25.8, 17.8, 16.7; FTIR (Neat Film NaCl) 2954, 2924, 2857, 1738, 1650, 1557, 1437, 
1378, 1347, 1302, 1241, 1166, 1103, 1070, 975, 951, 872, 829 cm–1; HRMS (Multimode-
ESI/APCI) m/z calc’d for C20H26O6 [M+H]+: 363.1802, found 363.1792. 
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Transtaganolides C (9) and D (10).  To assure absolute purity of 141 (10 mg, 0.029 
mmol), directly following its isolation, the substrate (141) was submitted to 1H NMR in 
C6D6 and upon confirmation of its purity, the solvent was pumped off in the anti-chamber 
of a nitrogen filled glove box.  This limited the possibility of substrate 141 decomposition 
as well as removed any deleterious, residual water.  While the NMR solvent was removed 
in the anti-chamber, in the nitrogen filled glove box, the reaction glassware was silylated 
by the addition of BSA (20 µL), triethylamine (0.41 µL), and PhMe (5 mL).  This 
solution was heated to 70 °C and stirred for 30 min.  The solution was then cooled to 
ambient temperature and then discarded.  The reaction vessel was then rinsed with PhMe 
(3 x 1 mL).  Once all C6D6 was removed from the substrate 141, 141 (10 mg, 0.029 
mmol) was transferred to the previously silylated reaction vessel with PhMe (600 µL, 
0.05M).  To this solution was then added BSA (17.8 µL, 0.073 mmol) and triethylamine 
(0.041 µL, 0.0029 mmol).  The reaction solution was heated to 70 °C and stirred for 2.75 
OO
O
O
141
OMe
O
O
MeO
H
O
O
transtaganolide C 
(9)
BSA (2.5 equiv)
NEt3 (10 mol%)
PhMe, 70 °C
2.75 h
O
O
MeO
H
O
O
transtaganolide D 
(10)
+
2:1 mixture of
diastereomers
OTMSO
O
O
142a
OMe
+
OTMSO
O
O
142b
OMe
PhMe, 70 °C
5.25 days;
then MeCN, pH 7
phosphate buffer
23 °C, 3 h
(14% yield)
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h, at which point the Ireland–Claisen rearrangement had gone to completion.  The 
reaction was then cooled to ambient temperature and diluted with PhMe (9.2 mL, 
0.003M) that had been doped with excess BSA (12.25 µL, PhMe:BSA = 1 mL:1.25 µL).  
The reaction mixture was then reheated to 70 °C and stirred for 5 d and 6 h.  The reaction 
mixture was cooled to ambient temperature and removed from the nitrogen filled 
glovebox.  The solution was concentrated by rotary evaporation and to the crude reaction 
residue was added MeCN (8 mL) and pH 7 phosphate buffer (100 µL).  This solution was 
stirred at 23 °C for 3 h to allow for silyl cleavage and cyclization to the desired natural 
products (9 and 10).  MeCN was then removed by passing a stream of air over the 
solution (rotary evaporation could not be accomplished without bumping the crude 
reaction mixture), and the remaining aqueous solution was further diluted with water 
(800 µL) and saturated brine (200 µL).  The aqueous solution was then extracted with 
EtOAc (5 x 1 mL).  The organics were pooled, dried over Na2SO4, and then concentrated 
by rotary evaporation.  The crude oil was purified by normal phase HPLC (30% EtOAc 
in hexanes) to yield 0.90 mg (9% yield) of transtaganolide C (9) and 0.46 mg (5% yield) 
of transtaganolide D (10).  The spectroscopic data obtained from synthetic 9 and 10 
match those published from natural sources. 
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A8.1 SYNTHETIC SUMMARY FOR BASILIOPYRONE AND 
TRANSTAGANOLIDES C AND D 
Scheme 8.1.1.  Protecting-group-free synthesis of basiliopyrone (3). 
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Scheme 8.1.2.  Protecting-group-free syntheses of transtaganolides C and D (9–10). 
 
 
OO
O
O
141
OMe
O
O
MeO
H
O
O
transtaganolide C 
(9)
BSA (2.5 equiv)
NEt3 (10 mol%)
PhMe, 70 °C
2.75 h
O
O
MeO
H
O
O
transtaganolide D 
(10)
+
2:1 mixture of
diastereomers
OTMSO
O
O
142a
OMe
+
OTMSO
O
O
142b
OMe
PhMe, 70 °C
5.25 days;
then MeCN, pH 7
phosphate buffer
23 °C, 3 h
(14% yield)
Appendix 9–Gas Chromatography and Supercritical Fluid 
Chromatography Data: Relevant to Chapter 3 263 
 
 
 
 
APPENDIX 9 
Gas Chromatography and Supercritical Fluid Chromatography 
Data: Relevant to Chapter 3 
 
  
Appendix 9–Gas Chromatography and Supercritical Fluid 
Chromatography Data: Relevant to Chapter 3 264 
A9.1 GAS CHROMATOGRAPHY DATA FOR ORGANOZINC CROSS-
COUPLING OPTIMIZATION 
 
 
Yields of methyl ester 1391 and consumption of vinyl iodide 1372 were quantified 
using the calibration curves (Figure 9.1.1A and B), which graph the area ratio of gas 
chromatography (GC) peaks as a function of the molar ratio of either the methyl ester 139 
and the tridecane internal standard or substrate 137 and the tridecane internal standard.  
This data was collected from several individual GC runs depicted in Table 9.1.1. 
Figure 9.1.1.  A) Calibration curve used to determine cross-coupling yields comparing methyl ester 
139 and tridecane internal standard.  B) Calibration curve used to determine cross-coupling 
substrate consumption by comparing vinyl iodide 137 and tridecane internal standard. 
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Table 9.1.1.  A) The molar ratio of product 139 and tridecane with the associated peak area ratio 
obtained from GC analysis.  B) The molar ratio of substrate 137 and tridecane with the associated 
peak area ratio obtained from GC analysis. 
 
A9.2 SUPERCRITICAL FLUID CHROMATOGRAPHY DATA FOR 
ORGANOZINC CROSS-COUPLING OPTIMIZATION 
 
 
Yields of eneyne 141 were quantified using the calibration curves (Figure 9.2.1), 
which graph the area ratio of supercritical fluid chromatography (SFC) peaks as a 
function of the molar ratio of eneyne 141 and the diphenylether internal standard.  This 
data was collected from several individual SFC runs depicted in Table 9.2.1. 
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Figure 9.2.1.  Calibration curve used to determine cross-coupling yields comparing eneyne 141 and 
diphenylether internal standard. 
 
Table 9.2.1.  The molar ratio of product 141 and diphenylether internal standard with the associated 
peak area ratio obtained from SFC analysis. 
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A9.3 NOTES AND REFERENCES 
 
(1) Methyl ester 139 was synthesized for GC studies using known methods: Kapferer, 
T.; Brückner, R. Eur. J. Org. Chem. 2006, 2119–2133. 
(2) Iodo-cyclohexene (137) synthesized for GC studies using known methods: Kropp, 
P. J.; McNeely, S. A.; Davis, R. D. J. Am. Chem. Soc. 1983, 105, 6907–6915. 
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Figure A10.1.2 infrared spectrum (Thin Film, NaCl) of compound 141. 
Figure A10.1.3 13C NMR (125 MHz, CDCl3) of compound 141. 
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Figure A10.2.2 infrared spectrum (Thin Film, NaCl) of basiliopyrone (3). 
Figure A10.2.3 13C NMR (125 MHz, CDCl3) of basiliopyrone (3). 
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